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STELLING EN 
BEHOREND BIJ HET PROEFSCHRIFT 
DRUG TREATMENT FOR BURULI ULCER 
1. The WHO guidelines on treatment of Buruli ulcer should be changed in that injected 
aminoglycoside can now be reduced from eight to four weeks (this thesis). 
2. Paradoxical responses after start of antimicrobial treatment for Buruli ulcer explain why 
the effectiveness of antibiotics has not been recognized earlier (this thesis). 
3. Until a sensitive and specific test to monitor response to Buruli ulcer treatment has been 
developed, clinical judgment of the lesion is more important than consecutive surface 
area measurement to differentiate a paradoxical response from treatment failure (this 
thesis). 
4. The preponderance of Buruli lesions on one side of the body should be explored for 
possible routes of transmission (this thesis). 
5. In non-ulcerative Buruli ulcer lesions, ulceration is not prevented by antimicrobial 
treatment as it occurs in the majority of cases (this thesis). 
6. Financiering van klinisch wetenschappelijk onderzoek naar 'Neglected Tropical Diseases' 
zou hoger op de ranglijst dienen te staan bij subsidie verstrekkers. 
7. De waarschijnlijk uit Afrika afkomstige, maar in Nederland ingeburgerde zegswijze 'het 
vergt een heel dorp om een kind groot te brengen', wordt aldaar nog gewaardeerd en 
nageleefd, dit in tegenstelling tot in Nederland. 
8. Door vol te houden bereikte de slak de ark {Charles Haddon Spurgeon1 By perseverance 
the snail reached the ark). 
9. De kunst is niet alleen je eigen hersenen te gebruiken, maar ook alle die je kunt lenen 
(Woodrow Wilson1 I not only use all the brains that I have but all that I can borrow). 
10. De p-waarden zeggen of de getallen liegen, het waarheidsgehalte zegt of het artikel liegt 
(Yvo Smulders). 
11. Het gezegde 'niet over een nacht ijs gaan' gaat niet op voor Hollanders die direct een 
optie nemen op een hotelkamer in Leeuwarden, zodra het een nacht gevroren heeft 
{Corne/is Halma). 
12. Het leven is als een multiple choice vraag: hoe meer keuzemogelijkheden, hoe moeilijker. 
13. Wanneer de deadline is gehaald komt de promovendus weer tot levE n.Ccmrale 
Mcdische 
. . . . . . . bibliotheek 14. Sa 1s 't en net oars, want as 1t oars w1e, w1e 't net sa {Fnese wtdrukk11 g ron· mgen 
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Drug treatment for Buruli ulcer 
Buruli County was once the name of a district in central Uganda near the Nile river. 
This district is now called Nakasongola, after the name of its major town (figure I ). 
Half a century ago, a report was published in the Lancet about skin ulcers occurring in 
that region [ I ].The authors called the causing agent of the skin ulcers Mycobacterium 
buruli [2]. Some years hereafter, refugees from Rwanda who moved to Uganda into 
a settlement located near a swampy area in the Nile river basin also developed 
extensive and crippling ulcers [3]. Earlier, in the 1950s, several reports came from 
Zaire -now DR Congo-, describing necrotizing skin lesions with large loads of acid­
fast bacilli [4,5]. All of these reports addressed the disease now commonly called 
Buruli ulcer disease or Mycobacterium u/cerans infection. The first description in 
West Africa was from Nigeria in 1967 [6]. In 1971, two cases were reported from 
Ghana [7]. Since then the disease has emerged in western parts of Sub-Saharan 
Africa. Reports have however come from over 30 countries around the world. The 
first report with a clear description of the clinical presentation and histopathology 
identifying the causative pathogen, dates back to 1948. In this report from Australia 
it was shown that a slowly growing mycobacterium could be cultured around 30°C, 
and that the subsequent inoculation of these bacteria in experimental animals caused 
similar pathology [8]. Cases of Buruli ulcer have also been reported from scattered 
foci in Asia and South America [9-11 ]. 
The micro-organism is generally believed to be an environmental mycobacterium 
residing in swampy, riverine areas in humid climates, but the reservoir is not fully 
understood [9]. Likewise, the exact mode of transmission is still unknown [ 12]; 
person-to-person transmission is however extremely rare [ 13]. Circumstantial 
evidence suggests that trauma introduces the etiologic agent into the skin and the 
subcutaneous tissue [ 14-17]. 
Mycobacterium u/cerans infection usually starts as a nodule, papule, plaque, or edema 
(figure 2-4). When the lesion breaks open, a typical painless ulcer with undermined 
edges appears (figure 5), which can progress to a large necrotic wound. Lesions 
predominate on the limbs, and children of school-going age, residing in remote areas, 
are most often affected. The disease can be self-limiting [9, 18, 19], but leaves patients 
often with large scars and deformities. Stigmatization is still common, and is one of 
the reasons for delay in reporting [20,21 ]. Even large lesions rarely cause pain or 
systemic symptoms, which is another source of delay in seeking treatment early 
[22,23]. 
Since its first description, different treatments have been investigated, but surgery 
has dominated. Even Albert Cook, who described lesions we now recognize as 
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typical for Buruli ulcer as early as 1897 [24,25], tried surgical removal of affected 
tissues. In Australia Maccallum et al. reported surgical treatment with subsequent 
healing [8]. In 1964 Lunn et al. concluded from several observational reports that 'in 
all these, chemotherapy alone was ineffective as a sole means of treatment, though varying 
degrees of activity against the causative mycobacterium have been demonstrated in vitro' 
[26]. In 1970, the Uganda Buruli Group reported that 'we do use antimycobacterial 
drugs for hospital patients, but it seems that the most important factor in healing is surgical 
technique' [27]. Surgery cannot completely remove all bacilli. Recurrence is common, 
with reported rates varying between 6% [28] and 47% [29].Although larger excisions 
might be more effective, the inherent tissue damage increases duration of treatment 
0 50 100 150 200 
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Figure I: Map of Uganda showing the high incidence of mycobacterial ulcers in de the Buruli area. 
Patients' homes are shown with a dot. With permission from Clancey et al., Mycobacterial skin ulcers 
in Uganda, the Lancet 196 I 
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Figure 2: Nodule above the elbow 
Figure 3: Plaque on the knee 
Figure 4: Edema of the right arm 
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Figure 5: Ulcer on the left shoulder 
and chances of residual functional limitations. Many antimycobacterial agents show 
activity against Mycobaeterium u/cerans in vitro and in animal models [30-40]. As 
early as in the 1950s and 1960s, success was reported with clofazimine and with 
streptomycin for the treatment of early experimental infection in mice [26,41,42]. In 
1972 the in vitro sensitivity of Mycobaeterium ulcerans to rifampicin was found to be 
similar to that of Mycobaeterium tuberculosis [43]. Heat therapy in combination with 
rifampicin yielded good results in the mouse footpad infected with Mycobaeterium 
ulcerans [44].Two randomized placebo controlled trials have been carried out using 
clofazimine and dapsone plus rifampicin. Neither of these trials showed a difference 
in rate of healing between groups [45,46]. Chemotherapy was generally disappointing. 
Extensive surgical debridement became the standard, with or without subsequent 
skin grafting. In 2003 a study in Ghana was conducted in patients with pre-ulcerative 
(nodular) lesions. The number of study participants was relatively small, and only 
21 had their Mycobaeterium u/cerans disease confirmed by PCR testing. The study 
participants received variable periods of streptomycin plus rifampicin treatment.All 
lesions were surgically removed, and histopathology, PCR and culture was performed 
of all resected tissues. In some of the lesions Mycobaeterium ulcerans could be 
cultured, but in none of the tissues of affected individuals receiving drug treatment 
of 4 weeks or more, showing that Mycobaeterium ulcerans can be killed in human 
tissues by drug treatment alone [47]. Antibiotics were used erratically in regions 
15 
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where surgery was not easily accessible, with the imminent danger of developing 
resistance resulting from mono-therapy or sub-therapeutic dosage drug treatment 
[48].Therefore WHO issued preliminary guidelines for the drug treatment of Buruli 
ulcer disease in 2004, with 8 weeks of standard antibiotic treatment, with or without 
surgery [ 49]. In an observational study reported in 2007, promising clinical efficacy 
of the combination streptomycin and rifampicin was reported from Benin, where 
close to 50% ( I 02 out of 224) of the included Buruli ulcer patients were treated 
successfully with antibiotics alone. Of those, two recurrences were reported after 
one year. In the other patients it was judged necessary to add surgical treatment; in 
113 successfully treated patients one recurrence was reported after one year [50]. 
Buruli ulcer disease is one of 19 neglected tropical diseases addressed byW HO in its 
Global plan to combat neglected tropical diseases 2008-2015 [51 ]. Here the organization 
describes Mycobacterium ulcerans infection as a disease for which there are no cost­
effective control methods. This thesis addresses drug treatment for Buruli ulcer. 
Should antibiotics be given for Buruli ulcer? 
Does treatment using streptomycin and rifampicin given for 8 weeks, without the 
use of large debridement surgery, result in healing of Mycobacterium ulcerans infection 
without recurrence of disease? Is an oral regimen using clarithromycin instead of 
streptomycin during the second 4 weeks inferior compared to 8 weeks of injection 
therapy? 
In Chapter 2 we test the hypothesis that early (duration less than 6 months), limited 
(lesion cross-sectional diameter smaller than IO cm) Mycobacterium ulcerans infection 
can be cured with 8 weeks of antimycobacterial therapy, without adding debridement 
surgery. Studies in animal models showed that aminoglycosides - e.g. streptomycin 
and amikacin - and rifampicin have strong bactericidal activity [33-35]. The most 
harmful side effects of aminoglycosides are ototoxicity and renal toxicity [52-54], 
and administration is contra-indicated during pregnancy because of potential toxic 
effects on the fetus. In highly endemic areas such as Sub-Saharan Africa, hygiene is 
a concern as aminoglycosides can only be administered through injections [55-58]. 
We therefore tested a second hypothesis - i.e., whether switching injected 
streptomycin to oral clarithromycin after 4 weeks would be equally effective, or at 
least, non-inferior to the streptomycin-based therapy. Earlier, clarithromycin showed 
bacteriostatic and weak bactericidal activity in vivo when the study was designed 
[34,35]. 
16 
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Clarithromycin for Bunlli ulcer 
Does rifampicin co-medication result in lower serum concentrations of clarithromycin 
when treating Mycobaeterium u/cerans infection? What is the additional effect of the 
metabolite 14-hydroxyclarithromycin ( 14-OH clarithromycin) in the treatment of 
Mycobaeterium u/cerans infection? 
Co-medication can result in significant drug-drug interaction.This can be so profound 
that a decrease to sub-therapeutic serum concentrations might result. Rifampicin is 
known to induce cytochrome P450 (CYP) enzymes, which are responsible for the 
hepatic metabolism of many active drugs [59-61 ].As CYP3A4, one of those enzymes, 
is involved in the elimination of clarithromycin [61,62], a faster metabolism into its 
major - and, possibly also active - metabolite 14-OH clarithromycin will result [63]. 
Clarithromycin, on the other hand, is known to inhibit CYP450 enzyme systems 
[60,64,65]. Chapter 3 explores the drug-drug interaction between rifampicin and 
clarithromycin in a subset of patients that participated in the randomized trial 
described in chapter 2. The extent of the drug-drug interaction of these two drugs 
had not been studied earlier in this population and with the present prescription 
used (clarithromycin 7.5 mg/kg of body weight, once daily; rifampicin IO mg/kg, 
once daily). Furthermore, in chapter 3, minimal inhibitory concentrations (MICs) 
of clarithromycin and 14-OH clarithromycin are determined for a Ghanaian and a 
Malaysian Mycobaeterium u/cerans strain. For 14-OH clarithromycin the activity against 
Mycobaeterium ulcerans has never been described, and it is unknown to what extent 
the antimycobacterial effects of the metabolite add to activity of clarithromycin itself. 
We hypothesized that despite the described drug interactions, effective inhibitory 
concentrations of both combined drugs would be achieved for at least some period 
of time [66], and that therefore no inadvertent mono-therapy would jeopardize 
the effectiveness of treatment with possible selection pressure allowing naturally 
occurring drug-resistant mutant organisms to repopulate Buruli ulcer lesions [48,67]. 
Response patterns to drug treatment of Buruli ulcer 
Why have antibiotics long been thought to be ineffective for the treatment of 
Mycobaeterium ulcerans infection? Is there evidence for a paradoxical response 
accompanying antimicrobial treatment for Buruli ulcer disease? 
When carrying out the randomized controlled trial described in chapter 2, we were 
struck by the fact that, overall, healing was slow. Moreover, in quite some patients it 
looked like healing set in after an initial worsening of disease had been noticed. This 
led to the hypothesis of a paradoxical reaction accompanying effective mycobacterial 
killing. In the past, paradoxical reactions might have been misunderstood as treatment 
17 
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failure [68,69]. T his could, in part, explain why the effectiveness of antimicrobial 
therapy for Buruli ulcer disease has not been recognized earlier. Paradoxical reactions 
are well known in other mycobacterial diseases, particularly tuberculosis [70-72]. 
After starting anti-tuberculosis treatment, immediate effect can be observed by a 
decrease in symptoms. Despite a possible paradoxical reaction, treatment is likely 
to be continued, as the phenomenon is recognized as such, and not misinterpreted 
as treatment failure. A paradoxical reaction in (pulmonary) tuberculosis might be 
less obvious than in a skin disease like Buruli ulcer, where treatment responses 
are observed continuously in case of non-ulcerative lesions, or whenever dressing 
changes allow observation of the lesion, as is the case in ulcerative stages of disease. 
Besides, initial improvement may be more subtle in Mycobacterium u/cerans infection, 
as the disease is not associated with systemic symptoms, unless secondary infection 
is present. Early surgical intervention might have biased results of clinical trials and 
observations on antibiotic treatment for Buruli ulcer. Chapter 4 describes disease 
response patterns after start of antibiotic therapy for Buruli ulcer disease in patients 
who healed on therapy, intending to find support for the hypothesis of paradoxical 
reactions accompanying antimycobacterial killing. 
Streptomycin for Buruli ulcer - ototoxicity screening in the field 
Can screening for aminoglycoside-induced ototoxicity be reliably performed in the 
field? 
Measurement of hearing levels can be used as a screening method for developing 
hearing impairment as a result of streptomycin toxicity [52,73]. Chapter 5 addresses 
the feasibility and reliability of measuring hearing levels using portable audiometry in 
a field hospital setting. We hypothesized that this screening method can be reliably 
used in hands of inexperienced, briefly trained health personnel, preventing the need 
for sending patients to specialized centers for audiometry, which are often far away, 
and not easily accessible. 
Genetics and vitamin D in Buruli ulcer 
Does serum vitamin D concentration influence susceptibility to develop Buruli 
ulcer disease, or the response to antibiotic treatment? To what extent do genetic 
polymorphisms in the vitamin D receptor, or in other candidate genes, play a role in 
susceptibility to develop Buruli ulcer disease after Mycobacterium ulcerans infection, 
and do genetic polymorphisms play a role in response to treatment? 
Vitamin D has been considered as a treatment option in tuberculosis in the pre­
antibiotic era, along with other supportive measures [74]. Later it was shown that 
18 
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metabolites of this hormone-like molecule are essential in the antimicrobial immune 
reaction cascade, triggered upon contact with certain pathogens that enter the 
human body, like mycobacteria [75,76]. Vitamin D effects depend on the presence 
of adequate stores, best measured by blood concentrations of 25-hydoxyvitamin D 
[77,78], and on the genetically determined susceptibility of the vitamin D receptor 
[79]. Most tissues and cells in the body have vitamin D receptors, and the majority 
of immune cells, notably monocytes and macrophages, have the ability to convert 
vitamin D into its active form, 1,25-dihydroxyvitamin D [78]. In this way the supra­
physiological concentrations of active vitamin D, necessary to modulate immune 
responses at the local level, can be reached [76]. Epidemiological evidence suggests 
there is a relation between vitamin D deficiency, as well as polymorphisms in the 
vitamin D receptor gene, and susceptibility to tuberculosis [80-84]. Certain vitamin 
D receptor gene polymorphisms have also been found to be associated with 
leprosy type (tuberculoid versus lepromatous) [85].A study that assessed outcome 
of tuberculosis treatment showed an association between vitamin D receptor 
polymorphism and time to sputum culture conversion during anti-tuberculosis 
treatment [86]. In a study that assessed the potential of vitamin D suppletion in 
tuberculosis patients, vitamin D receptor polymorphism was associated with time to 
sputum culture conversion as well [87]. In summary, there is evidence to suggest that 
host response after mycobacterial infection is related to vitamin D status and vitamin 
D receptor polymorphism status. In chapter 6 we therefore studied the hypothesis 
that vitamin D serum concentration and vitamin D receptor polymorphism is 
associated with Mycobacterium ulcerans infection, as well, and that response to 
treatment depends on vitamin D status and vitamin D receptor polymorphism. 
Only a certain percentage of individuals infected with Mycobacterium ulcerans develop 
overt clinical disease [88-92]. Like in tuberculosis and leprosy, a combination of 
environmental and inherited factors seem to determine this clinical response; apart 
from the vitamin D receptor gene, other genes are known to influence susceptibility 
to Mycobacterium tuberculosis and Mycobacterium leprosy [93-96]. For Mycobacterium 
u/cerans infection, the only published study on genetic susceptibility reported that 
a certain polymorphism in the SLC I I A I gene increased the chance of developing 
Buruli ulcer disease by 13% [97]. In chapter 6 we seized the opportunity to try 
confirm this finding, and apart from the SLC I I A I and the VDR gene, we studied the 
MBL (mannose binding lectin) gene. We tested the hypothesis that polymorphisms 
in these candidate genes are associated with Buruli ulcer disease in our population, 
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Background Surgical debridement was the standard treatment for 
Mycobaeterium ulcerans infection (Buruli u lcer disease) until WHO issued 
provisional guidelines in 2004 recommending treatment with antimicrobial 
drugs (streptomycin and rifampicin) in addition to surgery. These 
recommendations were based on observational studies and a small pi lot 
study with microbiological endpoints. We investigated the efficacy of two 
regimens of antimicrobial treatment in early-stage M ulcerans infection. 
Methods In  th is paral lel, open-label, randomised trial undertaken in two 
sites in Ghana, patients were el igible for enrolment if they were aged 5 
years or older and had early (duration <6 months), l imited (cross-sectional 
diameter < I O  cm), M ulcerans i nfection confirmed by dry-reagent-based 
PCR. El igible patients were randomly assigned to receive intramuscular 
streptomycin ( 1 5  mg/kg once dai ly) and oral rifampicin ( I O  mg/kg once 
dai ly) for 8 weeks (8-week streptomycin group; n=76) or streptomycin and 
rifampicin for 4 weeks followed by rifampicin and clarithromycin (7 ·5 mg/ 
kg once daily) ,  both oral ly, for 4 weeks (4-week streptomycin plus 4-week 
clarithromycin group; n=75). Randomisation was done by computer­
generated minimisation for study site and type of lesion (ulceration or no 
ulceration).The primary endpoint was lesion heal ing at I year after the start 
of treatment without lesion recurrence or extensive surgical debridement. 
Analysis was by intention-to-treat.This trial is registered with Cl inicalTrials. 
gov, number NCT0032 I 1 78. 
Findings Four patients were lost to follow-up (8-week streptomycin, one; 
4-week streptomycin plus 4-week clarithromycin, three) . Since these four 
participants had healed lesions at their last assessment, they were included 
in the analysis for the primary endpoint. 73 (96%) participants in the 8-week 
streptomycin  group and 68 (9 1 %) in the 4-week streptomycin plus 4-week 
clarithromycin group had healed lesions at I year (odds ratio 2 ·49, 95% Cl 
0 ·66 to i nfin ity; p=0 · 1 6, one-sided Fisher's exact test) . No participants had 
lesion recurrence at I year.Three participants had vestibulotoxic events (8-
week streptomycin, one; 4-week streptomycin plus 4-week clarithromycin, 
two). One participant developed an injection abscess and two participants 
developed an abscess close to the initial lesion, which was incised and 
drained (all three participants were in the 4-week streptomycin plus 4-week 
clarithromycin group). 
Should antibiotics be given for Buruli ulcer? 
Interpretation Antimycobacterial treatment for M ulcerans infection is 
effective in early, limited disease. 4 weeks of streptomycin and rifampicin 
followed by 4 weeks of rifampicin and clarithromycin has similar efficacy to 
8 weeks of streptomycin and rifampicin; however, the number of injections 
of streptomycin can be reduced by switching to oral clarithromycin after 
4 weeks. 
Funding European Union (EU FP6 2003-INCO-Dev2-0 15476) and Buruli 




Buruli  ulcer is a necrotising infection of subcutaneous tissue caused by Mycobacterium 
ulcerans. 1 The name Buruli ulcer comes from a region near the Ni le River delta in 
Uganda, named Burul i  County, where the disease was highly endemic in  the I 960s.2 
Today, the disease is emerging in west African countries with thousands of cases 
every year, mainly in chi ldren.3•4 A plasmid of M u/cerans encodes the production 
of mycolactone,4•5 an immunomodulatory macrolide toxin that causes tissue 
necrosis.6 M u/cerans is acquired near slow-flowing and stagnant water in  tropical 
and subtropical environments. The natural reservoir and mode of transmission of 
the infection remain largely obscure and might differ between endemic foci around 
the world.7•8 However, skin injury9 and insect bites 1 0  have been proposed as modes 
of transmission. 
M ulcerans infection usually starts as a nodule, papu le, plaque, or oedema. When left 
alone, the lesion breaks open and a typical pain less ulcer with undermined edges 
appears, which can progress to a large necrotic lesion.WHO has defined lesions with 
a cross-sectional diameter of less than 5 cm as category I, 5- 1 5 cm as category 1 1, and 
more than I 5 cm, lesions on important sites ( eye, breast, and genitalia), or multiple 
les ions as category I l l .  M ulcerans infection can be self-l imiting, but scar tissue and 
contractures in joints leave patients with functional l imitations and social stigma. 
1 1 • 1 2  The diagnosis can be made clinically but culture i s  the gold standard. However, 
this method is difficult and has low sensitivity. 1 •3•4• 1 3  Since the development of PCR 
targeting insertion sequence 2404 (IS2404)-a repetitive oligonucleotide unit with 
more than 200 copies in the genome of M ulcerans 1 4-diagnostic confirmation has 
improved substantially. 1 3• 1 5• 1 6  
Buruli u lcer i s  one of 19  neglected tropical diseases addressed byWHO in its Global 
plan to combat neglected tropical diseases 2008-20 1 5. 1 7  In this plan, the organisation 
describes Buruli ulcer as a disease for which there are no cost-effective control 
methods. Since the disease's first description in 1 948, 18 different treatments have 
been investigated. Extensive surgical debridement, with or without subsequent skin 
grafting, is standard treatment. However, surgery cannot completely remove all 
baci l l i 1 9  and recurrence is common, with reported rates varying between 6% and 
47%.20-22 Although larger excisions might be more effective, they can increase chances 
of residual functional l imitations. In the first of two randomised controlled trials for 
M u/cerans infection, clofazimine did not show a significant benefit compared with 
placebo.23 In individuals with small (<S cm), non-ulcerated lesions, recurrence-free 
heal ing without surgery was reported in five of eight participants who were treated 
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with clofazimine compared with five of 17 who were treated with placebo. In ten 
patients with larger and ulcerated lesions, all except one (in the placebo group) 
needed surgery.A second study compared the effect of dapsone plus rifampicin with 
placebo. Of 41 randomised patients, 30 completed the 2-month trial. Rate of healing 
did not differ between groups. Uneven baseline characteristics might partly explain 
why patients assigned to active treatment had a larger reduction in lesion size than 
did patients assigned to placebo.24 
Many antimycobacterial agents show activity against M ulcerans in vitro, and 
experiments in animals, such as the mouse footpad model, show that streptomycin 
in combination with rifampicin is highly bactericidal. In a pilot study sponsored by 
WHO, 31 patients clinically diagnosed with pre-ulcerative M ulcerans infection were 
treated with streptomycin and rifampicin for 0, 2, 4, 8, or 12 weeks.25 All lesions 
were excised; M ulcerans infection was confirmed by PCR in 21 cases. In ten patients 
who were treated for 2 weeks or less, viable bacilli could be isolated from excised 
tissues, whereas M ulcerans could not be cultured from tissue taken from I I patients 
who were treated for 4 weeks or longer. Lesions either reduced or stabilised in size 
in all patients.25 On the basis of these findings, preliminary guidelines were issued 
by WHO recommending streptomycin in combination with rifampicin as standard 
treatment for M ulcerans infection, with or without additional surgical debridement 
or skin grafting.26 When our study was designed, clarithromycin was believed to have 
only bacteriostatic activity in vivo. 3•27 
We assessed the efficacy of antibiotic therapy with oral rifampicin and intramuscular 
streptomycin given for 8 weeks for treatment of early M ulcerans infection in patients 
from Ghana. This regimen was compared with rifampicin and streptomycin given 
for 4 weeks, followed by an oral combination of clarithromycin and rifampicin for 4 
weeks. Our aim was to identify an effective alternative treatment to extensive surgical 
debridement, and to explore possibilities to keep the use of injectable antimicrobial 
treatment to a minimum. 
Methods 
Participants 
The study design was partly based on discussions within a WHO expert group on 
Buruli ulcer that took place between 200 I ,  and 2003. Between April, 2006, and January, 
2008, patients were recruited at two sites (Nkawie-Toase Government Hospital, 
Nkawie, and Agogo Presbyterian Hospital, Agogo) in Ghana. Patients clinically 
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diagnosed with M ulcerans disease were recruited by active case finding. Patients 
were eligible for enrolment if they were aged 5 years or older, had a reported disease 
duration of less than 6 months, and had lesions with a cross-sectional diameter 
(indurated area) of IO cm or less. M u/cerans infection was confirmed by IS2404 
dry-reagent- based PCR.28 Exclusion criteria were pregnancy, drug in-tolerance, and 
renal, hepatic, and acoustic impairment. 
The protocol and consent forms were approved by the Committee on Human 
Research, Publication, and Ethics of the School of Medical Science, Kwame Nkrumah 
University of Science and Technology, Kumasi, and the Komfo Anokye Teaching 
Hospital, Kumasi (CHRPE/07/0 1/05), and by the Ethical Review Committee of Ghana 
Health Services (GHS-ERC-0 I /0 I /06).The Medical Ethics Review Committee of the 
University Medical Centre Groningen, Netherlands, reviewed the protocol before 
ethics clearance in Ghana.Written and verbal informed consent was obtained from al l 
participants aged 12 years or older, and from parents, carers, or legal representatives 
of participants aged 18 years or younger. 
Procedures 
After participants had given informed consent, we obtained demographic and clinical 
information and took blood samples. We undertook pregnancy tests in female 
participants aged IO years or older, and hearing tests in all participants (AS208 
portable equipment; lnteracoustics,Assens, Denmark) to obtain baseline audiometric 
data. HIV antibody testing was done with cold-stored sera after completion of the 
study. Lesions were photographed and traced onto acetate sheets. Three 3 mm 
punch biopsy samples were taken under local anaesthesia; two swabs of ulcerated 
lesions were also taken. All samples were transported to the Kumasi Centre for 
Col laborative Research in Tropical Medicine laboratory in Kumasi, Ghana, for 
IS2404 dry-reagent-based PCR and Ziehl-Neelsen staining to detect acid-fast bacil li; 
mycobacterial culture was done on Lowenstein-Jensen slopes at 32°C. 1 3  One punch 
biopsy was reserved for histopathological examination. 
Participants started streptomycin ( I 5 mg/kg once daily intramuscularly) and rifampicin 
( IO mg/kg once daily orally) after the diagnostic procedures. After assessments and 
start of treatment at the hospital, most participants were treated as outpatients. 
Once a week, participants were given study drugs to take to the nearest health 
facility to receive directly observed treatment (DOT) for the subsequent days, with 
daily wound care. Only participants that had extensive oedema or lesions at difficult 
sites (joints, eye, or genitalia), or lesions with suspected secondary infection were 
admitted to hospital; participants who could not receive DOT or wound care at 
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home were also admitted to hospital. DOT was recorded on forms by the health­
care worker or helper who was observing the treatment. Participants were followed 
up at weekly intervals during the first 8 weeks. At these visits, clinical assessments 
and digital photographs were taken, DOT forms were checked, and participants were 
invited to report any adverse events. Once every 2 weeks, the size of the lesion was 
traced onto an acetate sheet and blood cell counts were taken; we also undertook 
liver and kidney function tests and hearing tests in all participants, and pregnancy 
tests in female participants aged IO years or older. 
Randomisation and masking 
Before the end of week 4, participants with M u/cerans infection confirmed by PCR 
were randomly assigned to receive streptomycin intramuscularly and rifampicin orally 
for 4 more weeks (8-week streptomycin group) or rifampicin and clarithromycin (7 ·S 
mg/kg once daily), both orally, for another 4 weeks (4-week streptomycin plus 4-week 
clarithromycin group). Randomisation was done with minimisation for study site and 
type of lesion (ulceration or no ulceration).The study coordinator (WAN) forwarded 
the information of every enrolled participant by mobile telephone text messaging 
to a statistician OPS) at the Department of Epidemiology, University Medical Centre 
Groningen, Netherlands. There, a computer-generated randomisation program was 
used, and the randomly assigned allocation was then sent by text message to the 
study coordinator. Individuals who were clinically diagnosed with M ulcerans disease 
but who did not have confirmation by PCR continued treatment with streptomycin 
plus rifampicin and were not randomised; these individuals were followed up and 
analysed separately.This was an open-label trial. 
Follow-up and study outcomes 
After 8 weeks of antimicrobial treatment, missed doses were not supplemented. 
Participants were followed up at week IO and week 12 after start of treatment, and 
then monthly to week 36, and bimonthly to week 52. Study visits included clinical 
assessment with reporting of adverse effects, measurement of lesion size (if not 
healed) by tracing onto an acetate sheet, and photography of the lesion. Participants' 
travel costs were reimbursed and small monthly incentives (sugar, condensed milk, 
and cocoa powder) were offered for time spent in the study. 
Treatment failure was recorded if a participant's lesion had not healed by week 52, 
lesion recurrence occurred within I year, or lesion size increased to I 50% or more 
at any timepoint compared with baseline with surgical debridement undertaken as 
deemed necessary by the attending doctor in the hospital. The investigators who 
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took measurements of the lesions were not masked to treatment assignment. The 
attending doctor in the hospital making the final decision for extensive surgical 
debridement was unaware of treatment allocation. Removal of necrosis and slough 
is part of normal wound care and skin grafting speeds up heeling but does not 
affect bacterial load. These interventions were therefore not regarded as evidence 
of treatment failure. 
The primary clinical endpoint was lesion healing (complete re-epithelialisation) 
at I year after the start of treatment without recurrence or extensive surgical 
debridement. Secondary outcomes were time to wound healing and time to complete 
wound coverage by a crust. Daily sterile dressings were only applied at the health 
facility if lesions were open and discharging. 
Before final healing occurs, lesions might turn dry with a crust. At this stage, 
participants could cover the lesions for protection at home, without visiting the 
health facility to receive wound care and sterile dressings. Since participants reported 
this stage of wound healing as beneficial, we also measured time to complete wound 
coverage by a crust without complete re-epithelialisation as a secondary endpoint. 
The safety outcome measure was occurrence of adverse events. 
Statistical analysis 
When the study was designed, there was no information available about healing 
rates for the proposed regimens; therefore, we assumed a healing rate of 80% in 
the 8-week streptomycin group.We calculated that a sample size of 148 randomised 
and fully assessable participants (74 in each group) would be needed to detect a 
difference in healing rate of 20% or more (<60% in the 4-week streptomycin plus 
4-week clarithromycin group) with a one-sided alpha of O -05 and a power of 80%. 
We calculated an odds ratio for the primary clinical endpoint by use of Fisher's exact 
test. Because secondary outcome data were interval-censored, we analysed the 
cumulative incidence of healing by use of actuarial life table analysis and weighted log­
rank tests for interval-censored data, in particular the group proportional hazards 
model29 and a generalised Wilcoxon-Mann-Whitney test,30 which emphasises early 
events. We calculated the exact permutation p value for the scores of the group 
proportional hazards model and Wilcoxon-Mann-Whitney tests and the non­
parametric maximum likelihood estimate of the survival distribution function.3 1  
Other secondary outcome measures were assessed by  actuarial life table analysis.All 
analyses were by intention to treat. Statistical analysis was done with SPSS version 
16.0, R version 0.7-5.5, and Stata version I 0. 1 .  
An independent data safety monitoring board reviewed the data for safety purposes 
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after inclusion of 57 and I 1 5  participants. Interim reports were discussed at the 
annual WHO meeting on Buruli ulcer in Geneva in 2007 and 2008, and presented at 
the 2008 combined ICAAC/IDSA Annual Meeting in Washington, DC, USA.32 After 
the trial had been completed, two independent wound experts from University 
Medical Centre Groningen, who were masked to treatment assignment, assessed 
the primary study endpoint (heal ing at I year) using the digital photographs of the 
lesions taken during the trial. This trial is registered with Clin icalTrials.gov, number 
NCT0032 1 1 78. 
Role of the funding source 
The sponsors of the study had no role in study design, data collection, data analysis, 
data interpretation, writing of the report, or in decisions about submission of resu lts 
for publication. The corresponding author had ful l  access to all the data in the study 
and had final responsibil ity for the decision to submit for publ ication. 
Results 
Figure I shows the trial profile. 1 80 eligible patients started treatment. 26 patients 
with suspected but unconfirmed M ulcerans infection received streptomycin and 
rifampicin for 8 weeks. Of 1 5 1  participants who were enrol led and randomised, eight 
had a clin ical diagnosis without confirmation of M ulcerans infection by PCR. Five of 
these eight participants had infection later confirmed by one or more diagnostic tests 
(Ziehl-Neelsen staining, two; culture, one; histopathology, two). Three randomised 
participants did not have diagnosis confirmed by any test. Table I shows baseline 
characteristics of study participants. Lesions were more frequently seen on the right 
side of the body (64%) than on the left side (36%; p<0 -000 I ).Three (2%) participants 
were H IV positive; these individuals had initial lesions and clinical presentations that 
were indiscernible from those of H IV-negative participants. 
One participant in the 8-week streptomycin group withdrew from the study at week 
6. In the 4-week streptomycin plus 4-week clarithromycin group, two participants 
moved out of the study area and were lost to follow-up (week 32 and 36) and one 
participant, who later tested positive for HIV infection, died in week 1 6  of urosepsis. 
Since these four participants had healed lesions at their last assessment, they were 




250 patients screened I 
70 ineligible 
18 lesion too large 
... 1 6  too young ... 7 pregnant 
2 hearing impairment 
7 recurrent disease 
20 doubtful diaJ!:nosis and PCR and AFB ne2ative 
.. 26 with clinical disease but without PCR confirmation* ... 
,r 
1 54 enrolled and started on treatment I 
3 withdrew/lost before randomisation 
I accidentally operated ... I diedt 
I non-compliant 
,, 
1 5 1  randomised 
1 43 with infection confirmed by PCR 
5 confirmed with infection by other method$ 
3 without confirmation of infection 
76 assigned to streptomycin 75 assigned to streptomycin and rifampicin 
and rifampicin for 8 weeks for 4 weeks followed by rifampicin and 
clarithromycin for 4 weeks 
H I withdrew (in week 6)§ I died (in week I 6)t§ 
1---. 2 migrated (in week 32 and 
week 36)§ 
,r ,, 
76 assessed for primary endpoint I 75 assessed for primary endpoint 
Figure I: Trial profile 
AFB=acid-fast baci l l i .  *Patients not enrolled but given 8 weeks of treatment with streptomycin 
and rifampicin. tParticipant died of cause unrelated to M u/cerans infection. $See text for details. 
§Healed at time of last assessment, included in the final analysis. 
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Table I: Patient baseline characteristics 
8-week 4-week streptomycin plus 
streptomycin group 4-week clarithromycin 
(n=76) group (n=75) 
Sex (male) 27 (36%) 1 9  (25%) 
Age (years) 1 2  (8- 1 8) 1 2  (9-22) 
Body-mass index (kg/m2) 1 6.6 ( 1 4.9- 1 9.4) 1 7.2 ( 1 5.4- 1 9.4) 
Study site 
Agogo 54 (7 1 %) 53 (7 1 %) 
Nkawie 22 (29%) 22 (29%) 
Tribe 
Akan 20 (26%) 1 8  (24%) 
Other 56 (74%) 57 (76%) 
Duration of disease (weeks) 4 (2-6) 3 (2-4) 
Lesion surface area (cm2) 29 (9-55) 26 ( 1 0-46) 
Category of lesion 
I 29 (38%) 29 (39%) 
II or I l l  47  (62%) 46 (6 1 %) 
Type of lesion 
No ulceration 49 (64%) 43 (57%) 
Ulceration 27 (36%) 32 (43%) 
Lesion distribution (side of body) 
Left 27 (36%) 28 (37%) 
Right 49 (64%) 47 (63%) 
H IV infection 0 (0%) 3 (4%) 
Data are n (%) or median (IQR). Patients in the 8-week streptomycin group were assigned to receive 
intramuscular streptomycin and oral rifampicin for 8 weeks. Patients in the 4-week streptomycin 
plus 4-week clarithromycin group were assigned to receive streptomycin and rifampicin for 4 
weeks followed by rifampicin and clarithromycin, both orally, for 4 weeks. 
Compliance to study treatment was assessed by use of DOT forms, signed by health 
personnel at the health facil ities. Compliance was 98% in the 8-week streptomycin 
group and 99% in the 4-week streptomycin plus 4-week clarithromycin group. 
Treatment failure was recorded in ten participants, three in the 8-week streptomycin 
group and seven in the 4-week streptomycin plus 4-week clarithromycin group.Table 
2 shows the characteristics of these individuals. Five participants were not healed at 
week 52, all of whom had a substantial decrease in lesion size. One participant had 
several lesions, and four had large lesions at the start of treatment ( one of whom 
had HIV infection). Of the five participants with treatment failure before week 52, 
two had large lesions, one had a pre-ulcerative lesion that ulcerated later, one had a 
progressive lesion, and one had a lesion that almost healed, but opened up again.  No 
participants with healed lesions had a recurrence at week 52. 
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Treatment failure was recorded if a participant's lesion had not healed by week 52, lesion recurrence occurred within I year, or lesion size increased 
to 1 50% or more at any timepoint compared with baseline with surgical debridement undertaken as deemed necessary by the attending doctor in the 
hospital. *Weeks after start of treatment. tResults for insertion sequence 2404-dry reagent based PCR, Ziehl-Neelsen (ZN) staining to indentify acid-fast 
bacill i , and M u/cerans culture. Patients in the 8-week streptomycin group were assigned to receive intramuscular streptomycin and oral rifampicin for 8 
weeks. Patients in the 4-week streptomycin plus 4-week clarithromycin group were assigned to receive streptomycin and rifampicin for 4 weeks followed 





























73 (96%) participants in the 8-week streptomycin group and 68 (9 1 %) participants 
in the 4-week streptomycin plus 4-week clarithromycin group had healed lesions 
at week 52 ( odds ratio for failure in heal ing for 4-week streptomycin plus 4-week 
clarithromycin vs 8-week streptomycin 2 49, 95% Cl O ·66 to infinity, p=O · 1 6) .  We 
obtained consistent findings when the four participants who were not followed up 
to week 52 were excluded from the analysis and when two wound experts masked 
to treatment assignment assessed the primary endpoint by use of photographs 
available at the different timepoints ( data not shown). 
Table 3 shows the actuarial l ife table for cumulative proportion of heal ing. The 
estimated cumulative proportion of patients healed at week 52 was O -99 (95% CI 
0 ·94- 1 -00) in the 8-week streptomycin group and O ·96 (95% Cl O ·88--0 ·99) in the 
4-week streptomycin plus 4-week clarithromycin group; a difference of O -034 (95% 
Cl --0 -024 to O -09 1 )  between groups. 
Figure 2 shows the non-parametric maximum likelihood estimates for heal ing in 
the intention-to-treat population. Neither the group proportional hazards model 
(p=O ·26; 99% CI O ·22--0 ·29) nor the generalised Wilcoxon-Mann-Whitney test 
(p=O -60; 99% Cl O ·56--0 -64) showed a significant difference in time to healing 
between groups. The group proportional hazards model suggested a shorter time 
to healing in the 8-week streptomycin group whereas the Wilcoxon-Mann-Whitney 
test suggested that time to heal ing was shorter in the 4-week streptomycin plus 
4-week clarithromycin group.Adjustment for study site and type of lesion (ulceration 
or no ulceration) did not affect the results (data not shown). 
Five participants received skin grafts, four in the 8-week streptomycin group (at week 
1 6, 24, 24, and 28), and one in the 4-week streptomycin plus 4-week clarithromycin 
group (at week 20). Time to healing of category I lesions (median 1 8  weeks, 95% Cl 
1 4-22) was significantly shorter than that for category II and I l l  lesions (30 weeks, 
95% Cl 26-34, p=O -002; data pooled for the two treatment groups; five participants 
with skin grafts not included).Time to complete wound coverage by a crust was also 
significantly shorter for category I lesions than category II and I l l  lesions ( 1 4  weeks, 
95% Cl I 1 - 1 8, vs 22 weeks, 95% Cl 22-26; p=O -002). 
Three participants had vestibulotoxic events, one in the 8-week streptomycin 
group (aged 49 years, starting after 7 weeks of treatment) and two in the 4-week 
streptomycin plus 4-week clarithromycin group (aged 24 years and 38 years, starting 
after 4 weeks and 3 weeks of treatment, respectively).Analysis of digital photographs 
showed that three participants had mi ld to moderate functional l imitations at the end 
of the study: one had a contracture with substantial decrease in range of movement 
of the thumb and index finger (4-week streptomycin plus 4-week clarithromycin 
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group); two had u lcers on the back of the hand and wrist that resulted in claw-hands 
( one in each group). No liver or kidney function test abnormalities or audiological 
deterioration occurred that necessitated termination of streptomycin treatment. 
One participant developed an injection abscess (4-week streptomycin plus 4-week 
clarithromycin group) and two participants (both in the 4-week streptomycin plus 
4-week clarithromycin group) developed an abscess close to the initial lesion which 
was incised and drained. One participant in the 8-week streptomycin group and two 
participants in the 4-week streptomycin plus 4-week clarithromycin group reported 
abdominal discomfort. 
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Table 4: M u/cerans isolated by culture of tissue specimens after 8-week treatment period 
Study Sex Age Category 
site (years) of lesion 
Patient I Agogo Female 1 2  I I  
Patient 2 Nkawie Female 1 2  I I  
Patient 3 Nkawie Female 5 I I  
Patient 4 Agogo Female 20 I l l  









Indication for Ttmepotnt Additional 
culture (weeks)* -
Lesion progression 1 1  
Development of a 1 4  
second lesion 
Pus collection 1 8  




Lesion healed without 
further intervention 
Lesion healed without 
further intervention 
Ulcer healed; multiple 
nodules u lcerated before 
healingt 
No complete heali ng at 72 Inadequate wound care; 










This analysis was not specified by the protocol. All five participants were in the 4-week streptomycin plus 4-week clarithromycin group (streptomycin 
and rifampicin for 4 weeks followed by rifampicin and clarithromycin for 4 weeks). *Time of tissue specimen collection (weeks after start of treatment). 
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Figure 2: Non-parametric maximum l ikelihood estimates for time to healing. 
The non-parametric maximum likelihood estimates for each treatment group are plotted with 
shaded rectangles denoting the indeterminate rises in the proportion healed during each time 
interval. Linear interpolation lines of healing within these indeterminate regions are also shown. 
Patients in the 8-week streptomycin group were assigned to receive intramuscular streptomycin 
and oral rifampicin for 8 weeks. Patients in the 4-week streptomycin plus 4-week clarithromycin 
group were assigned to receive streptomycin and rifampicin for 4 weeks followed by rifampicin and 
clarithromycin, both oral ly, for 4 weeks. 
Some participants had additional diagnostic tests not specified in the protocol. 
Table 4 shows the characteristics of the five participants in whom M u/cerans was 
isolated by culture after treatment; all were in the 4-week streptomycin plus 4-week 
clarithromycin group. Three of these five participants had treatment failure: in two, 
surgical debridement was done; in the third, multiple nodules ulcerated successively 
over 52 weeks before final healing. Two participants had lesion healing without 
further intervention within the study period. 
Discussion 
Our study has shown that early, l imited M ulcerans infection can be safely and 
effectively managed by antimicrobial treatment alone, without surgical debridement. 
The drug regimen proposed by WHO, consisting of 8 weeks of streptomycin and 
rifampicin, seemed effective and was not associated with deterioration requiring 
subsequent surgical debridement. Treatment with oral c larithromycin plus rifampicin 
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during the second 4-week period resulted in similar outcomes to continuation of 
treatment with streptomycin and rifampicin. Our findings are important for patients 
with M ulcerans infection who live in remote, resource-poor areas in West Africa, 
where people often need to walk for several hours to reach health-care facilities, 
skilled personnel are scarce, and patients tend to refrain from treatment because 
of fear of surgery. Our results also support the use of antimicrobial treatment in 
individuals who are unable to receive streptomycin--eg, pregnant women or those 
who cannot tolerate aminoglycosides. With few reported side-effects, the treatment 
regimens used in this trial seemed well tolerated, although vestibulotoxicity remains 
a concern. The rate of lesion recurrence in our study at 52 weeks was lower than 
that reported in retrospective studies assessing the effect of surgery, in which rates 
of between 6% and 47% were reported.20-22 
Time to healing was a median of 18 weeks for category I lesions and 30 weeks for 
larger lesions. The length of this healing period might have obscured the potential 
of antimicrobial treatment in earlier studies that either looked at healing after 2 
months,24 or assigned participants to surgery when early healing was not seen during 
follow-up.23 HIV was not an important confounder; most case-control studies from 
West Africa report a low incidence of HIV in patients with M ulcerans infection.33•34 
One strength of this study is the large proportion of participants ( 147 of 151) who 
were followed up to week 52. Second, most participants ( 148 of 15 I) had laboratory­
confirmed M u/cerans infection, which contrasts with previous trials that were partly 
undertaken before PCR-based diagnostic confirmation tests were available.23•24 Finally, 
the sample size in our study was substantially larger than that in earlier studies. 
A potential weakness of our study is the open-label design. However, masking would 
have substantially increased costs, and a trial in which children can be assigned to 
placebo injections is not justified for safety reasons. Moreover, although only one 
injection abscess was recorded, intramuscular injections in rural Africa are not the 
preferred option Another limitation of our study is that no formal external monitoring 
was done. However, limited auditing was organised. Additionally, consistent results 
were obtained when two wound experts who were masked to treatment assignment 
reviewed all digital photographs available at the different timepoints. We therefore 
believe that the study was robust. 
One concern is that healing took a fairly long time.Additionally, we could not address 
the issue of prevention of disabilities in a formal way, although our analysis of digital 
photographs combined with clinical assessment showed that only three participants 
had mild to moderate functional limitations at week 52 (all three involving hand 
function). Contractures and functional limitations are common in ulcers that are 
45 
Chapter 2 
close to joints. 1 1  Future studies should assess prevention of disabilities, include all 
categories of lesions, and investigate oral drug regimens. 
Thus, antimicrobial treatment is highly effective for treatment of early, limited M 
u/cerans infection, and the number of intramuscular injections of streptomycin can be 
reduced without compromising efficacy. 
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Summary 
In a randomized controlled trial in Ghana, treatment of Mycobaeterium 
u/cerans infection with streptomycin (SM)-rifampin (RIF) for 8 weeks was 
compared with treatment with SM-RIF for 4 weeks followed by treatment 
with RIF-clarithromycin (CLA) for 4 weeks. The extent of the interaction of 
RIF and CLA combined on the pharmacokinetics of the two compounds is 
unknown in this population and was therefore studied in a subset of patients. 
Patients received CLA at a dose of 7.5 mg/kg of body weight once daily, 
rounded to the nearest 125 mg. RIF was administered at a dose of IO mg/ 
kg, rounded to the nearest 150 mg. SM was given at a dose of 15 mg/kg once 
daily as an intramuscular injection. Plasma samples were drawn at steady 
state and analyzed by liquid chromatography-tandem mass spectroscopy. 
Pharmacokinetic parameters were calculated with the MW/Pharm (version 
3.60) program. Comedication with CLA resulted in a 60% statistically 
nonsignificant increase in the area under the plasma concentration-time 
curve (AUC) for RIF of 25.9 mg • h/liter (interquartile ratio [IQR], 21.9 to 
31.5 mg • h/liter), whereas the AUC of RIF was 16.2 mg • h/liter (IQR, 15.0 
to 17.6 mg • h/liter) in patients comedicated with SM (P = 0.09). The median 
AUCs of CLA and 14-hydroxyclarithromycin ( I 4OH-CLA) were 2.9 mg • h/ 
liter (IQR, 1.5 to 3.8 mg • h/liter) and 8.0 mg • h/liter (IQR, 6.7 to 8.6 mg • h/ 
liter}, respectively. The median concentration of CLA was above the MIC of 
M. u/cerans, but that of I 4OH-CLA was not. In further clinical studies, a dose 
of CLA of 7.5 mg/kg twice daily should be used (or with an extended-release 
formulation, 15 mg/kg should be used) to ensure higher levels of exposure to 
CLA and an increase in the time above the MIC compared to those achieved 
with the currently used dose of 7.5 mg/kg once daily. 
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Introduction 
Although many antimycobacterial agents appeared to be effective against 
Mycobacterium ulcerans infections in in vitro and in animal models (4, 1 1 , 27, 30), 
cl inical evidence of the effectiveness of antimicrobial treatment was predominantly 
based on a small study conducted with patients in Ghana ( 1 5) .  Conceivably, using 
antimycobacterial agents results not only in preventing bacil l i from replicating and 
kil l ing microorganisms but also in halting the production of the toxin mycolactone 
(36 ).This toxin that causes the tissue damage is produced by enzymes encoded by the 
pMUM00 I plasmid (33). Current WHO recommendations suggest 8 or more weeks 
of treatment with rifampin (RIF) plus streptomycin (SM) for all clinical forms of active 
Buruli ulcer disease (BUD). Daily injections with streptomycin are problematic, as 
most patients live in remote areas with l imited health care facil ities. Proper hygiene 
with these injections, as well as intrinsic ototoxicity and renal toxicity, is a concern. 
Therefore, an oral treatment schedule is urgently needed to reduce the number 
of injections and to improve the tolerability and safety of the proposed regimen. 
Pregnant women might also benefit from treatment without aminoglycosides. This 
problem was addressed by comparing 8 weeks of SM ( 1 5  mg/kg of body weight) 
and RIF ( I O  mg/kg) treatment (SSR arm) and 4 weeks of streptomycin and rifampin 
treatment followed by 4 weeks of RIF plus clarithromycin (CLA; 7.5 mg/kg) treatment 
(4SR/4CR arm) in a randomized controlled trial (the BURULICO trial) (26). CLA 
was chosen for inclusion in the treatment regimen because of in vitro data suggesting 
that this drug is active against M. u/cerans, for which the Ml Cs range from 0. 1 25 to 2.0 
mg/liter (30). In a pharmacokinetic (PK) study with adults who received doses of 500 
mg twice daily, plasma CLA concentrations (5) were well above the MIC for most 
M. u/cerans isolates. The clinical effectiveness of macrolides is only partly explained 
by pharmacokinetics, because these drugs typically accumulate in inflammatory cel ls, 
especially macrophages, at the site of infection ( I ) . Although M. u/cerans infection 
has long been regarded a predominantly extracel lu lar infection (20), evidence has 
emerged from animal models that M. u/cerans infection has an intracellular stage in 
which it multipl ies inside macrophages ( I 0, 34). These data taken together suggest 
that the intramacrophage CLA concentration might add to the beneficial effect of 
the drug to fight M. u/cerans infection and that CLA might exert its effect inside these 
immune cells without reaching inhibitory drug concentrations in the bloodstream. 
On the other hand, if plasma CLA concentrations do not reach inhibiting or 
mutant-inhibiting concentrations, at least in the extracellular space where baci l l i  
are present during later stages of the disease, inadvertent monotherapy with RIF 
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alone would result. At the time that the present study was designed, the activity 
of the 1 4-hydroxyclarithromycin ( I 4OH-CLA) metabolite against M. u/cerans 
was unknown, and sensitivity to I 4OH-CLA therefore had to be determined. 
In mycobacterial infections, monotherapy has invariably resulted in the failure 
of treatment, as drug-resistant pathogens within the total microbial load might 
escape and repopulate the diseased lesions in the host (9). RIF is known to induce 
cytochrome P450 isoenzymes ( e.g., CYP 3A4, involved in the elimination of CLA), 
while CLA is also known to inhibit the enzyme activity of CYP 3A4 (3, 18). The 
P-glycoprotein (Pgp) efflux transporter is also affected, as RIF induces and is the 
substrate of Pgp and CLA inhibits Pgp (7, 1 4). Earlier studies with patients with 
M. avium infections showed an induction of metabolism of CLA, but the data on 
I 4OH-CLA were not consistent between the two studies (28, 37). The purpose of 
the present study was to assess the influence of this CLA-RIF interaction on the 
areas under the plasma concentration-time curves (AUCs) for the 4SR/4CR study 
arm and to compare those AUCs to the AUC for RI F in patients who were treated 
in the 8SR study arm. In addition, the average time that plasma drug concentrations 
were maintained in excess of the MIC was studied. 
Materials and methods 
The open-label prospective pharmacokinetic study described here evaluated 
the pharmacokinetics of RIF and RIF combined with CLA in the treatment of 
Mycobaeterium ulcerans disease in patients already enrolled in the BURULICO trial. 
The study was conducted at the Nkawie-Toase Governmental Hospital and at the 
Agogo Presbyterian Hospital, both in the Ashanti region of Ghana. 
Study subjects 
Patients � IO years of age (male and female) were eligible for inclusion in this side 
study to assess the pharmacokinetics of clarithromycin and rifampin when they were 
allocated to the 4SR/4CR arm and the pharmacokinetics of rifampin when they 
were allocated to the SSR arm. Exclusion criteria for the BURULICO trial were 
treatment with macrolide or quinolone antibiotics, antituberculosis medication, or 
immunomodulatory drugs (including corticosteroids) within the previous I month; 
current treatment with any drugs likely to interact with the study medication, e.g., 
anticoagulants, cyclosporine, phenytoin, oral contraceptives, and phenobarbitone; a 
history of hypersensitivity to rifampin, streptomycin, and/or clarithromycin; and an 
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inability to take oral medication or the presence of a gastrointestinal disease likely 
to interfere with drug absorption. 
Drug administration 
Patients received CLA at a dose of 7.5 mg/kg once daily, which was rounded to the 
nearest 125 mg. RIF was administered at a dose of I O  mg/kg, which was rounded 
to the nearest 150 mg. The drugs were administered on an empty stomach, but the 
participants were allowed to take a light standardized breakfast after drug ingestion. 
Although food intake does not influence the AUC of CLA (8), it influences the 
AUC of RIF (39). By offering a standardized light breakfast approximately 30 min 
after drug ingestion, the effect on drug absorption would be minimized and equally 
distributed over both groups.The adherence to the treatment regimen was I 00%, as 
the participants were in a guided patient program. 
Pharmacokinetic assessment 
On the day of this PK study, a full pharmacokinetic curve was recorded at steady 
state after a minimum of 7 days of consecutive treatment with the same dose. Blood 
samples (2 ml, EDTA anticoagulant) were obtained before a dose of CLA-RI F  or 
RIF was administered (time zero) and at 0.5, I ,  1.5, 2, 2.5, 3, 5, 7.5, and I O  h after 
administration of the dose. This schedule was based on earlier data ( 17, 29), with the 
restriction that the participants in the present study had to be able to return to their 
homes (often, in remote rural villages) on the evening of the sampling day. Plasma was 
separated and frozen at 20°C until it was processed. 
Analytical methods 
The plasma concentrations of RIF and 25-desacetylrifampicin (25DA-RIF) and of 
CLA and I 4OH-CLA were determined at the Laboratory for Clinical Toxicology 
and Drugs Analysis of the Department of Hospital and Clinical Pharmacy of the 
University Medical Center Groningen, Groningen, Netherlands, using a validated 
liquid chromatography-tandem mass spectrometry (LC/MS/MS) assay ( 13). 
Pharmacokinetic analysis 
The values of the pharmacokinetic parameters were calculated using the KINFIT 
program (MW/Pharm, version 3.60; Mediware, Netherlands) (31 ). C!IUlZ was defined 
as the highest observed serum concentration, and Tmax was the time corresponding 
to C . C . was the serum concentration before intake of the dose. The AUC from 
max m,n 
time zero to 24 h (AUCo.-24) was calculated using the log-linear trapezoidal rule. 
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The elimination half-life (t 112) was calculated by 0.693/ke,. The apparent clearance of 
the drug (CUF) was calculated as the dose/AUC0--24, and the apparent volume of 
distribution (VIF) was calculated as the dose/concentration at steady state. 
For both treatment groups, a population one-compartment model with first-order 
absorption pharmacokinetics with lag time was generated using the RIF dose, the 
body surface area of the participants, and the observed RIF serum concentrations 
in an iterative two-stage Bayesian procedure (31 ). Pharmacokinetic parameters 
were assumed to be log-normally distributed. Residual error was assumed to be 
distributed normally with a standard deviation (SD) of 0.1 + (0.25 x q, where C is 
the serum rifampin concentration. Since the participants received RIF only orally, 
bioavailability could not be assessed and was fixed at a value of I ,  as the bioavailability 
of RIF is nearly complete. 
Bacteriologic assessment 
The Ml Cs of CLA and I 4OH-CLA were determined by the agar proportion method 
on Middlebrook 7H I I agar at pH 6.6 supplemented with I 0% oleic acid-albumin­
dextrose-catalase. For both drugs, 2-fold concentrations ranging from 0.125 to 8 
mg/ml were tested using two different strains of M. u/cerans: strain I 059, a recent 
human isolate from Ghana (38), and strain 1615 (ATCC 35840), a well-characterized 
Malaysian human isolate ( 16). The strains were subsequently passaged in mice in a 
laboratory at Johns Hopkins University School of Medicine. These reference strains 
instead of test isolates from our patients were used, as isolation of M. ulcerans by 
culture has a very low yield (21 ). Bacillary suspensions adjusted to an optical density 
at 600 nm of 1.0 were diluted to I o-s in phosphate-buffered saline; and 0.5 ml of each 
of the I 0- 1 , I 0-3, and I o-s dilutions was inoculated onto plates with and without drugs. 
The plates were then incubated at 32°C, and the colony counts were read 2 and 3 
months later.The MIC was defined as the lowest drug concentration inhibiting �99% 
of the colony counts on the control plates. 
Statistical methods 
Data are presented as median values and interquartile ranges (IQRs). Differences in 
age, body mass index, and the values of the pharmacokinetic parameters between 
the patients groups were assessed with the Wilcoxon rank-sum test (Mann-Whitney 
U test) for unpaired data.A sample size of IO was estimated to be needed to detect 
peak CLA concentrations of >0.5 mg/liter in 80% of the patients with a statistical 
power of 80% and a significance level of 5%.A sample size of five was estimated to be 
needed to detect a 20% increase in the RIF concentrations in the presence of CLA 
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compared to the RIF concentrations in the group treated with RIF and streptomycin 
with a statistical power of 80% and a significance level of 5%. 
Ethics 
The present study was a side study of a randomized trial (ClinicalTrials.gov identifier 
NCT0032 I 178).As for the main study protocol, written and verbal informed consent 
was obtained from participants of I O  years and over and from their custodians if they 
were below 18 years of age. The protocol for the present study was also approved 
by the local institutional ethics committees of the Kwame Nkrumah University of 
Science and Technology and the Komfo Anokye Teaching Hospital. Only individuals 
over age I O  years were eligible for participation in the present study. All study 
participants gave informed consent after being given an appropriate amount of time 
to consider their participation; a small incentive in cash and kind was offered, and 
for participants aged between I O  and 18 years, their parents or caretakers also gave 
written informed consent. 
Results 
Study subjects 
Thirteen patients ( 12 females and I male) were included in the present study: 8 
were in the 4SR/4CR arm and 5 were in the SSR arm. The baseline age, body weight, 
and body mass index characteristics were similar for the two groups. The patient 
characteristics are presented in Table I .  Twelve of 13 patients had Buruli ulcer 
lesions, as confirmed by 1S2404-based PCR (21 ). The Buruli ulcer lesions of these 
12 patients were completely reepithelialized within the time frame of the study 
(healing without a recurrence within I year after inclusion). The one unconfirmed 
lesion-a nodul�in a patient treated with SSR was excised 2 weeks after the end 
of treatment because another diagnosis was suspected. After excision, that patient 
also tested 1S2404-based PCR positive. 
Bacteriologic assessment 
The MICs of CLA were 0.25 mg/liter and 0.50 mg/liter for M. ulcerans I 059 and M. 
ulcerans 1 61 5, respectively. The MICs of I 4OH-CLA were 4 mg/liter and 8 mg/liter 
for M. ulcerans I 059 and M. ulcerans 1615, respectively. For both strains, the MIC of 
I 4OH-CLA was 16 times higher than that of CLA. 
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Pharmacokinetic study 
The patients in both study arms received the same dose of RIF per kg of body 
weight.The patients in the 8SR study arm received RIF at a dose of 8.8 mg/kg (IQR, 
8.6 to I 0.0 mg/kg) once daily, which was not significantly different from the RIF dose 
of 8.8 mg/kg (IQR, 8.4 to I 0.8 mg/kg) administered in the 4SR/4CR study arm (P = 
0.70). The patients had received the study medication for a median duration of 50 
days (IQR, 29 to 55 days) before blood samples were drawn.The RIF concentration­
time curves of both arms are displayed in Figure I . The CLA concentration-time 
curve is displayed in Figure 2. The values of the pharmacokinetic parameters of the 
two treatment arms are summarized in Table 2. Although the difference was not 
statistically significant (P = 0.09), the median increase in theAUC0--24 value for RIF was 
60% if theAUC0--24 of 25.9 mg • h/liter (IQR, 21.9 to 31.5 mg • h/liter) for the patients 
in the 4SR/4CR arm was compared to the median AUCa-24 value of RIF of 16.2 mg • 
h/liter (IQR, 15.0 to 17.6 mg • h/liter) for patients in the BSR arm. 25DA-RIF could 
be detected in only 5/ I 3 patients.The geometric mean AUC ratio of CLA to I 4OH­
CLA was 0.33 (range, 0.22 to 0.39). Population pharmacokinetic analysis showed 
that apparent clearance of RIF was (not significantly) reduced in patients who also 
received CLA but was due to interpatient variability in both groups (P = 0.17) (Table 
3).The median AUC/MIC ratio of RIF was 52 (IQR, 44 to 63) in patients treated with 
CLA as well, which was 63% higher (P = 0.09) than the median AUC/MIC ratio of 32 
(IQR, 30 to 35) in patients treated with RIF and SM. 
Table I: Baseline characteristics 





4SR/4CR (n=B) SSR (n=S) 
26.0 ( 1 3 .5-4 1 .0) 26.5 ( 1 9.5-36.3) 
0/8 1 /4 
53.5 (5 1 .5-56.5) 45.0 (35.0-60.0) 
1 8.7 ( 1 5.2-22.0) 20.5 ( 1 9.0-22.9) 





0. 1 7  
The times the concentrations remained above the MIC of CLA were 300, 210, 180, 
285, 300, 30, 300, and 90 min above 0.25 mg/liter and 170, I 05, I 0, 135, 190, 0, 200, 
and 0 min above 0.5 mg/liter for each patient. This resulted in median times that the 
concentration was above the MIC of 0.25 mg/liter and 0.5 mg/liter of 248 min and 
120 min, respectively. In two of the patients, the concentration never reached the 
MIC of 0.5 mg/liter. The concentration of I 4OH-CLA was never above MICs of 4 
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FIG. I: RIF/25DA-RIF concentration-time curve. Mean (standard error) plasma concentration­
time curves for RIF (solid symbols) and 25DA-RIF (open symbols) from the 4SR/CR4 arm (circles) 
and SRS arm (triangles) are shown. 
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FIG. 2 :  CLA/ I 40H-CLA concentration-time curve. Mean (standard error) plasma concentration­
time curves for CLA (solid circles) and 1 40H-CLA (open circles) from the 4SR/CR4 arm are 
shown. 
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0 . 6  0 . 6 2  
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1
, 2  
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2 . 1  ( 2 . 0  - 2 . 2 )  2 . 2  ( 1 . 3 - 3 . 1 )  
2 . 3  ( 1 . 9 - 2 . 4 )  0 . 1  0 . 3 5  
C U F  ( l i t e r / h )  8 9 . 2  ( 6 8 . 8  - 1 5 1 )  3 0 . 9  (  1 9 . 7  - 4 1 . 3 )  
I  1 . 9  ( 8 . 8  - 1 5 . 2 )  I  3 2  (  I  0 9  - I  5 6 )  I  8 . 5  (  1 7 . 0  - 2 1 . 1 )  
8 9 . 7  0 . 0 9  
V / F  ( l i t e r )  
1 7 4  (  1 4 4  - 2 1 4 )  1 4 1  (  I  1 7  - 2 3 0 )  
3 8 . 1  ( 2 6 . 4  - 5 0 . 8 )  4 2 5  ( 2 4 3  - 6 3 2 )  
5 8 . 6  ( 5 7 . 4  - 5 9 . 8 )  1 3 . 5  
0 . 2 7  
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Discussion 
The present study investigated the interaction between RIF and CLA in patients infected 
with M. u/cerans as part of a prospective randomized trial comparing two drug regimens. 
We observed that the median total RIF exposure was increased 60% in patients receiving 
CLA compared to that in patients receiving RIF combined with SM.This may be explained 
by the inhibitory effect of CLA on the Pgp-mediated efflux of RIF and not by the inhibitory 
effect of CLA on CYP3A4, as RIF is not a CYP 3A4 substrate. 
Our study had a relatively small sample size. and due to the high degree of variability in 
the results, only a trend toward significance could be shown.Although the difference 
was not significant in our study, it might sti l l  be relevant for clinical practice, as 
the increased exposure to RIF could have contributed to the efficacy of the drug 
treatment because the RIF AUC/MIC ratio is one of the best parameters predicting 
the efficacy of treatment of infections caused by Mycobaeterium tuberculosis (23). No 
differences in the concentration of 25DA-RIF were seen between the treatment 
arms. Due to the low of level exposure of 25DA-RIF in plasma, no additional 
bactericidal effect can be expected. The only effect of this metabolite may be 
expected in human bile, in which it tends to accumulate (22). The effect of RIF on 
CLA is more difficult to explain, as the present study lacked a study arm without 
RIF. We observed that the level of exposure to I 4OH-CLA was significantly higher 
than that to CLA.The median I 4OH-CLA concentration-time curve (Fig. 2) is higher 
than the median CLA concentration-time curve for the time period observed. This 
indicates that the metabolism of CLA to I 4OH-CLA is induced by RIF, as the I 4OH­
CLA concentration-time curve is higher than the CLA concentration-time curve. 
This is consistent with the findings of earlier studies (28, 37).The ratio of the parent 
drug to metabolite is, however, less than that reported earl ier (28). 
The results of our study are in l ine with the observations of the interaction of 
CLA and rifabutin (RBN), which has been studied in vol unteers infected with H IV. 
Rifabutin, l ike rifampin, induces Pgp and the CYP 450 system, but less profoundly than 
RIF does (2). In the present study, the CLA-RBN interaction resulted in a significantly 
decreased AUC for CLA compared to that before the introduction of RBN, but the 
I 4OH-CLA concentration increased significantly along with a significant increase in 
RBN drug concentrations ( 1 9).  
Our results are consistent with earlier data that the ratio of the C of CLA to the max 
Cmax of I 4OH-CLA is reduced to a greater extent when CLA is combined with RIF 
(28) than when RBN is combined with RIF (37) and no inducer is coadministered. 
The major concern in the case of these drug-drug interactions is that the resulting 
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antibiotic exposure is not efficacious due to the altered plasma concentrations. The 
decrease in CLA levels must therefore be compensated for by the increase in I 4OH­
CLA level and can be expressed as the ratio of the CLA level/ I 4OH-CLA level. 
Whether the observed ratio is sufficient for efficacious treatment depends on the 
in vitro susceptibility of the targeted microorganism to both CLA and I 4OH-CLA. 
In our study we observed that the concentration of CLA in plasma was above the 
MIC of 0.25 to 0.5 mg/liter for M. u/cerans for a median period of at least 1 20 to 
248 min.As the MIC for 14OH-CLA was 4 to 8 mg/liter, it was presumed that only 
CLA contributed to the bactericidal activity of the agent, as the level of exposure 
to I 4OH-CLA was always below the MIC. In other bacterial infections, CLA can be 
efficacious if the concentration is above the MIC for some part of the dosing interval 
( I ). The time above the MIC for CLA therefore seems to be less important than 
it is for, e.g., beta-lactam antibiotics and is difficult to correlate with efficacy ( I ). In 
addition, the plasma concentration of CLA does not necessarily reflect its intracellular 
bactericidal efficacy, as efficacy depends on the distribution of the antibiotic into the 
tissue and cells (6). Although the CLA concentration in the interstitial fluid of the 
skin might be lower than that in plasma (35), the concentrations of CLA in cells are 
expected to be higher than those in plasma (32). 
The present study was limited by the fact that neither the distribution of the antibiotic 
into the tissue and cells nor the concentration in the interstitial fluid of the skin was 
determined. On the basis of the results of the BURULICO trial, both CLA and RIF 
exposures appeared to be sufficient for the treatment of M. u/cerans infection, as 
no significant difference (one-sided Fisher's exact test, P = 0. 1 6) in the healing rate 
was observed between the 8SR (96%) and 4SR/4CR (91 %) arms (26). As 5 of the 
75 subjects treated with CLA appeared to be positive for M. ulcerans as a result of 
the non-protocol-driven testing of samples by culture, there are still some doubts 
about the total antibiotic exposure.Although the coadministration of RIF resulted in 
a lower level of CLA exposure, it should be mentioned that CLA was given at a low 
dose of 7.5 mg/kg once daily. During the design of the randomized controlled trial, 
concerns about the safety of CLA at a dose of 7.5 mg/kg twice daily resulted in the 
use of this dosage scheme. 
On the basis of these clinical results, it might be hypothesized that RIF was 
effective in reducing the M. ulcerans bacterial load or at least stopping mycolactone 
production, while CLA prevented the emergence of microorganisms resistant to RIF 
(25). The contribution of CLA is uncertain, however, and measuring the intracellular 
concentrations CLA would be the best method to assess the combined extra­
and intracellular exposures of M. ulcerans to CLA. Animal (mouse) model studies 
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of M. ulcerans infection have evaluated only the correlates between dosages and 
the bacteriological response and cl inical effects, especially in the footpad model ( I I ,  
1 2, 24). Future animal studies should address PK aspects, along with these cl inical 
and bacteriological responses, to develop PK/pharmacodynamic models for the 
prediction of outcomes. 
Table 3. Rifampin population pharmacokinetic model parameters valuesa 
Parameter 
CL (liters/hi 1 .85 m2) 
Yd (liters/kg LBMc) 
ka (h-1 )  
T tag (h) 
Result (mean ± SD) for each treatme�t arm 
4SR/4CR SSR 
24. 1 ±  9.8 
1 . 1 9  ± 0.2 1 
0.998 ± 1 .35 
2.07 ± 0.55 
37.3 ± 5.5 
1 .43 ± 0. 1 0  
0.807 ± 0.574 
1 .52 ± 0.86 
a Oral bioavailability was fixed at a value of I for both treatment arms. 
P value 
0. 1 7  
0. 1 7  
0.83 
0.44 
b LBMc, lean body mass; k
3
, absorption rate constant; T,.g• lag time; the other abbreviations are 
defined in the text. 
In further cl inical studies, a regular CLA dose of 7.5 mg/kg twice daily or a CLA slow­
release formulation at a dose of 1 5  mg/kg once daily should be used to ensure h igher 
levels of exposure to CLA and increase the time above the MIC compared to those 
achieved with the currently used dose of 7.5 mg/kg once daily, which appeared to be 
safe and well tolerated. 
Conclusion 
Combination of RIF and CLA resulted in a considerable but nonsignificant increase 
in plasma RIF levels compared to the RIF levels achieved with coadministration of 
RIF and SM.A decrease in plasma CLA levels and an increase in plasma I 4OH-CLA 
levels were observed, but the time that the concentrations of CLA in plasma were 
above MIC of M. ulcerans was reached for at least a part of the day. 
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In their Article on antimicrobial therapy for early, limited Mycobaeterium u/cerans 
infection in Ghana (Feb 20, p 664), 1 Willemien Nienhuis and colleagues conclude 
that 4 weeks of streptomycin plus rifampicin followed by 4 weeks of rifampicin and 
clarithromycin has similar efficacy to 8 weeks of streptomycin and rifampicin. Some 
concerns about the use of clarithromycin in Buruli ulcer need discussing. 
Treatment failure was higher in the 4-week streptomycin plus 4-week clarithromycin 
group than in the 8-week streptomycin group. Mycobacterium spp carry many 
macrolide resistance traits in their chromosomes and can confer high resistance 
to clarithromycin after exposure to similar classes of drug.2 One study in a mouse 
model revealed that, when given at a daily dose of I 00 mg/kg ( equivalent to I g 
per day in human beings), clarithromycin had an obvious bacteriostatic activity: the 
growth of M ulcerans in mice treated with clarithromycin was significantly delayed 
compared with that in control mice. 3 However, since the activity was not bactericidal, 
one may question the potential practical value of clarithromycin in the treatment of 
M u/cerans infection in human beings.The high rate of treatment failure in the 4-week 
clarithromycin group in Nienhuis and colleagues' study could reflect this limitation. 
Moreover, it is now generally accepted that a major protective antigen present in 
the Bacille Calmette-Guerin (BCG) vaccine is the so-called Ag85 complex which has 
84% sequence identity and 91 % similarity with M u/cerans Ag85A proteins.4 Logically, 
then, BCG-vaccinated patients should recover more quickly from Buruli ulcer than 
non-vaccinated individuals. 
I have been supported by the Canada Institute of Health Research. I declare that I 
have no conflicts of interest. 
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We appreciate and to a large extent share the concern of  Dewan Billal about the 
role of clarithromycin in the management of Buruli ulcer disease.Although patients 
who switched to oral treatment with rifampicin and clarithromycin had a statistically 
similar beneficial response to treatment, assessment of the added effect (if any) of 
clarithromycin is impossible. Indeed, presently the duration of therapy necessary to 
switch off mycolactone production and allow the immune system to recover and 
clear residual bacteria is unclear. Basically, we added clarithromycin to include an oral 
drug that was tested in vitro ' to prevent monotherapy with rifampicin and to limit 
the number of streptomycin injections. During the trial, in-vivo data were published 
that supported this choice.2 
We used a dose of 7 ·5 mg per kg bodyweight, once daily, as approved by the US 
Food and Drug Administration (FDA) and the European Medicines Agency (EMA). 
Our concern was that rifampicin co-medication might lower clarithromycin plasma 
concentrations by inducing cytochrome P450 isoenzymes. Preliminary data from 
a substudy suggest that clarithromycin drug concentrations are lower than the 
14-hydroxy metabolite of clarithromycin.3 Further more, preliminary results suggest 
that this metabolite does not con tribute to the antimicrobial activity against M 
u/cerans. Yet the median concentration of clarithromycin was above the minimal 
inhibitory concentration (MIC)-between O ·5 and 2 -0  mg/L for most M u/cerans 
strains tested.4 One should also consider accumulation of macrolide drugs in immune 
cells that might add to the clinical response seen, but the relatively short time above 
MIC for extracellular microorganisms is a concern if we are to consider testing a 
fully oral treatment schedule. 
Although we did not examine BCG scars in our study participants, most children in 
Ghana receive BCG vaccination in the first week after birth; the protection by BCG 
vaccination is short-lived and rather weak.5 BCG vaccination status is therefore 
unlikely to present a bias for the beneficial effect of antimicrobial treatment in both 
study groups. 
Eventually, a fully oral treatment would be highly desirable. Before a trial is undertaken, 
an extended-release formulation of clarithromycin combined with rifampicin, 
approved by the FDA and EMA, should first be tested.With this information, we can 
select the best possible rifampicin-based combination regimen for oral treatment, 
and compare it with the present WHO-standard regimen of 8 weeks of streptomycin 
injections plus rifampicin. 
We declare that we have no conflicts of interest. 
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Chapter 4 
Summary 
Background Antimicrobial killing in mycobacterial infections may be 
accompanied by (transient) clinical deterioration, known as paradoxical 
reaction. To search for patterns reflecting such reactions in the treatment 
1 of Buruli ulcer (Mycobaeterium ulcerans infection), the evolution of lesions of 
· I  
76 
patients treated with antimicrobials was prospectively assessed. 
Methods The lesion size of participants of the BURULICO antimicrobial 
trial (with lesions s IO cm cross-sectional diameter) was assessed by careful 
palpation and recorded by serial acetate sheet tracings. Patients were treated 
with antimicrobials for 8 weeks. For the size analysis, participants whose 
treatment had failed, had skin grafting, or were co-infected with human 
immunodeficiency virus were excluded. For every time point, surface area 
was compared with the previous assessment. A generalized additive mixed 
model was used to study lesion evolution. Nonulcerative lesions were studied 
using digital images recording possible subsequent ulceration. 
Results Of 151 participants, 134 were included in the lesion size analysis. 
Peak paradoxical response occurred at week 8; over 30% of participants 
showed an increase in lesion size as compared with the previous (week 6) 
assessment. Seventy-five of 90 (83%) of nonulcerative lesions ulcerated after 
start of treatment. Nine participants developed new lesions during or after 
treatment.All lesions subsequently healed. 
Conclusions After start of antimicrobial treatment for Buruli ulcer, new 
or progressive ulceration is common before healing sets in. This paradoxical 
response, most prominent at the end of the 8-week antimicrobial treatment, 
should not be misinterpreted as failure to respond to treatment. 
Clinical Trials Registration ClinicalTrials.gov, NCT0032 I 178. 
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Introduction 
Buruli ulcer (BU), caused by Mycobacterium ulcerans, is  a devastating mycobacterial 
disease [ 1 -3]. It is the third most common mycobacterial infection in immuno­
competent humans after tuberculosis and leprosy, and BU even outnumbers these 
infections in some areas in West Africa. Although most commonly seen in children, 
all age groups can be affected. It starts as a nodule, papule, plaque, or edema. If 
progressive, the skin breaks down and a typical painless ulcer appears with a necrotic 
center and undermined edges, surrounded by an indurated area. Surprisingly few 
patients present with accompanying systemic responses such as fever and malaise, 
even though ulcers may cover a substantial part of the body. Treatment, until recently, 
has been wide surgical excision of affected skin and surrounding normal tissue. In 
the past, antibiotics have been largely abandoned on the basis of disappointing field 
observations [4]. In a pilot study with antimicrobial end points, combination therapy 
with streptomycin and rifampicin was effective, and subsequent case series showed a 
beneficial clinical response [S, 6]. In the BU RU LICO trial we showed that early, limited 
BU lesions heal with antimicrobial treatment alone, without surgical debridement, in 
.90% of cases [7]. An additional 3 reports have supported the beneficial effects of 
antimicrobial therapy, 2 of them including larger lesions as well [8- 1 O]. 
In tuberculosis and leprosy, effective antimicrobial killing may be accompanied by 
(transient) clinical deterioration [ I 1 - 1 3]. In these diseases the deterioration is known 
as a paradoxical or a reversal (type I )  reaction.A paradoxical reaction in tuberculosis 
is defined as a transient worsening of a preexisting lesion or the development of 
new lesions under appropriate therapy-some definitions incorporating initial 
improvement-affecting 2.4%- 1 0% of individuals at time point 8- 1 0  weeks (median) 
after start of treatment [ 1 2, 1 4, I S]. The incidence of paradoxical reactions, which 
has also been described in intracerebral tuberculomas [ 1 2, 1 6], is probably highest in 
lymph node tuberculosis [ 1 1 ,  1 7].These reactions have been attributed to increased 
exposure to mycobacterial antigens, a decrease in suppressor mechanisms, or 
improved host cell-mediated immunity following bactericidal therapy [ I I ,  I S]. 
In the BURULICO trial [7], participants were followed up by analyzing serial surface 
area measurements of lesions and by digital imaging. Here we describe and compute 





In the present analysis we included a subset of participants of the BURULICO drug 
trial, a randomized controlled trial for the treatment of early (duration <6 months}, 
limited (cross-sectional diameter s I O  cm) M. ulcerans infection. Polymerase chain 
reaction (PCR) was the planned confirmation test for M. u/cerans infection, which 
was achieved in 95% of all participants. We compared 8 weeks of treatment with 
streptomycin and rifampicin, with 4 weeks of treatment with streptomycin and 
rifampicin followed by 4 weeks of rifampicin and clarithromycin. 
The primary outcomes of this trial have been reported elsewhere [7]. To study the 
lesion evolution during effective antimicrobial treatment, defined as healed by week 
52, participants whose treatment had failed, had skin grafting, or were coinfected 
with human immunodeficiency virus (HIV) were excluded. Treatment failure was 
recorded if a lesion had not healed by 52 weeks, lesion recurred within I year, or 
lesion size increased to 1 50% at any time point compared with baseline, with surgical 
debridement undertaken as deemed necessary by the attending doctor.The trial was 
conducted at 2 different hospital sites in the Ashanti region of Ghana. 
Study design 
To determine the pattern of healing in response to antimicrobial treatment, lesions 
were examined by inspection followed by careful palpation.The lesion circumference, 
as assessed by the above methods, was recorded on serial acetate sheet tracings, and 
digital images were made of each participant's lesion. Participants were treated for 8 
weeks and followed up for I year after start of treatment.Acetate sheet tracings and 
digital images were made at start of treatment, and at week 2, 4, 6, 8, I 0, 1 2, 1 6, 20, 24, 
28, 32, 36, 44, and 52, until complete healing (defined as complete reepithelialization) 
occurred. For participants with more than I lesion, only the largest was measured. 
Methods of measurements 
The members of the BU study teams that drew the lesions were instructed to palpate 
the extent of the indurated area around the visible skin defect and to include this 
induration in the tracing. Before treatment was started, from every non-ulcerated 
lesion 3 3-mm punch biopsies were taken under local anesthesia for diagnostic 
confirmation, including culture, microscopy, PCR [ 1 8] ,  and histopathology. From 
ulcerated lesions, in addition to punch biopsies, diagnostic swabs were taken [7].The 
acetate sheet recordings were disinfected and stored in the patient record files. At 
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the end of the study all sheets were scanned, and the surface area was calculated for 
every individual lesion at the different time points, using Adobe Photos hop (version 
CS3 Extended). Digital camera images were uploaded and stored in anonymized 
patient folders. 
Analysis of data 
Results of participants of the 2 antimicrobial regimens were taken together, as no 
significant differences were found for overall heal ing (heal ing at I year after start of 
treatment without recurrence or large debridement surgery) and time to heal ing. 
To precisely evaluate the effect of treatment, ongoing heal ing was recorded by 
comparing every lesion measurement to the preceding assessment and arranging 
them in I of 3 groups: ( I )  lesion size increased compared with last assessment, (2) 
size decreased compared with last assessment, and (3) lesion healed. 
Results were plotted over time. Generalized additive mixed models (GAMM) 
analysis [ 1 9] was used to create best-fitting curves for mean rate of heal ing over 
time, with allowance for group-specific and subject-specific smooth deviations and 
missing values. GAMM is a fixed-effects regression model with random-effect terms 
in addition to the fixed effects and with unknown smooth functions of some of the 
covariates making it appropriate for analyzing clustered-and therefore dependent­
data sampled over time, with missing values and with a nonlinear course (smooth) 
of the dependent variable with time. As basis functions, the truncated powers basis 
with 1 4  knots was used, with 90% confidence intervals (Cls) based on a bias-adjusted 
approximation of the covariance matrix. 
Lesions that were not measured because they were larger than the sheets used 
for drawing were analyzed as "previous size measurement + I ." Type of treatment 
combination, ulceration, and lesion category at inclusion were explored as possible 
influencing factors on lesion evolution. Category I comprises lesions <5 cm, category 
II lesions between 5 and I O  cm, and category I l l  lesions > I O  cm, multiple lesions, or 
lesions at critical sites. Several definitions of a paradoxical increase in surface area 
were depicted and percentages of participants were calculated meeting these criteria 
for every time point and for the overall study period.The percentage of participants 
with non-ulcerative lesions that subsequently ulcerated was calculated. Data were 
analyzed and figures drawn using SPSS software (version 1 6.0, IBM SPSS) and R 
software (R version 2. 1 3 .0, R Foundation for Statistical Computing) and Package 




The Medical Ethics Review Committee of the University Medical Centre Groningen, 
the Netherlands, reviewed the protocol of the trial. The protocol was approved by 
the Committee on Human Research, Publication, and Ethics of the Kwame Nkrumah 
University of Science and Technology and the Komfo Anokye Teaching Hospital, 
Kumasi (CHRPE/07/01/05), and by the Ethical Review Committee of Ghana Health 
Services (GHS-ERC-0 I /0 I /06). Written and verbal informed consent or assent was 
obtained from all participants aged :2:: 12 years, and consent from parents, caretakers, 
or legal representatives of participants aged � 1 8  years. 
Table I :  Baseline characteristics of the participants included in the Mycobacterium u/cerans lesion 
size analysis (n= 1 34) 
Sex. male 




Lesion surface area, cm2, median (IQR) 
Category of lesion at inclusion 
I 
I I  
I l l 




8 weeks streptomycin/rifampin 
4 weeks streptomycin/rifampin and 4 
weeks clarithromycin/rifampin 
Abbreviation: IQR, interquartile range. 
Results 
Patient population 
-��- (%) (n = 1 34) 
4 1  (3 1 )  
1 2  (8-20) 
95 (7 1 )  
39 (29) 
25 (9-45) 





69 (5 I )  
65 (49) 
Table I shows baseline characteristics of the participants. Of the 151 part1c1pants 
included in the BURULICO antimicrobial trial, 17 were excluded: I O  who had 
experienced treatment failure; 3 who were coinfected with HIV (of whom I 
experienced treatment failure) ; and 5 who had received skin grafts. Therefore, 1 34 
participants were included for the acetate sheet measurements analysis. Of those, 129 
(96%) were confirmed BU patients ( 124 by PCR; 3 by culture; I by histopathology; I 
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by microscopy). Five (4%) were not confirmed. Sixty-three of 134 participants (47%) 
missed at least I of the I 5 scheduled assessments. One participant's lesion was not 
measured at I time point because of the extent and was included as described in 
the Methods. 
cate o I 
� 
� 
I ,;.  
., -0 
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Figure I :  Course in surface area measurements of Mycobacterium ulcerans lesions plotted for 
every individual during and after 8 weeks of antimicrobial therapy. The number of M. u/cerans 
participants analyzed is 1 34 (all healed trial participants except skin-grafted and human immuno­
deficiency virus-coinfected persons). Category I (n = 55) is lesions < than 5 cm, category I I  (n = 
77) is lesions between 5 and I O  cm, and category I l l  (n = 2) is lesions > I O  cm, multiple lesions, or 
lesions at critical sites. 
Evolution of BU lesions during and after treatment 
Figure I shows the changes in lesion surface area plotted for every individual 
participant per lesion category. Figure 2 shows the percentage of participants in the 
3 different groups (increased, decreased, or healed) for every time point, including 
the number of missing assessments.After 2 weeks of treatment, approximately 18% 
of the lesions showed an increase in size compared with the previous assessment. 
T his percentage increased by approximately 30% at weeks 8, I 0, and 12. T he highest 
percentage of individuals with increased lesion size was recorded at week 8, with 
8 1  
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r&l1ncreased 1n size 
Figure 2: Patterns of response of M. u/cerans lesions during and after 8 weeks of antimicrobial 
therapy. Total count of lesions that showed complete healing (gray), an increase (hatched) or a de­
crease (white) in size as compared with the previous assessment, and missing assessments (black) 
are shown. The number of M. ulcerans participants analyzed is 1 34 (all healed trial participants 
except skin-grafted and human immunodeficiency virus-coinfected persons). 
Overall, I 05 of 134 participants (78%) showed an increase in lesion size compared 
with the preceding assessment, at some point in time. Increase in lesion size in 
excess of size at start of treatment was recorded in 40 of 134 participants (30%). 
Increase in lesion size in excess of 150% was recorded in 19 of 134 participants 
( 14%). According to the protocol, these 19 participants were discussed with the 
attending medical staff for possible debridement surgery, but as the overall clinical 
assessment was not unfavorable, with decrease in wound depth, edema, and necrosis, 
they were not operated on. Overall, healing was steady but slow. 
Table 2 shows the percentages of participants who met various exploring criteria 
that defined paradoxical responses in the pattern of healing. For example, when 
using an increase in surface area after a decrease in the preceding measurement, 
approximately 16% of participants met the definition at week I O  (measured at weeks 
8 and I 0) and week 12 (measured at weeks I O  and 12). Using the stricter criterion 
of 2 consecutive increases after I decrease, 7.5% of participants met the definition 
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figure 3: Generalized additive mixed model analysis for mean lesion surface area, for lesion 
category subgroups (with smooth subject-specific deviations from group specific curves; see text 
for details). The dotted lines show the upper and lower 90% confidence intervals. The number of 
M. u/cerans participants analyzed is 1 34 (all healed trial participants except skin-grafted and human 
immunodeficiency virus-coinfected persons).The number of category I M. ulcerans lesions was 55; 
the number of category I I  and Il l lesions was 79. 
Non-ulcerative lesions with subsequent ulceration before healing 
and new lesions 
Ninety-two of the 1 5 1  participants in the BURULICO anti-microbial trial had non­
ulcerative lesions. From these, 2 had treatment failure and 2 were HIV co-infected. 
Of the remaining 88 participants, 1 5  ( 1 7%) never had ulceration; they subsequently 
healed.The other 73 (83%) developed ulcers after a median period of 6 (interquartile 
range, 2-8) weeks but nonetheless healed subsequently (Table 3). Sixteen of these 73 
participants developed the ulcer after completion of antimicrobial treatment. Some 
participants reported increase of pain at the lesion site just before and at the time 
the lesion ulcerated. 
Disease-confirming punch biopsies were taken from at least I lesion of all included 
participants before start of treatment. Yet some participants had > I lesion ( only the 
largest lesion had a biopsy taken) or developed new lesions during or after treatment. 
Eleven participants had a total of 1 6  non-ulcerative lesions that were not biopsied. 
Ulceration l ikewise occurred in 1 5  of 1 6  lesions that did not have earl ier punch 
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biopsies; all of these lesions healed after the ulceration. One lesion was excised in a 
non-ulcerative state. T hirteen of 15 1 participants (9%) had > I lesion at any point in 
time. Four participants had > I lesion at start of treatment. In 5 participants, the second 
lesion became apparent during antimicrobial treatment. From 4 of these participants, 
swabs were taken at time of ulceration; 2 were microbiologically confirmed to be M. 
u/cerans lesions- I by PCR and I by microscopy. In 4 participants the second lesion 
appeared after treatment completion; I of these also developed a third lesion. From 
4 of these 5 lesions, swabs were taken when the lesion ulcerated; 2 were confirmed 
by PCR and I by culture.All of these lesions, except for I that was excised, ulcerated 
spontaneously and healed subsequently without further intervention. 
Table 2: Several definitions for paradoxical evolutions in surface area in ultimately healed partici-
pants with Mycobacterium ulcerans lesions per time point. 
I increase I increase in 2 increases 
I increase in SA after 2 increases SA after 2 in SA after I 
in SA, I decrease, in SA, decreases, decrease, 
Week No. (%) No. (%) No. (%) No. (%) No. (%) 
2 24 ( 1 7.9) 
4 2 1  ( 1 5.7) 1 4 ( 1 0.4) 7 (5.2) 
6 27 (20. 1 )  22 ( 1 6.4) 3 (2.2) 1 8 ( 1 3.4) 2 ( 1 .5) 
8 42 (3 1 .3) 3 1  (23. 1 )  8 (6.0) 27 (20.2) 6 (4.5) 
1 0  3 7  (27.6) 22 ( 1 6.4) 1 3  (9.7) 1 5  ( 1 1 .2) I O  (7.5) 
1 2  3 7  (27.6) 2 1  ( 1 5.7) 1 5  ( 1 1 .2) I O  (7.5) 9 (6.7) 
1 6  1 9  ( 1 4.2) I O  (7.5) 5 (3.7) 6 (4.5) 3 (2.2) 
20 8 (6.0) 7 (5.2) I (0.7) 2 ( 1 .5) 0 (0) 
24 9 (6.7) 7 (5.2) 2 ( 1 .5) 6 (4.5) 2 ( 1 .5) 
28 9 (6.7) 9 (6.7) 0 (0) 7 (5.2) 0 (0%) 
32 4 (3.0) 3 (2.2) 0 (0) 2 ( 1 .5) 0 (0%) 
Overalla I 05 (78.4) 94 (70. 1 )  39 (29. 1 )  76 (56.7) 3 1  (23. 1 )  
Criteria incorporate consecutive measurements. Percentages are taken from all healed trial 
participants except skin-grafted and human immunodeficiency virus-coinfected persons (n = 1 34). 
Missing measurements varied from 0.7% to 20. 1 % per time point. 
Abbreviation: SA, surface area. 
a Number of participants meeting the criterion at least once during the 52 weeks. 
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Discussion 
We describe a response pattern following antimicrobial therapy for BU that we 
characterize as paradoxical reaction.T his paradoxical reaction appears to be common 
and unexceptional. We show that during and shortly after anti-mycobacterial 
treatment for BU, 23% (using 2 consecutive measurements with an increase after I 
measurement with a decrease) to 78% (using I measurement) of lesions increased 
in size, and 83% of non-ulcerated lesions progressed to ulcers. Six percent of the 
participants enrolled developed lesions that were not clinically present at start of 
treatment. Eventually, all of these lesions healed within a follow-up period of I year. 
T he number of lesions that increased in size compared with the previous assessment 
peaked at weeks 8, I 0, and 12-just at the end of the 8-week treatment period. 
Paradoxical reactions in tuberculosis seem to appear around the same time [ 14, I 5]. 
Our results indicate that in BU, paradoxical reactions may be more common. It might 
also be that
l
the frequency of paradoxical reactions is comparable but more apparent 
in BU, because it affects the skin. Two studies that specifically looked at lymph node 
tuberculosis, in which paradoxical reactions are more objectively measurable than in 
pulmonary tuberculosis, reported transient enlargements in approximately 25% [ I I ,  
17], comparing more favorably with our results for BU.A recent publication on the 
efficacy of streptomycin combined with rifampicin in a study in Ghana also describes 
paradoxical responses, but not in the same frequencies as we describe [8]. 
Earlier observations in BU that lesions progress during antimicrobial treatment may 
have been misinterpreted as lack of antimicrobial killing. Two reports from Australia 
have suggested that paradoxical reactions in BU occur [20, 2 1  ]. In a trial in Uganda, 
the study drug, clofazimine, was probably not active; therefore, possible paradoxical 
reactions cannot be evaluated [22].T he paper, however, provides unique information 
on placebo-treated individuals-and those on clofazimine-that healed by virtue 
of their protective immune response without active drugs or surgery. Although 
participants had no disease confirmation, the spontaneous healing rate was 1 1  of 34 
participants (32%). In participants with non-ulcerated lesions who received placebo, 
I O  of I I participants progressed to ulcers before spontaneous healing occurred. In a 
drug trial for BU in which 2 months of rifampicin and dapsone were compared with 
placebo, lesion size was measured at 4 and 8 weeks after start of treatment [23]. Our 
results suggest that these time points may not be optimal to assess clinical success. 
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Table 3: Ulceration of non-ulcerative Mycobacterium ulcerans lesions after start of treatment in 
ultimately healed participants. 
Week New ulceration, No (%) 
2 24 (27.3) 
4 1 1  ( 1 2.5) 
6 1 0 ( 1 1 .4) 
8 1 2  ( 1 3.6) 
1 0  7 (&0) 
1 2  7 (&0) 
1 6  2 (2.3) 
No ulceration 1 5  ( 1 7) 
Of 88 healed, non-human immunodeficiency virus-infected participants with a nonulcerative lesion 
at start of treatment, ulceration occurred in 73 (83%) at a median time of 6 weeks after start of 
treatment (25th-15th percentiles: 2-8 weeks). 
We hypothesize that the transient clinical deterioration of lesions seen in our study 
is a result of restoration of local and systemic immune responses [24-27] . T he 
lesions that appeared and healed spontaneously during and after treatment probably 
reflect an inflammatory response as well; the live microbes-or microbial antigens of 
dead bacilli-already present in tissue initially failed to elicit a host immune response. 
Mycolactone, the exotoxin produced and secreted by M. u/cerans, has been proposed 
as the major cause of immune suppression [24, 26-29] . The immunosuppressive 
signature appears to wane over time following effective antimicrobial treatment 
[30, 3 I ], and we hypothesize that the pro-inflammatory response we describe as 
paradoxical response coincides with the wash-out of mycolactone from the lesion. 
This study is limited by the fact that 4 7% of participants missed at least I of the 
15 scheduled assessments. T he highest numbers of missing measurements occurred 
at weeks I O  and 12, the time points that showed the highest increases in surface 
area. This means that the number of participants with paradoxical patterns might be 
larger than described. By using a GAMM, we were able to include participants with 
missing data in the analysis. 
Another limitation is that measuring surface area of Buruli ulcers, which have an 
undermined edge and often a large indurated area, is difficult and not validated. A 
certain percentage of measurements will show an increase in surface area at the 
subsequent drawing, only by chance. However, stricter definitions (eg, ;a:2 consecutive 
measurements of increase in lesion size after an initial decrease) confirm paradoxical 
evolutions after start of treatment. 
We considered the possibility that the punch biopsies for disease confirmation may 
have elicited ulceration. We conclude from our study that ulceration is a common 
stage in the pattern of healing. Other lesions that were present at start of treatment 
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or appeared during or after treatment, and that were not biopsied, ulcerated as well .  
We assume that the ulcerative stage reflects the natural course of disease and is not 
necessarily related to the biopsy procedure. 
Isolating live M. u/cerans from such an u lcerating nodule does not necessarily imply 
failure of treatment. In the original report of the BU RU LICO trial [7], we described 
a patient who developed a nodule 8 weeks after treatment completion. This nodule 
ulcerated 6 weeks later, and M. ulcerans was cultured from th is lesion. This lesion 
healed without further intervention. 
In  conclusion, we describe new and progressive ulceration and appearance of 
new lesions in M. u/cerans infection, reflecting paradoxical reactions following 
antimicrobial treatment. These reactions were common and occurred during and 
after antimicrobial treatment.We show evidence from the literature that they mirror 
an enhanced host immune response. The time course might be compatible with 
arrest in production and gradual decrease of mycolactone concentrations in lesions, 
and possibly systemical ly, with restoration of the local and systemic host immune 
responses against mycobacterial antigens that were first suppressed by mycolactone. 
The evolution of lesions after start of antimicrobial treatment could be detected by 
careful observation, avoiding early referral for surgery. Further studies are required 
to improve our understanding of mycolactone kinetics over time and to l ink such 
data with host response patterns. Paradoxical reactions in BU may earl ier have gone 
unrecognized and been misinterpreted as failure to respond to treatment.A precise 
definition of paradoxical response would be welcomed, before a clinical decision rule 
can be developed to differentiate this entity from treatment failure. This information 
is important in the design of future cl inical studies as wel l  as in the management of 
patients with BU disease [32] .  
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Background Rural populations in developing countries have limited access 
to audiology services. In the context of a trial with a potentially ototoxic 
drug (the aminoglycoside streptomycin), we assessed the validity and test­
retest reliability of audiometric monitoring with battery-powered portable 
equipment. 
Methods For validity testing, readings of a portable conventional pure­
tone audiometer (AS208; lnteracoustics, DK-561 0 Assens, Denmark) were 
compared with readings of fixed, standard equipment, both in a sound-proof 
setting. In a field study the intra- and inter-observer reliability were tested. 
Results For comparison of standard and portable equipment, at least 96% 
of the repeated measurements in the 0.5 to 4 kHz range were within I 0 
dB. For intra- and inter-observer comparisons, at least 94% and 96% of the 
repeated measurements in the 0.25 to 4 kHz range were within I O  dB.At 6 
and 8 kHz, repeatability was less. Mean ambient noise was high [SO dB(A)]. 
Conclusions To pick up changes in hearing (> I O  dB) over time as a result 
of interventions, audiometric check-ups in the field with portable equipment 
are feasible, and reliable in the 0.25 to 4 kHz range.Absolute deviations from 
reference values should be interpreted with care, taking into account ambient 
noise. As aminoglycoside-induced ototoxicity (AIO) affects frequencies 
higher than 4 kHz first, early detection of AIO with portable audiometry in 
the field is limited. 
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Introduction 
Hearing impairment is  a problem worldwide.The WHO global estimate for disabl ing 
hearing impairment using a deficit >40 dB in the better ear in adults and > 30 dB in 
children, has more than doubled between 1 995 and 2005, from 1 20 mi l lion people 
to at least 278 mil l ion people (reference note I ). Of all deaf and hearing-impaired 
people, 80% l ive in low- and middle-income countries, and the number of chi ldren 
with hearing impairment is increasing [ I ] . 
Among the many causes of hearing impairment, acquired causes are more common 
in the less affluent rural communities [2,3]. Hearing impairment may be related 
to infections and treatment of infectious conditions. Aminoglycoside antimicrobial 
treatment has been an important cause of ototoxicity, especially among elderly 
patients with treatment of longer duration [ 4- 1 O]. Some individuals are extremely 
vulnerable to aminoglycoside-induced ototoxicity (AIO) and have idiosyncratic 
toxicity due to mutations in the I 2S subunit of ribosomal mitochondrial RNA [ I I ] . 
Several different mutations in this mitochondrial gene are associated with AIO, the 
most important being the A 1 555G and 96 1 mutations [7,9, 1 2] .  Up to 33% of patients 
with AIO may have such mutations. Information from African populations, where 
aminoglycoside use is more widespread than in any other continent, is left with a 
description of AIO within a South African family, associated with the A 1 555G point 
mutation [ 1 3] .  I n  Ghana, drugs were involved in only <2% of the causes of hearing 
impairment [2]. Because genetic testing identifies only individuals with idiosyncratic 
toxicity, and because pre-treatment genetic testing is not available, phenotypic 
testing must be used to demonstrate ototoxic effects [ 1 4] .  Audiometry has been 
recommended for this purpose [5,9] . 
For most inhabitants of rural areas in developing countries, facil ities to test hearing 
are not accessible. There are only a few otorhinolaryngology and audiology centers 
with soundproof audiometry facilities.The challenge is to provide audiometry services 
to reliably identify and refer subjects with impaired hearing for further investigation, 
treatment and/or counsel ing. Pure-tone audiometry using portable equipment has been 
used in less affluent areas in Africa [ 1 5, 1 6].Although pure tone audiometry has been 
tested for reliabil ity in standard conditions with low ambient noise [ 1 7- 1 9], it has not been 
tested for reliability under field conditions. Pure tone audiometry is basically subjective, 
but it appears to be reliable in cooperative subjects under controlled conditions [20]. 
The objectives of this study were (i) to determine the validity of pure-tone portable 
audiometry equipment by comparing readings in sound-proof conditions with standard 
equipment at the ENT department, Komfo-Anokye Teaching Hospital, Ghana; and (ii) 
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to determine intra- and inter-observer reliability of pure-tone portable audiometry in 
the 0.25 to 8 kHz frequency range in a rural hospital setting. In addition, we specifically 
related our results to ototoxicity screening, as pursuing reliable screening for possible 
AIO in the field was the initial reason for designing this study. 
Methods 
Study participants 
Study participants for validity testing of the portable equipment were recruited 
among out-patients attending the ENT Department (head: GKA) and the tuberculosis 
unit of the Komfo-Anokye Teaching Hospital (KATH) in Kumasi. Participants in 
intra- and inter-observer reliability tests were recruited at two rural hospitals in 
the Ashanti Region, Ghana -Nkawie-Toase Governmental Hospital and Agogo 
Presbyterian Hospital. Most of these study participants were Buruli ulcer patients 
who were also included in the BURULICO drug trial comparing 4 or 8 weeks of the 
aminoglycoside antibiotic streptomycin as part of different drug combinations (trial 
registration number NCT0032 I 178) [2 1]. For this drug trial the participants had to 
undergo audiometry regularly, and these assessments were integrated in the present 
study. Most of the drug trial study participants were between 5 and 15 years of age. 
Older participants were recruited from the ward, most of them admitted because 
of tuberculosis treatment. Participants were enrolled prospectively, in a consecutive 
order, during times the study team was present. Recruitment was done between 
August, 2006, and November, 2006. 
For all tests, persons with a deficit of >90 dB  hearing level (HL) for the worse ear 
and children under 5 years were excluded. Persons who were uncooperative or had 
difficulty in communicating were also excluded. Most of the volunteers did not speak 
English but rather Twii; English-Twii interpreters assisted by giving instructions during 
the instruction period and whenever necessary. 
Validity testing, standard versus portable equipment, KATH 
The equipment at the ENT department of Komfo-Anokye Teaching Hospital was 
chosen as reference standard, being the only available audiometry facility in the 
region. In the sound-proof room of the ENT department, one observer (GO: a 
trained audiology assistant) tested each individual study participant twice, using both 
fixed standard equipment and the portable equipment, in random sequence. 
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Intra- and inter-observer reliability, field studies 
For intra-observer reliability testing, participants were tested twice by the same 
observer (MMC: a Dutch medical student). For inter-observer reliability three 
different observers (MMC, WT and EA) performed the measurements by forming 
three different observer-pairs. Each participant was tested twice, one time by each of 
the observers of one observer-pair. The second observer was blinded to the results 
of the first observer. The sequence of the observers within the pairs was alternated 
to prevent sequence effects. 
The test room at Nkawie-Toase Governmental Hospital was an office in the public 
health department. In Agogo Presbyterian Hospital two test rooms were used. One 
was an isolation ward and the other was a room next to the consulting rooms near 
the outpatient department. 
Instrumentation 
In the audiometry unit in the Komfo-Anokye Teaching Hospital standard, fixed 
equipment was used (Kamplex AD27 Calibrated to ANSI (S3.6 - 1969) standard) 
for comparison with the portable equipment. The portable equipment consisted of 
full-range air conduction diagnostic audiometers, a model I nteracoustics AS 208 Type 
4 tone audiometer (for details and serial numbers see reference note 2 and 3) and 
matched circum-aural earphones with noise reducing Pelter mute cushions for air 
conduction. This equipment is powered with rechargeable batteries and designed 
for hearing testing in schools, industry, and primary care facilities. The audiometers 
were calibrated to ISO64, with biological calibration performed at frequent intervals. 
Ambient noise levels were measured with the Quest electronics model 2700 impulse 
sound level meter (for details see reference note 4), using slow meter response in A 
filter weighting. Since the human ear is not uniformly sensitive to all frequencies, this 
filter gives a weighted frequency response simulating the human ear. 
Audiometry tests 
MMC was instructed and trained at the Otorhinolaryngology Department,Audiology 
Unit, at the University Medical Centre of Groningen; EA and WT were instructed by 
MMC; at the Komfo-Anokye Teaching Hospital, the trained audiology assistant (GO) 
tested the participants. The protocol for the present validity and reliability study 
was tested before study participants were enrolled. Both ears were tested, the right 
ear first. Only this audiogram was used for analysis, since testing the second ear of 
a participant would be influenced by the experience of the first ear already tested. 
Pure tone hearing level thresholds were obtained for each participant. Frequencies 
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were tested in the following order: I ,  2, 4, 6, 8, 0.5 and 0.25 kHz, using descending 
levels of intensity. Testing started with presenting a loud tone. From this level the 
intensity was decreased in steps of 5 dB until the tone was not heard anymore. The 
last tone still heard was the level of audibility of the first test run.Then the intensity 
was increased with IO dB before being decreased again in steps of 5 dB, until the tone 
was no longer heard (the second test run). If the results of the two test runs were 
not identical, the process was repeated until two identical levels of audibility were 
found. This level was considered the hearing threshold. Thus each frequency was 
tested at least twice . At the Komfo-Anokye Teaching Hospital, a different protocol 
was used, following local practice; thresholds were measured with ascending levels 
of intensity, starting at O dB. From this level the intensity was increased in steps of 
5 dB until the tone was heard. This frequency was the level of audibility of the first 
test run. Then the intensity was decreased with IO dB before being increased again 
in steps of 5 dB, until the tone was heard again (the second test run). If necessary, 
the process was repeated until two identical levels of audibility were found. The 
same frequency order was used, and after studying the other frequencies, I kHz 
was re-tested. The portable audiometer is limited to a maximum of I 00 dBHL. 'No 
response' would be recorded as a I 05 dB hearing threshold.At least one hour, but 
no more than half a day (morning to afternoon), was scheduled between the first and 
the second test. No treatment was administered in between. 
Ethics 
The Committee on Human Research, Publications and Ethics, School of Medical 
Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, approved 
the study protocol and the consent procedure. From all participants > 12 years 
informed consent was obtained; parents, guardians or caretakers gave informed 
consent for all participants < 18 years. Information was provided about the purpose 
of the study and the extra time it would take to participate. Prospective participants 
were told that neither their enrolment in the study nor their refusal or withdrawal 
to participate would affect their health or treatment in any way.They were informed 
that the tests were an evaluation necessary for the study itself, and that the tests 
were not done because of suspected pathology. They were offered appropriate time 
to consider participation.A signature or a thumbprint confirmed verbal consent, as 
most of the participants were illiterate.All participants were offered a small incentive 
(food products). Travel costs were reimbursed. 
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Definitions 
In conventional audiometry, hearing impairment is classified by a pure-tone average 
of hearing thresholds over frequencies 0.5, I ,  2 and 4.0 kHz as follows: slight ( 16 - 25 
dBHL), mild (26 - 40 dBHL), moderate (41 - 55 dBHL), moderately severe (56 - 70 
dBHL), severe (71 - 90 dBHL) or profound (>90 dBHL) in the better ear [22]. 
An important concern about assessing hearing levels in the field is the influence 
of ambient noise. The American National Standards Institute (ANSI) has addressed 
this problem and specified maximum permissible ambient noise levels allowed in an 
audiometric test room to ensure that hearing thresholds obtained down to O dBHL 
will not be elevated due to masking by ambient noise. Maximum permissible ambient 
noise levels when testing in the 0.25 to 8 kHz frequency range, using a supra-aural 
earphone, are as follows: 39 dB at 0.125 kHz, 25 dB at 0.25 kHz, 21 dB at 0.5 kHz, 26 
dB at I kHz, 34 dB at 2 kHz, 37 dB at 4 kHz and 37 dB at 8 kHz [23]. 
Data analysis and reporting 
For the validity study as well as the intra- and inter-observer studies, Bland and 
Altman plots were made [24].These plots are designed to show differences between 
two measurements over their range. For each participant two measurements were 
available for each frequency tested.The difference between these two measurements 
was calculated per frequency, as well as the mean of these two measurements, per 
frequency.Thereafter a plot was made per frequency for the validity study as well as the 
intra- and inter-observer studies, of the differences between the two measurements 
(vertical axis) against the mean of these two measurements (horizontal axis). Then 
the mean of all plotted differences and the standard deviation of this mean difference 
were calculated per test frequency, as was the percentage of measurements within 
a 5 and a 10 dB difference between the two tests, per frequency. One-way ANOVA 
was used to analyze differences between the paired measurements for the three test 
locations (for the intra-observer reliability study), and for the three tester-pairs (for 
the inter-observer reliability study) for each frequency. Data were analyzed using 
SPSS 16.0 for Windows®. 
We used the format as reflected in the STARD statement (Standards for Reporting 




Overall, the plots for the validity and reliability studies showed no consistent relation 
between the mean of the repeated tests and the differences. This implies that the 
differences in hearing level observed in the two measurements did not vary in 
any systematic way depending on the (mean) level of hearing. The mean difference 
of the paired measurements was close to zero for all of the frequencies, i.e., the 
first measurement did not systematically affect the second. No ceiling effects were 
found; all of the participants had responded before reaching I 00 dBHL, the highest 
presentation level of the portable machine. 
Ambient noise measurements 
The mean ambient noise in Agogo Presbyterian Hospital was 50 dB(A) (range 49 -
53 dB: 5 measurements); the mean ambient noise in Nkawie-Toase Governmental 
Hospital was 47 dB(A) (range 43 - 49 dB: 12 measurements). In Komfo-Anokye 
Teaching Hospital no ambient noise was measured. 
Validity testing, standard versus portable equipment, KATH 
For the validity study, 47 participants were included; 5 1  % of the participants were 
female. The age ranged from 5 to 79 years (median 36; IQR 29 to 45 years); 92% 
of the participants tested underwent the hearing test for the first time in their life. 
Mean hearing thresholds in this group (using the mean of the first and the second 
measurement for every participant) were 24, 28, 27, 26, 28, 34 and 32 dBHL for 0.25, 
0.5, I ,  2, 4, 6 and 8 kHz respectively. 
Figure I shows a plot of the differences between the fixed equipment and the 
portable equipment against their mean at I kHz. Such a plot was made for each test 
frequency. 
Table I summarizes the differences between the fixed and the portable equipment 
per frequency tested (kHz). One outlier, resulting from a test session with an elderly 
person, was ignored.Additionally, the mean differences, the SD of the differences and 
the percentage of difference falling within 5 and I O  dB are presented in table I .  In 
brackets, results are given including the outlier. The percentage of differences falling 
within 5 and I O  dB also include the outlier. In the range 0.5 to 4 kHz, 96% of repeated 
measurements were within I O  dB.At higher and lower frequencies, differences were 
larger. 
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Figure I: Plot example of test-retest differences against their mean. The dotted line in the graph 
is the mean difference. Test validity at I kHz (n=47). 
Intra-observer reliabil ity, field study 
In Nkawie-Toase Governmental Hospital and Agogo Presbyterian Hospital, 5 1  
participants were included; 60% of the participating volunteers were female. Median 
age was 23 years (IQR 9 - 42 years); 34% of the participants tested underwent the 
hearing test for the first time in their l ife and the same percentage for the second 
time. Mean hearing thresholds in this group (using the mean of the first and the 
second measurement for every participant) were 22, 26, 25, 22, 23, 30 and 23 dBHL 
for 0.25, 0.5, I ,  2, 4, 6 and 8 kHz respectively. One younger participant was withdrawn 
from the study during the assessments for not being able to cooperate. 
Figure 2 shows a plot of the differences between the two testing sessions of the 
observer against their mean for I kHz. Such a plot was made for each test frequency. 
Table 2 summarizes the differences between the two measurements of the observer, 
per frequency. Additional ly the mean differences, the SD of the differences and the 
percentage of differences fall ing within 5 and I O  dB are presented in table 2. Here, 
94% of repeated measurements were within I O  dB in the range 0.25 to 4 kHz. 
No significant effect of test location on the differences between paired measurements 
was found (p>0. I for all the test frequencies), and no significant effect of previous 
experience with the test on the difference between paired measurements was found 
(p>0.2 for all the test frequencies). 
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Table 3: I nter-observer reliabil ity - differences between the two measurements of an observer-pair, per frequency, using portable equipment in the field 
(with number of subjects (n=52) in Italics). 
1 Freq Test-retest differences (dB) Mean of SD of dlff. ± 5 dB (%) ± I O  dB 
(kHz) -25 -20 - 1 5  - 1 0  -5 0 5 1 0  1 5  20 25 dlff. (dB) (dB) (%) --
0.25 0 0 0 3 6 24 / 2  5 2 0 0 1 .5 5.6 8 1  96 
o.s 0 0 0 I 9 20 / 4  8 0 0 0 1 .8 5. 1 83 1 00 
I 0 0 0 I 9 24 / 2  5 I 0 0 1 .4 5.0 87 98 
l 0 0 I 3 I I 1 7  / 4  5 I 0 0 0.7 6.0 8 1  96 
4 I 0 0 4 / 0  1 4  / 2  / 0  0 0 I 1 .4 7.8 69 96 
6* 0 2 2 I / 0  / 3  9 9 4 0 0 1 .3 (2.5)* 8.5 ( I  0.3)* 62 8 1  
8 I 0 I 7 / 3  I I I I  5 2 I 0 -0.4 8.3 67 9 1  
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Figure 2: Plot example of test-retest differences against their mean. The dotted line in the graph 
is the mean difference. Intra-observer reliability at I kHz (n=SO). 
Inter-observer reliability, field study 
In Nkawie-Toase Governmental Hospital and Agogo Presbyterian Hospital, 52 
participants were included; 50% of the participants were female, median age 27 years 
(IQR 16 - 47 years); 70% of the participants did the hearing test for the first time. 
Mean hearing thresholds in this group (using the mean of the first and the second 
measurement for every participant) were 20, 23, 23, 22, 25, 28 and 24 dBHL for 
0.25, 0.5, I ,  2, 4, 6 and 8 kHz respectively.As for validity and intra-observer reliability 
studies, plots were made of the differences between the two testing sessions against 
their mean for each frequency. Table 3 summarizes the differences between the two 
measurements of an observer-pair, per frequency; here, two outliers were ignored. 
These outliers resulted from a test session with a 50 year old and a 9 year old 
participant. In addition, the mean differences, the SD of the differences, and the 
percentage of differences falling within 5 and IO dB are presented in table 3. In the 
range 0.5 to 4 kHz, 96% of recordings were within IO dB. In brackets, results are 
given including the outliers. The percentage of differences falling within 5 and IO dB 
also include the outliers. 
No significant difference was observed between the three different observer pairs in 
the differences of the paired measurements (p>0.3 for all of the test frequencies), and 
no significant effect of previous experience with the test on the difference between 
paired measurements was found (p>O. I for all the test frequencies). 
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Discussion 
Though pure-tone audiometry using portable equipment has been used in rural 
Africa, this is the first formal reported evaluation of audiometry using portable 
equipment in field conditions in less affluent countries. This study shows that the 
validity and the reliability of the portable audiometer were satisfactory, especially 
in the 0.25 to 4 kHz frequency range. At 0.25, 0.5, I ,  2, and 4 kHz intra-observer 
test-retest repeatability was within IO dB for at least 94% of the measurements, 
and inter-observer test-retest repeatability was within IO dB for at least 96% of the 
measurements.At higher frequencies ( 6 and 8 kHz), measurements were less reliable. 
In clinical conditions, a pure-tone threshold measurement at a single frequency has a 
90% chance to be repeated within IO dB of the first measurement, assuming that no 
real change in hearing thresholds has occurred [20].Though formal reliability studies 
of field portable audiometry have not been reported, Robinson ( 199 1) examined 
audiometric repeatability in an industrial setting, in which the hearing level threshold 
at a single frequency was found to have a chance of 90% to be repeated within IO dB, 
even after an interval of several years [26].As part of a large national epidemiological 
study, Lutman et al. ( 1989) compared a manual and a computer controlled method 
[27].The thresholds measured were at 0.5, I ,  2 and 4 kHz. Standard deviations of the 
test-retest differences with a 2 to 3 years interval were provided, and were similar 
to those found in our field study.Ambient noise levels were not measured.Although 
the test conditions, which were not ideal, were close to the current study, the time 
lapse between tests was considerably longer. With more time lapse between tests, 
SDs will become larger [28].Authors of both studies concluded that shifts were due 
to random measurement error rather than actual shifts in hearing thresholds. 
In another study where a group of individuals with sensorineural hearing impairment 
and a group of healthy individuals were tested twice, within two weeks, in standard 
sound proof conditions, SDs were lower than in the current field study [29].The short 
interval between the tests was similar to this field study.The sound-proof conditions 
were not comparable. SDs in the normal and the cochlear-impaired group were 
equivalent. Table 4 and figure 3 show the SDs of the described studies together with 
those of the current study. For all studies, highest SDs were seen in the 6 and 8 kHz 
frequencies. Generally, reliability of conventional pure-tone audiometry decreases at 
higher frequencies.At these frequencies, a different positioning of the earphones has 
a higher influence on changes in the ear canal resonance, and therefore results in a 
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Figure 3: SDs ( dB) of the in the text described inter-observer studies together with the SDs of 
the present intra- and inter-observer reliabil ity study. 
The reliability of hearing level thresholds measured with circum-aural earphones in 
the 0.5 to 16 kHz frequency range was evaluated by Schmuziger et al [ 18]. At each 
individual frequency in the 0.5 to 8 kHz test frequency range, test-retest repeatability 
was within IO dB for at least 99% of the measurements. SDs were not provided.That 
study was performed in sound-proof conditions, and this probably explains why the 
repeatability in the current field study was less. Besides the ambient noise levels, 
other factors like differences in educational level might in part explain differences in 
study results. The mean age of the participants was similar to the mean age of the 
participants in our study. 
This study has several limitations. The fairly high levels of ambient noise measured 
in the current field studies may have caused variability to become larger. Ambient 
noise levels were variable within one test session but also between test sessions, so 
the ambient noise did not cause a systematic error and therefore does not present 
a source of bias, but merely caused a reduction in precision. This means that levels 
of hearing impairment might be overestimated, but that changes over time can be 
reliably detected. Secondly, although the influence of this factor was kept as small as 
possible by starting with a short period of practice, the differences in experience of 
study participants might have affected test results. For intra-observer testing, 66% 
of the participants had done the test before; for validity and inter-observer testing 
only 8% and 30% respectively had done the test before. Although statistically we 
could not show this, and the Bland and Altman plots did not confirm a learning curve 
from the first to the second test, lack of experience with the test can be one of the 
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causes of the observed difference in test validity, intra-, and inter-observer reliability 
results. Apart from ambient noise and experience, variation in response strategy, 
motivation, attention and intelligence of the participants may influence test reliability. 
Most participants were young, and they clearly had difficulty concentrating. 
Table 4: SDs ( dB) of repeated measurements per frequency in the different studies described in 
the text, compared to the results of the present study. 
Present Present 
study; intra- study; inter-
Lutman Robinson Jerlvall observer observer 
et al. et al. et al. reliability reliability 
No. of subjects 1 20 356 20 50 52 
Time lapse 2-3 years 1 3  months 2 weeks half a day half a day 
Study conditions industry - industry laboratory field field 
clinical 
0.25 (kHz) 5.2 4.3 5.6 
0.5 6.9 (dB) 6.5 3.9 4.7 5. 1 
I 4.8 5. 1 3.7 4.0 5.0 
2 5.0 5. 1 3 . 1 6.8 6.0 
3 3.0 4.0 
4 7. 1 5.9 4.0 6.0 7.8 
6 9.0 6. 1 7.9 8.5 
8 5.6 8.4 8.3 
Conclusion 
W HO recommends early detection and intervention as key to preventing and managing 
hearing impairment, and also states that most effective interventions can be done at 
the primary level of health care (reference note 5).T he results in this study show that 
the portable audiometer can serve the call to action, as it can be well operated in the 
field by different observers with minimal training, which is useful in daily practice. To 
pick up changes > I O dB over time as a result of interventions, audiometric check-ups 
in the field with portable equipment are feasible, and reliable, especially in the 0.25 
to 4 kHz range. As AIO affects frequencies higher than 4 kHz first, this study implies 
that early detection of AIO with portable audiometry in the field is limited. Absolute 
deviations from reference values should be interpreted with care, especially in relation 
to ambient noise. For this, studies comparing field and clinical audiometry are needed. 
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Background Serological studies show that only a small proportion of 
Mycabaeterium ulcerans infected individuals develop cl inical disease (Buruli 
u lcer disease).The genetic and environmental factors determining progression 
to overt M ulcerans disease are l ikely to be complex. 
Methodology/principal findings In a case-control study we sought 
confirmation of our earl ier finding that susceptibi l ity to M ulcerans disease 
is associated with certain polymorphisms in the SLC I I A I gene. We also 
investigated polymorphisms in the MBL2 and the VDR genes because of their 
association with tuberculosis and leprosy. Because of its association with 
tuberculosis, serum 25-hydroxyvitamin D concentrations were measured 
to explore a possible relation to disease status. 1 79 Ghanaian M ulcerans 
patients and 1 80 age, gender and ethnicity matched controls were included. 
Susceptibi l ity to develop M ulcerans disease appeared not associated with any 
of the polymorphisms studied. Serum vitamin D concentrations were lower 
in patients, compared to controls (65.9 vs 73 .0 nmol/L; p<0.00 I ) . 
Conclusions/Significance In this sample s ize with a different ethnic 
background (i .e., other tribal origins than the previous study), we were unable 
to confirm the association with SLC I I A I gene polymorphisms for M u/cerans 
disease. We found a significantly lower vitamin D blood concentration in 
patients as compared to control subjects. This finding might either reflect 
increased consumption of vitamin D by cel ls of the immune system at the 
site of infection, or less l ikely, decreased exposure to sunlight resulting 
from covered skin or inabil ity to participate in farming and other out-door 
activities, due to M u/cerans disease. 
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Author summary 
Buruli ulcer disease (Mycobacterium u/cerans infection) is a disabling, neglected disease, 
emerging around the world and notably in sub-Saharan Africa. Like tuberculosis and 
leprosy, environmental and inherited factors determine whether or not clinical 
disease follows after infection. We studied three genes, associated with tuberculosis 
and leprosy, among Buruli ulcer patients and matched healthy controls.We could not 
confirm our earlier finding of a strong association between polymorphisms in the 
SLC I I A I gene and Buruli ulcer, nor for the other genes (MBL2 and VDR) studied. 
T he majority of our Buruli ulcer patients were immigrants from Northern Ghana 
who had farms in the Buruli ulcer-endemic area where our study was conducted. 
Perhaps a difference in genetic background compared to the previous study explains 
why this time we found no genetic associations. 
Vitamin D is important in the defense against mycobacterial infection such as 
tuberculosis. Vitamin D is essential for the production of the anti-mycobacterial 
peptide cathelicidin.We found lower serum vitamin D concentrations in Buruli ulcer 
patients compared to control subjects. We speculate that consumption of vitamin 
D at the site of infection might explain this. T his new finding could be important in 
finding ways to improve disease management. 
Introduction 
Buruli ulcer disease (Mycobacterium ulcerans infection) is  an indolent, ulcerating and 
devastating disease of the skin [ 1,2]. If not diagnosed and treated early, it carries the 
risk of leaving patients with severe and permanent functional limitations [3]. It is 
the third most common human mycobacteriosis in immunocompetent individuals 
after tuberculosis and leprosy [4]. In the last decades Buruli ulcer disease (BUD) 
is emerging in dramatic numbers in sub-Saharan Africa. With an incidence in some 
areas surpassing that of tuberculosis and leprosy, Buruli ulcer has an immense social 
and financial impact on individuals and on the public health system [S]. T he W HO 
selected BUD as one of nineteen neglected tropical diseases [6]. Having its endemic 
places mostly in tropical countries in remote areas, Buruli ulcer is called a disease of 
the poor. Children are more often affected than adults.T he mode of transmission and 
reservoir of the disease are yet unknown [7], but are not restricted to the tropics 
alone; Australia being the second continent burdened by this disfiguring disease [8]. 
T here is no evidence for important person-to-person transmission. 
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Serological studies show that only a small proportion of M ulcerans infected individuals 
develop clinical disease [9, I O]. For tuberculosis and leprosy it is known that genetic 
predisposition plays an important role in the chance of developing disease [ I 1- 14]. 
Support for this idea came from observations of familial clustering, high concordance 
rates in identical twins and clear racial differences in the risk of developing disease. 
Like in tuberculosis and leprosy, the genetic influence on developing disease is likely to 
be complex, with several different genetic polymorphisms playing each a limited role 
to explain the variance observed in the population at risk. Earlier, our group reviewed 
possible genetic host susceptibility factors for BUD, relevant in other mycobacterial 
diseases [ I S]. Based on a limited sample of cases and healthy control subjects living 
in an endemic region in Ghana, it was shown that carrying the heterozygous GA 
genotype of the D543N polymorphism in the SLC I I A I (formerly Nramp I )  gene may 
be associated with an increased risk of developing BUD [ 16]. In the present study we 
intended to confirm these findings. The SLC I I A I gene encodes a transport protein 
expressed in the membrane of late endosomes mainly in macrophages, regulating 
antimicrobial activity. The exact mechanism by which microbial replication is blocked 
is not entirely clear. Several association studies have indicated that polymorphisms 
in this gene may be associated with clinical tuberculosis and leprosy [ 17, 18], as well 
as leprosy type [ 19]. 
We selected two other candidate genes from the published review that have not 
been studied before in relation with BUD, i.e., the mannose binding lectin (MBL) gene 
and the vitamin D receptor (VDR) gene. MBL is a liver derived complement activating 
serum protein [20], which can bind surface structures of several clinically important 
bacteria, yeast and viruses. It initiates complement activation and phagocytosis and 
induces inflammatory cytokine responses. In general, MBL deficiency, which is mainly 
determined by single nucleotide polymorphisms, is common en predisposes to 
various infections [2 1 ]. Low serum MBL levels may also confer protection against 
some intracellular parasites like leishmaniasis, leprosy and tuberculosis [22-25]. The 
high prevalence of infections caused by intracellular pathogens in people of African 
descent may explain the elevated frequency of alleles causing low levels of MBL as 
compared to people from European descent [26,27]. 
Vitamin D enhances antimycobacterial activity in in vitro systems and restricts growth 
of M tuberculosis [28]. The effect of the active metabolite ( 1,25-dihydroxyvitamin 
D), is exerted by interaction with the intranuclear vitamin D receptor [29,30]. 
Epidemiological evidence suggests there is a relation between vitamin D deficiency, 
as well as polymorphisms in the VDR gene, and susceptibility to tuberculosis [3 1-
34]. In a study that assessed the potential of vitamin D suppletion in tuberculosis 
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patients, VDR polymorphism seemed to be associated with time to sputum culture 
conversion [35].VDR gene polymorphism has also been found to be associated with 
leprosy type (tuberculoid versus lepromatous) [36]. 
The objective of this study was to investigate association of BUD with 
SLC I I A I ,  MBL and VDR gene polymorphisms, as well as with serum vitamin 
D concentrations, in patients and healthy controls coming from two regions 
in Ghana highly burdened with BUD. We hypothesized that the type of lesion, 
extent of disease, and response to antimicrobial therapy also may be determined 
by genetic host factors. 
Methods 
Participants: case ascertainment and matched control selection 
Blood samples were collected and demographic and clinical information was 
obtained from patients who were participating in a randomised controlled trial 
to compare two different antimicrobial regimens [37]. This trial was conducted in 
two hospitals located in the Ashante Region of Ghana. BUD patients were included 
from April 2006 to January 2008. Participants were aged ;;.:5 years, had early, limited 
and 1S2404 PCR confirmed disease and were followed for one year from start of 
treatment. Detailed inclusion criteria for the randomised trial can be found on 
ClinicalTrials.gov, identifier NCT0032 I 178. Patients that had clinical disease that 
could not be PCR confirmed were also treated and handled according to the same 
protocol. These were included in the present study too, as well as PCR confirmed 
patients that were not randomised for different reasons, but had blood samples 
taken. 
In June 2008, one or two matched community controls were enrolled per patient. 
Control subjects were preferably befriended with, and living close by the house 
of the BUD patient. We matched for age, as BUD is known to have a bimodal age 
distribution, with an increased incidence in young persons and in the elderly [38,39]. 
We matched for gender as some studies, as well as our antibiotic study population, 
show that women are more prone to develop BUD [37,40-42]. During patient 
recruitment for the antibiotic trial we were struck by the fact that the majority 
of BUD patients were not Akan, the dominant ethnic group where the study was 
conducted [37]. Therefore, we matched according to two major ethnic groups; 
Akan being individuals from the region where the study was conducted; and other, 
consisting of individuals mainly belonging to different ethnic groups from Northern 
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Ghana. If a study participant's parents were from different descent, we preferably 
chose the descent of the mother to select the matched control. 
Ethical considerations 
The protocol and consent forms were approved by the Committee on Human 
Research, Publication and Ethics of the Kwame Nkrumah University of Science and 
Technology and the KomfoAnokye Teaching Hospital, Kumasi (CHRPE/07/0 I /05) and 
by the Ethical Review Committee of Ghana Health Services (GHS-ERC-0 1 /0 I /06). 
Informed consent and assent was given by all participants aged :2: 1 2  years and/or 
from parents, care takers or legal representatives of participants s 1 8  years. 
Genotyping 
Blood samples in EDTA tubes for buffy coat were centrifuged within 24 hours after 
collection, stored at -20°C and sent in frozen condition from Ghana to the University 
Medical Center Groningen, the Netherlands, until processed. Genomic DNA was 
extracted using QiaAmp 96 blood kit (Qiagen). 
We genotyped four polymorphisms in the SLC 1 1  A I gene: rs59823 I 6 I (3'UTR TGTG 
ins/del); rs 1 7235409 (D543 G/A); rs373 I 865 (I NT4 G/C); and a (CA)n microsatellite 
in the immediate 5' region of the gene.The 5'(CA)n microsatellite analysis was done 
using the Applied Biosystems 3730 capillary sequencer; with fluorescent primer 
5'-ACTCGCATTAGGCCACAGAG and 5'-TTCTGTGCCTCCCMGTTAGC. 
Normal genotype was designated "200" and variant genotypes (202, 204) were 
pooled as "other". We genotyped two polymorphisms on the MBL2 gene as well. 
Both are known to cause inter-individual variations in serum MBL levels. One of 
these, rs I 80045 1 ,  is a point mutation on exon I at codon 57. Wild type is denoted 
as allele A. The minor C-allele is predominantly found in African populations. The 
second polymorphism, rs7096206, a base-pair substitution in the promoter region 
(G -> C at position 22 1 ), changes the (most common) allele calledY into allele X.The 
VDR single nucleotide polymorphisms genotyped were rs2228570 (Fok I ), a C-> T 
base change in exon 2; rs73 I 236 (Taq I ), a silent T->C base change at codon 352 
in exon 9; 1 5444 1 0  (Bsm I ), a T->C base change in intron 8; and rs7975232 (Apa I ), 
a G-> T base change in intron 8. TaqMan MGB-probes and primers were obtained 
through the Applied Biosystems assay-by-design service. 
Vitamin D serum concentration 
Blood samples in clotted blood tubes for serum were cooled until centrifuged within 
24 hours after collection, then stored at -20°C, and sent in frozen condition from 
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Ghana to the University Medical Center Groningen, the Netherlands, until processed. 
Serum concentration of 25-hydroxyvitamin D, the primary indicator of vitamin D 
status, was determined in duplex for every sample by a radioimmunoassay (DiaSorin, 
Stillwater, MN) [43].The mean of these two results was used for the analyses. 
Statistical analysis 
Baseline characteristics of the patient and the control group were compared using Mann­
Whitney U, Pearson Chi-Square and Fisher's Exact test as appropriate. Genotype and 
allele frequencies of individual polymorphisms were determined by direct counting and 
expressed as percentages. Genotyping was checked by assessing whether polymorphisms 
of controls were in Hardy-Weinberg equilibrium, using a x2 test with one degree of 
freedom ( dt). Association between BUD and the polymorphisms was studied using 
cross tabulation with x2 tests. The odds ratios (OR) and 95% confidence intervals (Cl) 
were determined using binary logistic regression. To adjust for potential confounding: 
age, gender, study site, ethnicity, and profession were included in the model. Because 
association studies have linked farming activities with the chance of acquiring BUD, 
profession was divided in farming and other. 
To study whether type of lesion (nodule, plaque, ulcer, edema), lesion category (category 
I; lesions < 5 cm diameter, or category 11/111; lesions >5 cm and multiple lesions) or 
response to therapy (healing or failure) were associated with certain polymorphisms, 
cross tabulation was used with x2 tests. Heterozygote and homozygote variant alleles 
were combined when individual groups were too small to perform the test, with Fisher's 
Exact as appropriate. For these multiple testing, the significance level was adjusted 
according to Bonferroni. 
Comparison of vitamin D levels between patients and controls, and between the 
different VDR polymorphisms, was performed by Mann-Whitney U tests for two 
independent samples and by Kruskal-Wallis tests for more than two categories. 
The association analyses were done with SPSS (version 16.0; Chicago, IL, USA). Hardy­
Weinberg equilibrium testing was performed in MS Excel. Unless stated otherwise, 
p-values less than 0.05 were considered significant. 
Results 
Of the BUD patients, 151 were participants in the randomised antibiotic trial. The 
other 28 patients were not randomised but received standard antibiotic treatment, 
and were handled according to the same protocol. Of the 179 patients, 163 (91 %) had 
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confirmed disease; 156 were at least PCR-confirmed; 7 were confirmed otherwise 
(Ziehl-Neelsen staining for acid-fast bacilli, culture and/or histopathology). 12 patients 
provided two controls and for I I patients no control could be selected, which 
resulted in a total of 180 controls. Table I shows the baseline characteristics of the 
179 BUD patients and the 180 controls included in the analysis.T hese characteristics 
were similar for both groups. 
Table I: Baseline characteristics of the Buruli ulcer disease patient group and the control group 
patients controls P* 
(n= l 79) (n= l 80) 
median age in years (IQR) 1 2  (8-20) 1 3  (9-2 1 )  0. 1 6  
male sex (%) 62 (35%) 63 (35%) 0.94 
ethnicity (% Akan vs other ethnic groups) 54 (3 1 %) 58 (32%) 0.73 
profession (% farmer vs other and pupils) 48 (27%) 49 (28%) 0.9 1 
study site (% Nkawie vs Agogo) 52 (29%) 5 I (28%) 0.88 
HIV infected individuals (n) 4 (2%) I (0.6%) 0.37 
* Mann-Whitney U test for continuous and Pearson Chi-Square test for categorical data, with 
Fisher's Exact test for tables where >20% of the expected frequencies were <5 
T he selected polymorphic markers and their genotype frequency distributions are 
shown in table 2, 3 and 4. T here was no suggestion of gross genotyping errors, as all 
polymorphisms in the control group were in Hardy-Weinberg equilibrium. Missing 
data were less than 6% for all polymorphisms genotyped. None of the polymorphisms 
of the SLC I I A I ,  MBL andVDR genes studied were significantly associated with having 
BUD. Results did not change when only PCR confirmed patients were included, or 
when HIV-infected individuals were excluded from the analysis (data not shown). 
When using Bonferroni correction for multiple testing, the polymorphisms were not 
associated with stage of disease, with type of lesion, or with response to treatment 
(data not shown). 
In 345 individuals vitamin D concentrations could be obtained from serum, 14 
individuals ( 12 patients and 2 controls) had a missing value. Table 5 shows median 
25-hydroxyvitamin D serum concentrations for patients and for controls, grouped 
by gender. Serum vitamin D concentrations were different (p<0.00 I )  in patients and 
controls, with for patients a median of 65.9 (25-75th percentile: 55.9-77.6) nmol/L 
and for controls 73,0 (63. 1-84. 1) nmol/L. In males the difference was larger than in 
females. 
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Table 2: SLC I I A I genotype frequencies in Buruli ulcer patients and in controls 
Bun.Iii ulcer controls crude odds adjusted odds 
patients (n= 1 79) (n= I SO) ratio (95%CI)• ratio (95%Cl)b 
INT4 
GIG 1 5 1  (87%) 1 57 (9 1 %) I I 
G/C 2 1  ( 1 2%) 1 5  (9%) 1 .46 (0.72-2.93) 1 .45 (0.72-2.94) 
CIC I ( 1 %) 0 (0%) NA NA 
missing 6 8 
D543N 
GIG 1 48 (85%) 1 52 (86%) I I 
GIA 26 ( 1 5%) 23 ( 1 3%) 1 . 1 6  (0.63-2. 1 3) 1 . 1 7  (0.64-2. 1 5) 
A/A I ( 1 %) I ( 1 %) 1 .03 (0.06- 1 6.6) 1 .08 (0.07- 1 7.5) 
missing 4 4 
3'UTR 
TGTG ins/ins 89 (5 1 %) 94 (55%) I I 
TGTG ins/del 74 (43%) 67 (39%) 1 . 1 7  (0.75- 1 .8 1 )  1 . 1 4  (0.73- 1 .79) 
TGTG del/del I O  (6%) 1 1  (6%) 0.96 (0.39-2.37) 0.98 (0.40-2.44) 
missing 6 8 
5' (CA)n 
200/200 94 (56%) I 06 (62%) I I 
200/other 65 (38%) 58 (33%) 1 .26 (0.8 1 - 1 .  98) 1 .2 1  (0.77- 1 .  92) 
other/other 1 0  (6%) 8 (5%) 1 .4 1  (0.53-3.72) 1 .53 (0.56-4.22) 
missing 1 0  8 
aQdds ratios are for comparison with the most common genotype for each polymorphism. 
bQdds ratios via binary logistic regression analysis with gender, age, ethnicity and profession as 
covariates in the model. 
Table 3: MBL genotype frequencies in Buruli ulcer patients and in healthy controls 
Buruli ulcer controls crude odds adjusted odds 












YY 1 34 (77%) 
Y/X 39 (22%) 
XIX 2 ( 1 %) 
missing 4 
Y = common allele of -22 1 polymorphism 
86 (50%) 
72 (42%) 
1 5  (9%) 
7 
1 32 (75%) 
42 (24%) 
2 ( 1 %) 
4 
X = less frequent allele of -22 1 polymorphism 
WT = common allele of 57 codon polymorphism 
M = mutant allele for 57 codon polymorphism 
I 
1 . 1 4  (0.73- 1 .76) 
0.6 1 (0.26- 1 .48) 
I 
0.92 (0.56- 1 .5 1 )  
0.99 (0. 1 4-7. 1 0) 
I 
1 . 1 2  (0.72- 1 .75) 
0.63 (0.26- 1 .54) 
I 
0. 94 (0.56- 1 .55) 
0.98 (0. 1 4-7. 1 2) 
aQdds ratios are for comparison with the most common genotype for each polymorphism. 
bQdds ratios via binary logistic regression analysis with gender, age, ethnicity and profession as 
covariates in the model. 
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Discussion 
This study does not confirm the strong association of carrying one of the SLC I I A I 
polymorphisms with susceptibility for Mycobaeterium ulcerans infection, as shown 
earlier; nor do the MBL or VDR polymorphisms show an association with infection. 
We show that vitamin D serum concentration is associated with M ulcerans infection. 
We speculate that the reduced 25-hydroxyvitamin D serum concentrations that 
we found in patients compared to control subjects, is related to consumption of 
vitamin D at the site of infection. In tuberculosis, formation of activated vitamin D 
( 1,25-dihydroxyvitamin D) from 25-hydroxyvitamin D upregulates the production of 
cathelicidin,an antimicrobial peptide [30,44-47].The vitamin D mediated antimicrobial 
activity against intracellular M tuberculosis was found to be dependent on cathelicidin, 
via activation of toll-like receptors (TLRs) on human monocytes and macrophages 
[48]. After infection with M tuberculosis, TLR activation results in conversion of 
25-hydroxyvitamin D into 1,25- dihydroxyvitamin D, within human macrophages, at 
the site of infection [49]. Blockade of LL-37, the active peptide form of cathelicidin, 
results in increased growth of M ulcerans in human epidermal keratinocytes [SO]. 
It is probable that M ulcerans, like M tuberculosis, activates TLRs, resulting in the 
formation of cathelicidin via conversion of vitamin D.Another cause of lower serum 
vitamin D concentrations in patients might be less sunlight exposure, resulting from 
the stigma and functional limitations known to be associated with Buruli ulcer disease 
[51,52]. Thirdly, a pre-existing low vitamin D concentration - either as a result of 
reduced dietary intake, or less exposure to sunlight, might result in less protective 
immunity against M ulcerans, with a larger chance of developing clinical disease after 
infection. The very small difference in median serum vitamin D concentrations 
between patients and controls, and the overall high vitamin D concentrations make 
this explanation less probable. 
We realized that the different time period in which vitamin D serum samples were 
taken could have induced bias. Samples from patients were taken throughout the year, 
while samples from controls were taken in the month of June, during rainy season. 
The relatively cloudy weather in the rainy season would have favoured lower, not 
higher vitamin D concentrations; the bias would rather be in the opposite direction 
than what we found, and it is therefore not very likely that differences in sampling 
time between cases and controls explain our findings. 
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Table 4: VDR genotype frequencies in Buruli ulcer patients and in healthy controls 
Bun.Iii ulcer controls crude odds adjusted odds 
patients (n= 1 79) (n= l 80) ratio (95% Cl)· ratio (95%Cl)b 
Fok l 
CIC 1 04 (6 1 %) 1 1 4 (66%) I I 
CIT 64 (38%) 5 1  (30%) 1 .38 (0.87-2. 1 7) 1 .36 (0.86-2. 1 7) 
TIT I ( 1 %) 7 (4%) 0. 1 6  (0.02- 1 .29) 0. 1 5  (0.02- 1 .2 1 )  
missing 1 0  8 
Taq l 
TIT 93 (55%) 1 07 (62%) I I 
TIC 69 (40%) 56 (32%) 1 .42 (0.9 1 -2.22) 1 .33 (0.84-2. 1 0) 
CIC 9 (5%) 1 0  (6%) 1 .04 (0.40-2.66) 1 .04 (0.40-2.67) 
missing 8 7 
Bsm l 
TIT 77 (46%) 89 (5 1 %) I I 
TIC 8 1  (48%) 67 (39%) I .40 (0.90-2. 1 8) 1 .38 (0.88-2. 1 7) 
CIC 1 1  (6%) 1 7  ( 1 0%) 0.75 (0.33- 1 .69) 0.75 (0.33- 1 .70) 
missing 1 0  7 
Apa l 
TIT 9 1  (53%) 79 (46%) I I 
GIT 69 (40%) 77 (44%) 0.78 (0.50- 1 .2 1 )  0.82 (0.53- 1 .29) 
GIG 1 1  (7%) 1 8  ( 1 0%) 0.53 (0.24- 1 . 1 9) 0.53 (0.23- 1 .20) 
missing 8 6 
•Odds ratios are for comparison with the most common genotype for each polymorphism. 
bQdds ratios via binary logistic regression analysis with gender, age, ethnicity and profession as 
covariates in the model 







patients (n= l 67) 
65.9 
55.9 - 77.6 
65.9 (n= I I I ) 
54.7 - 78. 1 
65.9 (n=56) 
58.6 - 76.8 
controls (n= 1 78) 
73.0 
63. 1 - 84. 1 
7 1 .4 (n= 1 1 6) 
59.8 - 8 1 .4 
76.9 (n=62) 
67.9 - 93.5 





Contrary to our earlier study [ 16], the present study could not confirm an important 
share of the SLC I I A I D345N polymorphism in acquiring clinical M ulcerans disease. 
Both studies were of the same sample size. In addition to matching for age and 
gender like the former study, in the present study we matched for ethnicity as well. 
As 75% of the Buruli ulcer patients that were included in the antimicrobial trial were 
from northern ethnic origin while the study took place in the centre of Ghana [37], 
we aimed at preventing confounding as a result of background genetic differences.As 
genetic studies in African populations are challenging because genetic information is 
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highly diverse within confined areas, confounding as a result of ethnic differences in 
our study population cannot be excluded [53]. We matched according to two major 
ethnic groups - Akan and other. As other consisted of over 13 ethnic groups -mainly 
from the northern part of Ghana, this group was probably still diverse in genetic 
background. However, separate analysis of only Akan individuals, as the former study 
included probably mainly Akans, did not change results (data not shown). 
Susceptibility to develop Buruli ulcer neither seems to be related to MBL and VDR 
polymorphisms in our population. The median serum vitamin D concentration 
was around 70 nmol/L. Possibly, VDR polymorphisms only play a major role when 
vitamin D serum concentrations are lower. In a study that looked at serum vitamin 
D concentrations in Asian individuals that migrated to London,VDR polymorphisms 
influenced susceptibility for tuberculosis only in the subgroup with deficient or 
undetectably vitamin D serum concentrations [3 1 ]. 
A limitation of the present study is the unpowered sample size. An association 
with the polymorphisms therefore cannot be excluded. As in the former study a 
significant association with one of the SLC I I A I polymorphisms was found with a 
relatively small sample size, we decided the sample size would be high enough for 
reproduction. Higher samples sizes are difficult to obtain for M u/cerans infection. 
Studies like this are nevertheless important as results might add to developing ways of 
preventing or managing disease. Further analysis of the mechanisms of action and the 
downstream cellular pathways of susceptibility and resistance genes of the host, may 
lead to new approaches to control disease. Likewise, it will be helpful in identifying 
individuals in endemic areas that have increased risk to develop disease, giving them 
the opportunity to protect themselves against behavioural risks and to be aware 
of, and recognize M ulcerans infection in an early stage. In these individuals other 
strategies to combat disease, like a newly produced vaccine, could be considered 
when living in an endemic area [54]. 
In conclusion, no appreciable influence of carrying one of the SLC I I A I ,  MBL and 
VDR polymorphisms was found on developing Buruli ulcer disease. Buruli ulcer 
patients had significantly lower serum vitamin D concentrations than controls, 
which we relate to local activation and consumption of vitamin D by cells of the 
immune system, possibly resulting in production of the antimicrobial peptide 
cathelicidin. Insight in the role of susceptibility genes and further analysis of the role 
of vitamin D, cathelicidin and other antimicrobial peptides is important to increase 
our understanding in the pathology and evolution of this disabling disease, aiming for 
novel tools to combat Mycobacterium ulcerans infection. 
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Burul i  ulcer disease, a neglected tropical ulcerating skin disease caused by 
Mycobaeterium u/cerans [ 1 ,2] , is denoted tool-deficient by the WHO, as it lacks 
cost-effective control methods [3]. This thesis focused on the effectiveness of drug 
therapy to control infection. Chapter I provided a brief introduction into the history 
of treatment for Buruli ulcer disease, in which surgery dominated [4] . Disappointing 
results of chemotherapy were poorly understood, as in laboratory experiments 
antibiotics appeared effective against the causative organism Mycobaeterium u/cerans. 
The clinical effectiveness of combined therapy with streptomycin and rifampicin -
with or without surgery, as advised by WHO from 2004 on [5], was not studied in a 
wel l-designed clinical trial with robust follow-up and pre-defined clinical end-points 
[6]. Chapter I described the scope of the thesis and outl ined the hypotheses that 
were tested in the following chapters. 
In chapter 2 we unambiguously showed the effectiveness of antibiotics for the 
treatment of Buruli ulcer disease, defined as cl inical cure at time point 52 weeks 
after start of treatment [7]. In a non-inferiority design, we compared standard 
streptomycin and rifampicin for 8 weeks with a schedule of rifampicin for 8 weeks 
and streptomycin for only 4 weeks, with a switch to oral clarithromycin for a further 
4 weeks. Of the 1 54 participants with early, l imited Buruli ulcer lesions that were 
included in the trial, 1 5 1  were randomized. Four were lost to follow-up before the 
primary end-point -complete heal ing at one year after start of treatment - was 
reached; but these four participants had healed lesions at the time of their last 
assessment, and were included in the analysis. Randomization was done remotely 
in the Netherlands with help of cell-phone text messaging. Five participants needed 
extensive surgery, and of six participants lesions were not healed at time point one 
year. 73 (96%) participants in the 8-week streptomycin group and 68 (9 1 %) participants 
in the 4-week streptomycin plus 4-week clarithromycin group had healed lesions at 
one year (odds ratio 2 49, 95% Cl 0 ·66 to infi nity; p=0 · 1 6, one-sided Fisher's exact 
test). No participants had lesion recurrence at I year. Five participants received skin 
grafting. Few side effects were reported; three participants had vestibulotoxic events, 
three reported abdominal d iscomfort, one developed an injection abscess and two 
developed an abscess close to the initial lesion, which was incised and drained. 
It can be concluded from this study that antimycobacterial treatment for 
Mycobaeterium u/cerans infection is highly effective in early, limited disease. As both 
study arms had simi lar efficacy, the number of injections of streptomycin can be 
reduced, by switching to oral clarithromycin after 4 weeks. 
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In chapter 3 we discussed the complex bidirectional pharmacokinetic interactions 
involved when combining rifampicin and clarithromycin in the treatment for 
Mycobacterium u/cerans infection [8]. We showed that adding clarithromycin to 
rifampicin resulted in a 60% non-significant, but possibly relevant, increase in plasma 
rifampicin concentration. In addition, we found that the exposure to the drug metabolite 
14-hydroxyclarithromycin [9] was significantly higher than that to clarithromycin. 
This is probably an effect of rifampicin co-medication, inducing the clarithromycin 
metabolism in the liver [ I 0-12]. The minimal inhibitory concentration (MIC) of 
14-hydroxyclarithromycin for Mycobacterium ulcerans was studied by DeepakAlmeida 
at the mycobacteriology laboratory of Professor Grosset at the Johns' Hopkins, 
Baltimore. The MIC appeared too high to expect any additional antimycobacterial 
effect on Mycobacterium ulcerans. The median time above MIC for the Ghanaian 
Mycobacterium ulcerans strain [ 13] (0.25 mg/I) was about 4 hours per 24 hours. In all 
eight patients, blood concentrations remained above MIC for at least some period 
of time. However, for the Malaysian Mycobacterium ulcerans strain [ 14], two patients 
did never reach the MIC (0.5 mg/I). Neo-macrolide antibiotics, like clarithromycin, 
have different pharmacokinetics and pharmacodynamics than other antibiotic classes 
[ 15]. This class of antimicrobial agents is characterized by a combination of low 
serum concentrations and high concentrations in phagocytes, while there is debate 
about actual soft tissue concentrations [ 16-18]. As Mycobacterium ulcerans has an 
intracellular -stage [19-21], clarithromycin might particularly be effective during this 
phase of infection [22]. Nevertheless, we concluded that, to ensure higher levels of 
exposure and time above MIC, a dose of 7.5 mg/kg should be given twice daily - or 
an extended release formulation once daily -, as the dose which was used presently 
appeared to be well-tolerated. In this way, the chance of inadvertent mono-therapy 
as a result of drug-drug interaction can be brought to minimum, reducing the chance 
of inducing drug resistance for rifampicin as well as for clarithromycin. 
In chapter 4 we supported our hypothesis on paradoxical reactions accompanying 
effective treatment for Mycobacterium ulcerans infection by describing three 
observational phenomena in the evolution of disease after start of therapy: (i) 
transient increases in lesion size; (ii) ulceration of non-ulcerative lesions; and (iii} 
development of new lesions [23].The three response patterns were observed during 
therapy, as well as after the 8 week antimicrobial therapy had ended. For the lesion 
size analysis 134 Buruli ulcer patients were included; these were participants of 
the randomized trial described in chapter 2. To be able to show response patterns 
during effective antimicrobial treatment, included for the lesion size analysis were 
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participants that healed on treatment. Participants that failed on treatment, were 
HIV co-infected, or had skin grafting were excluded. Peak 'paradoxical response' 
occurred at week 8, when over 30% of patients showed an increase in lesion size 
as compared to the previous (week 6) assessment. To strengthen the analysis, we 
performed a sensitivity analysis by varying the definitions of paradoxical response, 
e.g. two consecutive increases or an increase after a decrease in surface area, which, 
likewise, confirmed the presence of the phenomenon we describe as paradoxical 
response.A total of 90 participants had non-ulcerative lesions at time of inclusion; 75 
(83%) of these lesions ulcerated after start of treatment. Nine participants developed 
new lesions during or after treatment.All lesions subsequently healed.We concluded 
from this analysis that, after start of antimicrobial treatment for Buruli ulcer, new 
or progressive ulceration is common before healing sets in. Moreover, the chapter 
emphasizes that this paradoxical response should not be misinterpreted as failure to 
respond on treatment [24,25]. 
In chapter 5 we showed that early detection of aminoglycoside-induced ototoxicity 
in a field setting by means of a portable audiometer - with no soundproof 
audiometry facilities - is limited (manuscript submitted). Though aminoglycoside­
induced ototoxicity affects the higher frequencies first [26,27], intra- and inter­
observer measurements were less reliable at 6 and 8 kHz. However, in the normal 
hearing range (0.25 to 4 kHz), the intra- and inter-observer reliability of the portable 
audiometer was satisfactory. The study showed that a portable audiometer can be 
well operated in the field by different observers with minimal training, which is useful 
in general daily practice. Levels of hearing impairment might be overestimated as a 
result of ambient noise, but changes over time can be reliably detected. 
In chapter 6 we describe a patient-control analysis in which significantly lower vitamin 
D blood concentrations were found in the 179 Buruli ulcer patients as compared 
to the 180 matched control subjects (65.9 vs 73.0 nmol/L; p<0.001) (manuscript 
submitted). Possible explanations for the lower vitamin D serum concentrations 
are increased consumption of vitamin D by cells of the immune system at the site 
of infection [28-30], or less likely, decreased exposure to sunlight resulting from 
covered skin or inability to participate in farming and other out-door activities, due 
to Mycobacterium ulcerans disease. This new finding could be important in finding 
novel ways to improve disease management. 
We were unable to confirm the earlier established association of SLC I I A I gene 
polymorphisms with susceptibility for Buruli ulcer disease [31 ]. The sample size was 
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similar to the previous study, but the population presently studied had a different 
ethnic background (i.e., other tribal origins), which could be a possible explanation 
for the conflicting results. In our patient population, we were unable to detect 
polymorphisms in the VDR gene or in the MBL gene that were associated with 
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With the study described in chapter 2 [ I ], we intended to make the first step 
towards developing a fully oral regimen for the treatment of Mycobacterium u/cerans 
infection.Although a switch to oral drugs after four weeks of standard streptomycin 
injection-based treatment is advantageous in reducing potential additional infectious 
risks associated with the injections, as well as in reducing logistic challenges incurred 
by injection therapy in rural Africa [2-5], a fully oral regimen would be the preferred 
treatment [6-1 0] . The findings of the present trial led to the preparation of a new 
trial, addressing the question whether a fully oral treatment is non-inferior to the 
standard streptomycin and rifampicin treatment. 
Apart from finding new and better antimycobacterial treatment combinations, 
the minimal duration of antimicrobial therapy to cure infection should be another 
focus of investigation. We hypothesize that antimicrobials shut down mycolactone 
synthesis so as to allow the immune system to recover and initiate an immune 
response adequate to fight Mycobacterium ulcerans [ I 1- 1 7] .  Once this adaptive 
immune response is established, infection might be controlled without additional 
antimicrobial treatment. Support for this hypothesis comes from our observation 
of ultimately healed lesions in which living bacteria were found after the 8 week 
antimicrobial treatment had been discontinued [ I ] . Besides, an unknown but 
considerable proportion of individuals is able to spontaneously clear pre-clinical or 
clinical infection, without active treatment, which supports the major importance of 
an adequate immune response in defense for this particular mycobacterium [ 18-26] . 
The virulence of Mycobacterium u/cerans depends on its formation of mycolactone 
[27-3 1 ] . Arresting the mycolactone synthesis machinery by interfering with (post-) 
translation of the mycolactone synthesis genes on the plasmid and the cellular 
genome, the immune system might control the infection. In this view, even single-drug 
treatment would possibly be adequate in treating Mycobacterium u/cerans infection. 
No resistant Mycobacterium u/cerans strains have been cultured from human tissues 
to date. Indeed, the risk of spreading resistant mycobacteria is much smaller in 
Mycobacterium u/cerans infection than in e.g. tuberculosis, in which, unlike Buruli ulcer, 
humans are the reservoir of the infectious agent. In fact, unpublished information 
shows that Buruli ulcer has been treated with rifampicin alone in many endemic 
areas in the seventies and eighties of the twentieth century [ IO] . WHO discourages 
the use of mono-therapy for Mycobacterium u/cerans infection. One might argue that 
even a more wide-spread policy of mono-therapy of an assumedly environmentally 
acquired infection would probably not be associated with an appreciable risk of 
drug resistance. The most important concern is however that such treatment 
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might be associated with recurrence or persistent infection, especially in immune­
compromised hosts. 
Further, aspects of local treatment, like type of dressing materials [32], frequency 
of dressing changes, the role of skin grafting as well as the role of limited surgical 
excision of necrotic tissue in larger lesions [33] should be studied, intending to 
fasten the slow pace of healing shown in the present study.Topical use of autologous 
blood products like platelet gel or fibrin sealant [34-38] could be suitable to fasten 
wound healing as preparation is simple and therefore applicable in resource poor 
circumstances. 
T he role of mycolactone, which could have an important role in the slow pace of 
wound healing, should be another focus of research. T he kinetics of mycolactone 
in tissue and blood should be studied [39]. Ways to halt or decrease mycolactone 
production, to increase or stimulate its tissue washout, or products that have the 
ability to degrade the molecule should be developed and tested in vitro. 
Apart from its antibacterial effects, clarithromycin is known to have short- and long­
term anti-inflammatory effects [40-43]. lmmunomodulation might result in faster 
healing, fewer or less intense paradoxical reactions, or other anti-inflammatory 
benefits. In the present study we were not able to find support for this, but when 
clarithromycin is given from start of treatment this positive impact on inflammation 
might become obvious. 
Strikingly, the majority of our patient population presented with lesions on the right 
side of the body, an observation that has been reported previously in Ghana as well 
[44,45]. T his confirmed finding could be an important additional clue in unraveling 
the mode of disease transmission. Treatment of Mycobacterium ulcerans infection 
might become superfluous if transmission could be prevented. Despite large and 
intense research efforts, neither the reservoir nor the transmission to humans has 
been elucidated [46].T he study of reservoir and transmission is complicated by the 
fact that transmission can vary over time [ 4 7-49]. Possibly several different modes 
of transmission occur in different endemic foci [46]. For the first years to come, 
the main focus of research should be improving patient treatment. In the absence 
of adequate prevention, early diagnosis and prompt and adequate treatment should 
prevent large lesions with subsequent important sequelae and functional limitations 
[50-52]. 
Future clinical antibiotic studies for Buruli ulcer treatment should be accompanied 
by more extensive pharmacokinetic and -dynamic studies, to confirm drug intake, 
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and to confirm adequate drug concentrations in blood and especially in affected 
tissues. Limited tissue sampling techniques combined with minimally invasive finger 
prick blood specimens air-dried on filter paper which simplify transport conditions 
could be helpful to study drug-exposure in  a larger number of patients [53], and 
mycobacterial d rug resistance testing should be carried out when possible [54,55] . 
Cost-benefit analyses could strengthen the results of antimicrobial treatment for 
Burul i  ulcer; more attention to this important factor should be given in future trials, 
as wel l  as to the prevention of disabil ity. Disabil ities are obviously less when surgery 
is brought to a minimum, but without surgery, lesions on or close to joints are 
sti ll p rone to heal with functional l imitations [56] . Providing appropriate tools and 
specialized personnel in the field of prevention of disabi l ities should be an integrated 
part of Burul i  ulcer treatment, and importantly in future cl inical trials money should 
be budgeted for this, which should improve qual ity of l ife for affected individuals. 
In the analysis of paradoxical worsening of disease under antibiotic treatment, 
we could not l ink the wound surface area measurements with biomarkers or 
histopathology to confirm our observations with biological phenomena that might 
explain our findings. Since we first reported our observations of paradoxical 
responses after start of antibiotic treatment at the WHO meeting on Buruli  ulcer in 
Geneva 2009, case reports that combined cl inical and h istopathological findings on 
this phenomenon were subsequently reported [ 1 4, 1 6] .  To study the phenomenon in 
a large clinical trial, biomarkers obtained in  repeated blood samples in this respect 
is a more patient friendly way than obtain ing consecutive multiple histo-pathological 
specimens. Future studies should focus on exploration of biomarkers to differentiate 
paradoxical responses from treatment failure, as a paradoxical response is a reason 
to continue antibiotic treatment or wait-and-see, while treatment failure would be a 
reason to switch antibiotic treatment, or to proceed to more costly and potentially 
disfiguring surgical interventions. 
No studies have addressed the question how paradoxical reactions should be 
prevented or managed. The immunosuppressive drug prednisone has been used for 
treating paradoxical, immune-mediated responses in tuberculosis, but no association 
was found between the use of steroids and the duration of the reaction [57] .  
Steroids might be efficacious especially when the central nervous system is  involved; 
they might reduce symptoms by control l ing disease associated edema [58]. The 
' immune reconstitution inflammatory syndrome' (I RIS) is a paradoxical response 
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following immune recovery in the context of starting antiretroviral therapy for H IV 
infection [59,60]. IRIS is associated with inflammation in response to an infectious 
agent, sometimes to dead bacil lary antigens, and may present as the unmasking of 
an initially subclinical co-infection, or as a deterioration of a co-infection under 
treatment [6 1 ,62]. In  paradoxical tuberculosis-associated IRIS, the use of steroids 
has been addressed in a randomized clin ical trial [63]. Prednisone provided benefit 
as it reduced the need for hospitalization and therapeutic procedures, hastened 
improvements in symptoms and qual ity of l ife, despite a higher risk of nonsevere 
opportunistic infections. Case reports and series describe NSAIDs, thal idomide 
and leukotriene receptor antagonists as potentially beneficial; and TNF-a inhibitors, 
chemokine receptor antagonists, vitamin D and statins have been suggested to 
prevent IRIS or its complications [60]. These agents might have a possible beneficial 
role in treating or preventing paradoxical responses in Mycobaeterium ulcerans 
infection as wel l. 
To explore possible genetic associations with Buruli u lcer,response to treatment-(time 
to) healing, paradoxical reaction-, pharmaco-genetics as well as pharmacokinetics and 
-dynamics, future studies should enroll larger patient populations. Whole Genome 
Analysis could be a next step to gain more knowledge on these issues, to be able to 
use this knowledge to improve treatment strategies.An international bio bank could 
be set up, which provides the opportunity to strengthen collaboration in Buruli u lcer 
research and to merge small databases and scattered patient information. 
The interesting finding of serum vitamin D concentrations, which were lower in 
untreated Burul i  u lcer patients as compared to healthy controls [64] should be 
followed by a confirmation study. This study could also incorporate vitamin D 
measurements after treatment has finished and at the moment patients are healed, to 
differentiate pre-existing differences in vitamin D status from vitamin D consumption 
by cells of the immune system or a decrease in sunl ight exposure resulting from 
covered skin, stigma, or the impossibil ity to work outside. Furthermore, our 
proposed possible role of cathelicidin [65], a peptide that is related to vitamin D 
dependent antimicrobial effects should be investigated, which might give clues to 
fight Buruli ulcer disease in different ways. Final ly, supplementing vitamin D might be 
worth studying, as has been tried in tuberculosis [66,67] . 
In conclusion, the randomized trial we performed has clearly answered the question 
whether patients with Mycobaeterium u/cerans infection should have antimicrobial 
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treatment:the evidence base is sufficiently strong for a high grade of recommendation 
[7].All-oral schemes should be developed, ways to fasten healing should be provided 
and the newly introduced phenomenon of paradoxical response to treatment 
should be studied and explored with the intention to provide definitions, criteria 
and treatment recommendations to optimize treatment for Buruli ulcer. 
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Buruli ulcus (Buruli zweer of afgekort BU) is een tropische, zwerende huidinfectie 
veroorzaakt door Mycobaeterium ulcerans. Toen in de jaren zestig uit Oeganda, ender 
andere uit het Buruli-district, vele meldingen kwamen over het v66rkomen van de 
infectie, raakte de naam 'Buruli ulcus' in zwang. Na tuberculose en lepra, die net als 
BU door mycobacterien, een speciale groep micro-organismen, warden veroorzaakt, 
is BU de derde belangrijkste mycobacteriele infectieziekte bij mensen met een 
normale afweer. De bacterie - M. u/cerans - kan in het laboratorium gekweekt 
warden en groeit het beste bij temperaturen rand 32 °C. De bacterie heeft als 
unieke eigenschap dat het in staat is om een giftige stof - mycolacton - te maken; 
deze stof is de oorzaak van de uitgebreide weefselschade zeals die bij patienten, en 
ook bij proefdieren optreedt. 
BU komt op dit moment met name voor in West-Afrika. Het merendeel van de 
patienten woont in arme, afgelegen gebieden, in een moerassige of vochtige omgeving. 
De infectie begint als een subcutane nodus (onderhuidse bobbel), een plaque 
(plaatachtige verharding van de huid) of oedeem (zwelling gepaard met vochtuittreding 
in weefsels), die samen aangeduid warden als de niet-ulceratieve lesies. Op een 
gegeven moment breekt de huid open en ontstaat er een zweer met ondermijnde 
rand en centraal veel dood weefsel, de ulceratieve lesie (zie plaatjes bij hoofdstuk I ). 
De infectie is pijnloos en wordt vooral gezien op de armen en benen van kinderen. 
Het is onbekend hoe de infectie wordt opgelopen. De Wereldgezondheidsorganisatie 
(WH O) schaart BU - samen met 18 andere tropische aandoeningen - ender de 
"verwaarloosde tropische ziektes". In hun Plan to combat Neglected Tropical Diseases 
(2008-20 1 5) stelt de WHO dat er geen bevredigende mogelijkheden zijn om de 
infectie te bestrijden. Dit proefschrift richt zich op de effectiviteit van antibiotica 
voor de behandeling van BU. 
Moet Buruli ulcus behandeld worden met antibiotica? 
Hoofdstuk I geeft een inleiding in de geschiedenis van de behandeling van BU. Bij 
tuberculose en lepra bestaat de belangrijkste behandeling uit een combinatie van 
ten minste twee anti-mycobacteriele middelen. Bij BU leken deze antibiotica niet 
te werken: er was tijdens de behandeling geen duidelijk effect zichtbaar en soms 
namen de afwijkingen alleen maar toe in grootte en ernst. Lang heeft men daarom 
gemeend dat een operatieve verwijdering van aangedaan weefsel de enige goede 
kans op genezing bood. Hoewel M. u/cerans, de bacterie die BU veroorzaakt, bij 
testen in het laboratorium gevoelig bleek voor verschillende antibiotica, en deze 
antibiotica ook effectief waren in een diermodel waarbij M. u/cerans werd ingespoten 
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in voetkussens van muizen, waren de resultaten van behandeling met antibiotica 
in de praktijk vaak teleurstellend. De principiele vraag of antibiotica in staat zijn 
M. ulcerans bij de mens uit te schakelen, moest eerst beantwoord worden. Door 
een studiegroep van de WHO werd daarom een onderzoek opgezet en uitgevoerd 
waarbij uiteindelijk 21 patienten met een onderhuidse nodus door M. u/cerans, een 
van de niet-ulcererende vormen van BU, enkele weken werden behandeld met een 
combinatie van twee antibiotica. De keuze viel op twee middelen - streptomycine 
(S), een middel dat alleen als injectie gegeven kan worden, en rifampicine (R), wat als 
tablet kan worden toegediend. Op basis van eerdere experimenten met meerdere 
antibiotica - zowel in kweekproeven als in diermodellen, was de combinatie SR als 
de meest krachtige naar voren gekomen. Na de antibiotische behandeling die steeds 
varieerde in tijdsduur, werd de lesie operatief verwijderd, en het weefsel gekweekt. 
Bij de patienten die twee weken waren behandeld met SR werden nog levende 
bacterien aangetoond in het verwijderde weefsel, maar bij geen van de patienten die 
vier, acht of twaalf weken waren behandeld werden nog levende bacterien ge"isoleerd. 
Op basis van deze resultaten die tijdens de WHO Buruli ulcus bijeenkomst in 2004 
werden gepresenteerd en later ook gepubliceerd, ontstond een omslag in het den ken 
over de rol van antibiotica bij de behandeling van BU. Antibiotica werden steeds 
meer voorgeschreven - zeker daar waar geen mogelijkheden voor chirurgische 
behandeling voorhanden waren. Het effect van antibiotische behandeling bij de 
meest bekende presentatie van de ziekte - het ulcus - was echter niet onderzocht 
in een goed opgezet klinisch (patient-gebonden) wetenschappelijk experiment. 
Ook was onbekend of de niet-ulceratieve lesies bij de patienten in het beschreven 
onderzoek inderdaad genezen waren als deze niet chirurgisch verwijderd zouden 
zijn. Is de dosering en behandelduur die gekozen was voor de patienten met de 
nodus vorm van BU afdoende voor alle vormen van BU? Hoe groot is de kans 
op genezing als geen operatie wordt uitgevoerd naast antibiotische behandeling? 
Is er kans op antibiotica resistentie, bijvoorbeeld door te lage dosering met te 
lage weefselconcentratie van antibiotica, of kan de behandeling falen door een te 
korte behandelduur? Hoe groat is de kans op bijwerkingen en toxiciteit (schade) 
door antibiotische behandeling? Is de genezing blijvend of komt de ziekte weer 
terug, bijvoorbeeld een jaar na staken van de behandeling, zoals vaak het geval is 
bij chirurgische behandeling? Acht weken dagelijkse injecties met streptomycine is 
vooral voor kinderen maar ook voor volwassenen een probleem. Op het Afrikaanse 
platteland waar BU het meest voorkomt is het moeilijk om injecties op steriele wijze 
te geven; gezondheidsposten zijn soms nog ver verwijderd van de plaats waar de 
patienten wonen; en de overdracht van HIV door ongelukken met injectiespuiten is 
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in Afrika ten zuiden van de Sahara aanzienlijk. Is het mogelijk om het aantal injecties 
te beperken en althans een deel van de kuur met andere antibiotica te behandelen? 
Hoewel al deze vragen nog onbeantwoord waren was de druk om antibiotica in te 
voeren zo groot dat de WHO in 2004 in een voorlopige richtlijn adviseerde om 
BU voortaan te behandelen met de SR combinatie. De behandelduur evenals de 
beslissing om aanvullend te opereren werd aan het klinisch oordeel overgelaten: SR 8 
tot 12 weken werd als standaard therapie geadviseerd, met eventueel chirurgie, ook 
al was duidelijk dat er aanvullend onderzoek nodig was om de nog vele openstaande 
vragen te beantwoorden. Hoofdstuk I beschrijft, in relatie tot deze vragen, de opzet 
van het proefschrift met de onderzoeksvragen die in de volgende hoofdstukken 
worden getoetst. 
Wat is de werkzaamheid van de 'standaard' (door de WHO geadviseerde) 
behandeling van Buruli ulcus met 8 weken streptomycine + rifampicine, 
zonder uitgebreide chirurgie? Is de behandeling ook effectief wanneer het 
injecteerbare antibioticum (streptomycine) na 4 weken wordt vervangen 
door tabletten (claritromycine)? 
In hoofdstuk 2 wordt de werkzaamheid van antibiotica voor de behandeling van BU 
onomstotelijk aangetoond. De 'standaard behandeling' streptomycine en rifampicine 
gedurende 8 weken (8SR) werd vergeleken met een schema van rifampicine gedurende 
8 weken en streptomycine gedurende maar 4 weken, waarna de behandeling werd 
voortgezet met claritromycine (C) gedurende 4 weken (4SR/4CR). Dit laatste schema 
heeft als voordeel dat de injecties na 4 weken worden omgezet in tabletten. 15 1 
deelnemers met een vroege (niet langer dan 6 maanden bestaande), beperkte (niet 
groter clan IO cm in diameter) vorm van BU werden, nadat zij hiervoor toestemming 
hadden gegeven, willekeurig verdeeld over de twee behandelschema's. De loting 
voor een van de twee behandelschema's werd uitgevoerd met behulp van een 
computerprogramma in Nederland, vervolgens werd de toewijzing overgezonden; 
de communicatie verliep via SMS berichten tussen Nederland en Ghana. De 
steekproefgrootte was zodanig gekozen dat wanneer tenminste 148 deelnemers 
tot het einde van het onderzoek - 52 weken na start van behandeling - gevolgd 
zouden worden, een voldoende betrouwbaar antwoord gegeven kon worden op 
de onderzoeksvraag: hoe vaak treedt genezing op zonder terugkeer van ziekte? Dit 
primaire eindpunt werd vergeleken tussen de deelnemers van de twee verschillende 
behandelschema's. Vier van de 15 1 deelnemers konden om verschillende redenen 
niet worden gevolgd tot week 52, maar op het moment dat zij voor het laatst 
gecontroleerd werden was hun lesie genezen; zij werden daarom ook meegenomen 
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in de analyse. In totaal was er bij I I van de 15 1 deelnemers sprake van 'therapiefalen': 
de lesie van vijf deelnemers verslechterde in die mate dat behandelteams besloten tot 
uitgebreide chirurgie, en de lesie van zes deelnemers was nog niet genezen op week 
52. Dit resulteerde in een statistisch gezien niet verschillende behandeleffectiviteit 
van 96% (73/76) in de 8SR groep en van 9 1  % (68/75) in de 4SR/4CR groep. In geen 
van beide groepen trad een recidief op van het ziektebeeld. Vijf deelnemers werden 
behandeld met behulp van een huidtransplantatie vanwege de grootte van het 
huiddefect. Er werden weinig bijwerkingen gemeld; drie deelnemers klaagden over 
duizeligheid (gevolg van streptomycine); drie meldden buikklachten; een ontwikkelde 
een injectie abces. Twee deelnemers ontwikkelden een abces in de buurt van de 
oorspronkelijke lesie. Uit deze studie kan geconcludeerd worden dat antibiotische 
behandeling gedurende 8 weken uitermate effectief is voor BU patienten met een 
vroege, beperkte infectie, en dat injectietherapie verkort kan worden naar 4 weken 
door de patienten verder met tabletten te behandelen. 
Be"invloeden rifampicine en claritromycine elkaars werkzaamheid en wat 
heeft dat voor consequenties voor de behandeling van Buruli ulcus? 
In hoofdstuk 3 wordt de complexe wisselwerking tussen twee van de in hoofdstuk 
2 gebruikte antibiotica, rifampicine en claritromycine - wanneer deze middelen 
tegelijkertijd worden toegediend - bestudeerd. Rifampicine kan de lever aanzetten 
tot een versnelde afbraak van bepaalde stoffen, waaronder claritromycine. Dit 
kan leiden tot een lagere concentratie van claritromycine in het bloed, met als 
eventueel ongewenst effect een lagere werkzaamheid en resistentievorming, dat 
wil zeggen het ongevoelig worden van de bacterie voor het antibioticum door 
een onvoldoende krachtige behandeling. Anderzijds zorgt claritromycine voor een 
vertraagde afbraak van bepaalde stoffen in de lever, waaronder rifampicine. Dit 
kan juist resulteren in een verhoogde concentratie van rifampicine in het bloed, 
waardoor er sneller bijwerkingen zouden kunnen ontstaan.Voor dit type onderzoek 
waarbij het verloop van bloedconcentraties in de tijd worden vergeleken, worden 
meestal kleine aantallen deelnemers onderzocht; 13 deelnemers uit de studie 
beschreven in het vorige hoofdstuk namen deel aan dit farmacologische onderzoek. 
Gedurende een behandeldag werd frequent bloed afgenomen om het verloop van 
de concentraties van de antibiotica in de tijd te kunnen bepalen. De inname van 
claritromycine in de onderzochte patienten resulteerde in een 60% hogere bloed 
concentratie van rifampicine. In deze kleine groep deelnemers was het verschil niet 
significant, maar mogelijk wel van belang.Verder bleek dat bij de meeste deelnemers 
gedurende tenminste enige tijd van de dag concentraties van claritromycine in 
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het bloed werden bereikt die hoog genoeg waren om de groei van Mycobaeterium 
u/cerans tegen te gaan. De concentratie van het afbraakproduct van claritromycine, 
1 4-hydroxy-claritromycine, bleek veel hoger dan van claritromycine zelf. H ierop 
werd samenwerking tot stand gebracht met het laboratorium van Professor 
G rosset in het Johns Hopkins ziekenhuis in Baltimore. Door de groep van Grosset 
werd onderzocht of deze afbraakstof - die naast het antibioticum zelf bij andere 
bacterien vaak een goed antibiotisch effect heeft - ook invloed heeft op de groei van 
Mycobaeterium ulcerans. De antibiotische werking van 1 4-hydroxy-claritromycine op 
M. u/cerans bleek zwak en niet bijdragend. 
Claritromycine is onderdeel van een groep antibiotica genaamd neo-macroliden, 
d ie hun antibiotische werking uitoefenen op bacterien door de eiwit aanmaak in  
de bacterie te  remmen. Neo-macrol iden hebben een opval lend lage concentratie 
in het bloed, maar juist een hoge concentratie in cel len. Met name fagocyten, d it 
zijn afweercellen die een rol spelen in het 'opeten' van bacterien, kunnen hoge 
concentraties bevatten. Omdat M. u/cerans in de eerste fase van de infectie in de eel 
zit, is mogelijk tijdens deze fase de activiteit van claritromycine  tegen de bacterie 
het sterkst. Desondanks concluderen wij aan het einde van het hoofdstuk op basis 
van bovenstaande resultaten dat, om voldoende werkzaamheid te garanderen 
en om resistentievorming te voorkomen, claritromycine in de toekomst liefst 
hoger gedoseerd moet worden wanneer gecombineerd met rifampicine voor de 
behandeling van BU, mede omdat met het gebruikte doseringsschema het middel 
goed werd verdragen. 
Waarom heeft men zo lang gedacht dat antibiotica niet werkzaam zijn 
tegen Buruli ulcus? Is er bewijs voor een met de antibiotische behandeling 
gepaard gaande paradoxale reactie? 
In hoofdstuk 4 onderzochten en beschreven wij het fenomeen paradoxale reactie bij 
de behandeling van Buruli ulcus. Een paradoxale reactie wil zeggen dat er tijdens de 
behandeling een kl inische verslechtering van de ziekte optreedt, terwijl de bacterien 
die de infectie veroorzaken ju ist goed onderdrukt worden, en waarbij uiteindelijk de 
behandel ing effectief blijkt te zijn. Dit fenomeen is bekend bij tuberculose (vooral 
lymfkliertuberculose) en bij lepra. Bij BU werden er enkele gevallen beschreven 
nadat wij hier in 2009 in een mondelinge presentatie over hadden gerapporteerd. 
Wij hadden tijdens de uitvoering van het onderzoek beschreven in hoofdstuk 2 
opgemerkt, dat het regelmatig leek alsof {i) wondoppervlaktes groter werden voor 
er genezing optrad, (ii} lesies met een intacte huid eerst openbraken, voordat er 
genezing optrad, en { i i i) er bij patienten tijdens of na de behandel ing n ieuwe lesies 
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ontstonden, die genazen zonder iets in de behandeling aan te passen. 
Voor dit onderzoek wilden wij patienten met een normale afweer onderzoeken, 
die volgens de tevoren vastgestelde criteria zoals beschreven in hoofdstuk 2 waren 
genezen. Deelnemers die met HIV ge'infecteerd waren, en ook deelnemers die met 
een huidtransplantatie of andere operatie waren behandeld werden uitgesloten; de 
gegevens van 1 34 deelnemers werden geanalyseerd. Tijdens elke controle werd het 
wondoppervlak van de lesie van elke deelnemer bepaald - dit door te kijken naar 
de afwijkingen van de huid, maar ook door de huid ronddom te betasten - waarbij 
de afwijking die in de huid werd gevoeld ook werd gemarkeerd op de huid. Met 
behulp van een doorzichtige sheet werd dan de grootte van de lesie vastgelegd. 
Deze sheet werd gedesinfecteerd en bewaard, om later ingescand te worden. Met 
behulp van een grafisch programma werd het wondoppervlak met de computer 
berekend. Per deelnemer werd het verloop van het oppervlak van de lesie bekeken 
door elke meting te vergelijken met de meting ervoor. Hierbij viel op dat er in 
week 8 een piek werd gezien in het optreden van een paradoxale respons; meer 
dan 30% van de deelnemers had in week 8 een toename van het wondoppervlak 
in vergelijking met week 6. Omdat het onbekend is hoe betrouwbaar eenmalige 
wondoppervlakte metingen zijn, werden meer analyses verricht, waarbij de definitie 
van paradoxale reactie werd verscherpt, bijvoorbeeld twee opeenvolgende toenames 
of een toename na een afname in wondoppervlak; ook als we de definitie aanpasten 
werd het optreden van paradoxale reacties bevestigd. 90 deelnemers hadden bij 
aanvang van het onderzoek een niet-ulceratieve lesie. Bij 75 (83%) van deze lesies 
ontstond alsnog een zweer, soms tijdens en soms na afronden van de antibiotische 
behandeling, voordat genezing optrad. Negen deelnemers ontwikkelden nieuwe 
lesies tijdens of na de antibiotische behandeling, die alle ulcereerden, maar zonder 
aanvullende maatregelen weer genazen. De bovenstaande observaties deden ons 
concluderen dat na het starten van antibiotische behandeling wegens BU vaak 
nieuwe lesies ontstaan, of bestaande zweren toenemen in grootte voordat genezing 
optreedt. Deze opvallende bevinding zou kunnen verklaren waarom de effectiviteit 
van antibiotica in het verleden is onderschat, en dat ver-keerde conclusies werden 
getrokken uit waarnemingen met onvoldoende duur van follow-up. Deze paradoxale 
reacties moeten dus niet verward worden met therapiefalen. Dit onderscheid is 
moeilijk omdat wij therapiefalen eerder hadden aangeduid als toename van lesies tot 
meer dan 1 50% van de grootte bij het begin van de behandeling. De discussie over 
paradoxale reacties is natuurlijk niet alleen van groot praktisch belang, maar is ook 
belangrijk bij het ontwerpen van toekomstige onderzoeken om BU met antibiotica 
te behandelen. 
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Is draagbare audiometrie geschikt voor het aantonen van gehoors­
vermindering door het antibioticum streptomycine? 
Streptomycine is onderdeel van een groep antibiotica genaamd aminoglycosides. 
Naast een krachtige bacteriedodende werking hebben deze middelen ook 
bijwerkingen, waaronder gehoorschade, met name wanneer er hoge doseringen 
worden gegeven of wanneer er langdurig behandeld wordt. In hoofdstuk 5 laten wij 
zien dat het vroegtijdig vinden van door aminoglycoside veroorzaakte gehoorschade 
door middel van een draagbare audiometer in een ziekenhuis zonder geluidsdichte 
kamer, moeilijk is. De betrouwbaarheid van de draagbare audiometer werd bepaald 
door deze eerst te vergelijken met de apparatuur van de geluidsdichte kamer in het 
universiteitsziekenhuis van Kumasi, en daarna door dubbelmetingen met maximaal 
enkele uren tussenpoos bij verschillende vrijwilligers in de ziekenhuizen waar het 
onderzoek beschreven in hoofdstuk 2 werd verricht. Hier was geen geluidsdichte 
kamer en het niveau van achtergrondgeruis was hoog met een geluidssterkte van 
ongeveer 50 dB. In de 0,5 tot 4 kHz frequenties ( dit zijn de toonhoogtes of frequenties 
waarin de normale spraak zich bevindt) bevond de tweede meting zich in meer dan 
95% procent van de gevallen binnen de algemeen geaccepteerde bandbreedte van ± I 0 
dB ten opzichte van de eerste meting. In de 6 en de 8 kHz was de betrouwbaarheid 
van de test minder goed. Omdat hoorschade als gevolg van aminoglycosides meestal 
begint bij de hogere tonen, dat wil zeggen in de frequenties die boven het normale 
spraakgebied liggen, kan het vroeg aantonen van gehoorsvermindering niet met 
voldoende betrouwbaarheid worden vastgesteld met behulp van de gebruikte 
apparatuur in de beschreven setting. In de frequenties van het normale spraakgebied 
is de betrouwbaarheid van de draagbare audiometer acceptabel voor het aantonen 
van veranderingen van gehoor in de tijd, alhoewel absolute gehoorsvermindering 
overschat kan worden door achtergrondgeluid. De studie liet overigens ook zien 
dat de draagbare audiometer goed bediend kan worden door mensen na minimale 
training, wat bruikbaar is in de dagelijkse praktijk. 
Speelt vitamine D een rol in de afweerreactie tegen Mycobacterium 
ulcerans, de verwekker van Buruli ulcus? Spelen normaal voorkomende 
variaties in genen een rol in de vatbaarheid voor het krijgen van Buruli 
ulcus? 
In hoofdstuk 6 werden de BU patienten uit hoofdstuk 2 vergeleken met gezonde 
controle personen die zo werden gekozen dat ze zo goed mogelijk vergelijkbaar 
('gematched') waren met de patienten. De controle personen werden geselecteerd 
op grond van het geslacht, de leeftijd en de stam van waaruit de patient afkomstig was. 
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Antibiotica voor Buruli ulcus 
Bij tuberculose en lepra is eerder gebleken dat vitamine D, dat in voeding voorkomt, 
maar dat vooral ender invloed van zonlicht in de huid wordt aangemaakt, belangrijk 
is voor beschermende immuunreacties.Voor het antibioticatijdperk was zonlicht een 
geaccepteerde vorm van behandelen van tuberculose, en inname van extra vitamine 
D kan in bepaalde gevallen de behandeling van tuberculose gunstig be·invloeden. In 
het bleed van de patienten en de controlepersonen werd het vitamine D gehalte 
bepaald: deze bleek bij de BU patienten lager dan bij de controle personen, waarbij 
het verschil overigens niet groot was (65.9 nmol/L vs 73.0 nmol/L; p<0.00 I ). Wij 
speculeren over mogelijke verklaringen voor deze bevinding, waarbij het kan zijn dat 
ook bij BU patienten, net als bij tuberculose en lepra, afweercellen ter plekke van de 
infectie vitamine D gebruiken om goed te kunnen functioneren. Minder waarschijnlijk 
is dat een afgenomen aanmaak van vitamine D door een verminderde blootstelling 
aan zonlicht, vanwege het bedekken van de huid door stigma of het niet kunnen 
uitvoeren van werkzaamheden op het land door functionele beperkingen, hiervan de 
oorzaak is. De bevinding zou van waarde kunnen zijn om de ziekte in de toekomst 
beter te kunnen begrijpen en te behandelen. 
Niet alle personen die in aanraking komen met Mycobacterium ulcerans ontwikkelen 
BU. In eerder onderzoek werd aangetoond dat bepaalde natuurlijk voorkomende 
varianten (polymorfismen) in een bepaald gen (SLC 11 A I )  de kans op het krijgen 
van BU in zeer sterke mate verhoogde; eerder was dit effect ook al beschreven 
bij lepra en tuberculose. Dit gen is betrokken bij transport van zware metalen en 
heeft vermoedelijk een functie bij de afweer tegen bacterien in de macrofaag ( de 
afweercellen die bacterien 'opeten'). Wij besloten in het bloed van onze patienten 
en controles hetzelfde gen te onderzoeken, waarbij de uitslag van het eerdere 
onderzoek niet kon worden bevestigd. Dit is mogelijk te verklaren door verschillen 
in genetische afkomst van onze patienten in vergelijking met die van het eerder 
uitgevoerde onderzoek. Naast dit gen werden twee andere genen onderzocht, 
namelijk het vitamine D receptor gen, dat de gevoeligheid voor vitamine D mede 
bepaalt; en het M BL gen, omdat variaties in dit gen de vatbaarheid voor krijgen 
van tuberculose en lepra, de twee andere belangrijke mycobacteriele infectieziekten, 
kan be"invloeden. Net zeals het SLC I I A I gen bleken het MBL en het vitamine D 
receptor gen in onze patienten en controles niet te verschillen, althans niet voor wat 
betreft de onderzochte variaties. 
Samenvatting 
Hoofdstuk 7 geeft een Engelstalige samenvatting van het proefschrift. 
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Discussie en toekomstperspectieven 
Hoofdstuk 8 geeft een afsluitende discussie met ideeen voor verder onderzoek, 
als mogelijk vervolg op de in dit proefschrift beschreven studies. Een belangrijke 
vervolgstap zou zijn het verder ontwikkelen van een volledig orale antibiotische 
behandeling van BU (met tabletten, zonder injecties). De voorbereidingen voor 
een studie die een volledig oraal schema zal vergelijken met de standaard 8SR 
injectietherapie zijn in volle gang. Onze studie heeft slechts een tevoren vastgestelde 
behandelduur voor BU geevalueerd. Of de 8 weken durende antibiotische behandeling 
eventueel verkort zou kunnen worden of in bepaalde gevallen juist langer zou moeten 
duren is nog onduidelijk. Ook is nog behoefte aan onderzoek naar verbetering van 
de lokale wondbehandeling; wondverzorging met moderne verbandmiddelen lijken 
op het eerste gezicht kostbaar, maar als het aantal verbandwisselingen kleiner is 
zou dit misschien toch geld en mankracht besparen, en comfort voor patienten 
bieden. Ook zouden bepaalde chirurgische technieken wellicht de genezing van 
BU nog kunnen versnellen. Ons onderzoek naar paradoxale reacties bleef beperkt 
tot het beschrijven en analyseren van observaties. Er is onderzoek nodig naar het 
vinden van de immunologische mechanismen en daaraan gepaard, het vinden van 
immunologische merkers (tests, bijvoorbeeld in een bepaling in een bloedmonster, 
die de aanwezigheid van een paradoxale reactie aangeven) voor dit fenomeen. De 
belangrijke uitdaging is om therapiefalen van een paradoxale reactie te onderscheiden, 
omdat een paradoxale reactie een uiting is van een in principe adequate behandeling, 
en therapiefalen juist het tegenovergestelde. Ook weten we niet hoe paradoxale 
reacties therapeutisch benaderd moeten worden. Bij tuberculose en lepra is het 
gebruikelijk, om deze reacties te onderdrukken met afweer-onderdrukkende 
medicatie zoals prednisolon. Moeten paradoxale reacties ook bij BU geremd en 
behandeld worden met aanvullende medicatie? 
Meer informatie over genetische aanleg voor het ontwikkelen van BU, na het in 
aanraking komen met M. ulcerans, zou inzicht kunnen geven in welke personen 
speciale maatregelen zouden moeten treffen om de ziekte te voorkomen. 
De lagere concentratie vitamine D die werd gevonden in bloed van patienten in 
vergelijking met gematchte controlepersonen moet door nieuw onderzoek worden 
bevestigd. De rol van vitamine D bij BU zou ook in laboratoriumexperimenten 
moeten worden ontrafeld. Ook zou bekeken kunnen worden of het vitamine D 
gehalte van succesvol behandelde patienten na verloop van tijd weer stijgt, en wat dit 
zou kunnen betekenen voor de (aanvullende) behandeling van patienten. 
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Antibiotica voor Buruli ulcus 
Concluderend heeft ons onderzoek de vraag beantwoord of BU behandeld meet 
warden met antibiotica: er is voldoende bewijs om antibiotica te beschouwen als de 
basis voor de behandeling.Nieuwe antibiotische schema's moeten ontwikkeld warden; 
de behandelduur bij patienten met hele kleine of juist hele grate afwijkingen meet 
eventueel aangepast warden; een snellere genezing kan mogelijk bereikt warden door 
onderzoek naar verbetering van de wondbehandeling (verbandmiddelen, eventueel 
met toepassing van op de wend aangebrachte middelen; en misschien bepaalde 
vormen van chirurgie). Er is beter inzicht nodig in het wezen van een paradoxale 
reactie, en daaraan gekoppeld, het ontwikkelen van tests om het onderscheid met 
therapiefalen te maken; en het ontwikkelen van een behandeling van patienten met 
zo'n reactie is tenslotte een nog verder verwijderd doel. 
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In het Twii bedank je mensen door te zeggen meda wo ase, wat letterlijk betekent ik 
leg mij aan je voeten. lk vind het een prachtige uitdrukking, een die veel respect toont. 
lk wil mij dan ook figuurlijk aan jullie voeten leggen. Jullie zijn allemaal in meer of in 
mindere mate onderdeel geweest van het hele proces: zonder jullie zou dit proef­
schrift er niet zijn geweest of niet zijn zeals hij nu is. 
Allereerst ben ik mijn patienten veel dank verschuldigd. Jullie stelden vertrouwen in 
ons en kwamen steeds maar weer voor de geplande controles, zelfs al waren won­
den genezen en hadden jullie belangrijkere dingen aan je hoofd dan een drug trial. lk 
heb veel respect voor jullie! 
Beste Prof. dr. van der Werf, mijn promoter, Tjip. Jouw enthousiasme voor het onder­
werp is besmettelijk. lk ken niemand die zo snel reageert op 'drafts'. Zander elkaar 
gesproken te hebben vroeg je mij dit onderzoek te coordineren. Onze verschillende 
karakters botsten wel eens, wat we misschien niet eens zo vaak doorhadden vanwege 
de grote letterlijke afstand die vaak tussen ons in zat. Zander jou was het onderzoeks­
plan er niet geweest, was het uitgevoerde onderzoek niet van deze kwaliteit geweest 
en was ook dit proefschrift niet geschreven. Jij benaderde mij soms met vaderlijke 
strengheid, maar gaf complimenten wanneer je ergens tevreden over was. Heb ik je 
al bedankt voor het mij over de lijn dwingen? Als jij dat niet had gedaan dan zou ik nu 
nog steeds zeggen: ik ben ermee bezig! Wat heerlijk dat het nu af is. Mijn grate dank. 
Beste Dr. Stienstra, mijn co-promoter, Ymkje. lk mocht voortborduren op jouw inge­
zette onderzoek. lk heb altijd veel bewondering voor je gehad, bedankt dat je mij wilde 
begeleiden en sturen, dit ondanks je sommige ergernissen over mijn vertragingen. Jij 
bent erg praktisch en oplossingsgericht, en vaak dacht ik mi met jou gepraat te hebben: 
oh ja zo kan het ook! Jouw ontzettend veel goede ideeen, tips en adviezen over de me­
thodiek, de tekst en de onderbouwing in de manuscripten maakten mij wel eens moe, 
maar ik ben er je dankbaar voor. Ze dwongen mij om na te blijven denken. 
Dear Kabiru Mohammed Abass, without you we would still not have reached our 
calculated sample size! Your positivity, enthusiasm, discipline and great talent to 
motivate people are priceless. It was just great to work with you in Agogo, and I 
value you and your wife's friendship highly. Dear Wilson Tuah, thanks for your always 
inexhaustible energy to run the Buruli clinic in Nkawie. Not only one day a week, but 
always when necessary you gave your time. Your accurate character and laboratory 
skills were of great help, and made you a very suitable person to help in the research. 
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Dear Victoria Ahiable (Vic), Mr. Frimpong, Edmund Atakora 0/Vofa Yaw) and Justice 
Abotsi: together we've traced, seen and treated lots of patients! I admire every one of 
you for the time and the effort you have shown in sometimes difficult circumstances. 
We had great times together. Dear Mr. Dyabaah (head Agogo Community Health 
Office),Ju lianaAgyeibei (nurse/midwife health postAnanekrom),Josephine Kyerewaah, 
Janet Duah-Agyekum and Yaw Gyewonu (theatre nurses Nkawie). Without you the 
trial would not have succeeded. 
Dear Dr. Peter Awuah and Dr. Wil l iam Thompson, thank you for welcoming me as a 
stranger in your hospital, and thank you for your collaboration and advise whenever 
necessary. Dear Prof. Ohene Adjei, I remember you brought me to Ghana for the 
first time, when we came from Benin.Thank you for taking care of me, and thank you 
for your guidance. Dear Dr. Thomas Kruppa, thank you too for having me in KCCR. 
Dear Nana Yaa Awua-Boateng, Vera Siegmund and Dr. Gisela Bretzel: working i n  a 
laboratory can be quite stressful, especial ly in tropical circumstances and when the 
time-pressure of a randomized trial comes in! Thank you for your col laboration and 
the desire to del iver h igh qual ity work. 
Dear Prof. dr. Geoffrey Kwabla Amedofu, thank you for the very nice collaboration 
at the ENT department of Komfo-Anokye Teaching Hospital. 
Dear Dr. Kingsley Asiedu, thank you for your support concerning our project, and 
for the very important work you do at the WHO office concerning Buruli ulcer. Dr. 
Edwin Ampadu, thank you for allowing me to somehow be part of your National 
Buruli Ulcer Control Program when I was in Ghana. I also thank the other personnel 
at the National Buruli Ulcer Office in Accra for the collaboration. 
Dear Dr. Phil l ips, Richard.You became not only my advisor and tutor, but also my friend, 
and I appreciated the times I could spend with your great family. I deeply admire you 
for your ongoing energy to combine patient care with Buruli ulcer research. 
I thank the Data Safety Monitoring Board consisting of Prof. Wil l iam R Faber, Prof. 
Paul DR Johnson and Dr.Alan J Knell for their wil l ingness to spend time on evaluating 
the results and the progress of the trial. Dear Cari Stek, thank you for the monitoring 
activities you performed for the drug trial. It was very nice to have you there. 
I am honored that the reading committee consisted of Prof. dr. B.C.  de Jong, Prof. dr. 
B. Fleischer and Prof. dr.WR. Faber.Your effort is highly appreciated. 
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Dear Prof. Fleischer, Bernhard. I thank you for the energy consuming work you did 
on coordinating the BURULICO project, but I also warmly thank you for the moral 
support you gave me every now and then. 
Thanks also to all other collaborators and work packages in the BURULICO project. 
Beste Jan Schouten.Jij bent van onschatbare waarde geweest voor belangrijke statis­
tiek in dit proefschrift. lk vond het altijd weer leuk om met jou hiernaar te kijken. 
Dank je voor je hulp, zelfs na je pensionering, bij jou thuis. 
Beste Jan Breeuwsma, de financien doen zal nooit mijn favoriete bezigheid zijn, al 
houd ik er wel van om alles goed op een rijtje te hebben. Oat was in Ghana lastig 
met al die duizenden bonnetjes en de niet te voorspellen uitgaven. Bedankt voor je 
structurering en begeleiding. 
Beste Dr. Eveline van derVeer, ik wil je bedanken voor je begeleiding betreffende de vita­
mine D materie. Na lange radiostiltes reageerde je zo enthousiast dat dat mij weer ener­
gie gaf. Ook Jan en Karin Koerts wil ik bedanken voor de snelle vitamine D bepalingen. 
Beste Prof. Dr. Pieter Dijkstra, dank je voor je altijd positieve input bij dat ene voor 
mij lastige artikel waar jij bij betrokken werd. Jouw advies om mijn eigen keuzes te 
maken omdat je niet iedereen kan behagen had ik nodig. Beste Prof. Hero Wit, dank 
u voor de introductie in de voor mij totaal onbekende audiometrie. 
Beste Pieter van der Vii es en Cleo van Diemen, nog steeds is genetica en de daarbij 
behorende statistiek voor mij lastige materie. Het was leuk om met jullie hulp daar­
aan gesnuffeld te hebben. 
Beste Johan Bijzet, bedankt voor je zorg voor mijn monsters. lk hoop dat wij ooit een 
eigen vriezer zullen krijgen ... 
Beste Prof. dr. Bert Niesters en Rob Faber, bedankt voor jullie hulp door middel van 
virologie bepalingen, tussen alle verbouwingen door. 
Beste Marieke de Waard en Janneke Huizinga. lk ben jullie dankbaar voor het -in jul­
lie vrije tijd- geblindeerd beoordelen van alle Buruli ulcer foto's. 
lk wil alle Nederlandse en Ghanese studenten en de studenten van andere nationali­
teiten bedanken die op wat voor manier dan ook hebben geholpen met de studies en 
de patientenzorg. Daarbij wil ik expliciet noemen Rachael Bonawitz, en Meys Cohen 
voor je gezellige company, de studie die je hebt gedaan, en voor het helpen opvoeden 
van Emma,onze plassende waakpuppy.Jannes Sipkens dank ik voor de nare klus van het 
invoeren van alle audiometrie data, en Bram Zuur voor het plotseling enthousiast op­
pakken van de PKPD studie, en voor de ontzettend gezellige tijd die we hebben gehad. 
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Beste Gerrit en Maaike van Herwijnen. Dank voor het vervoeren van medische spul­
len naar Ghana, en voor jullie aandacht en vriendschap toen ik in Ghana was. 
Beste Dr. W im van Brakel and dear Dr. Ruth Butlin. Thank you for guiding my very 
first research project at The Leprosy Mission in India. You have laid the foundation 
for my further research activities. 
Beste Dr. Kees Halma, mijn opleider in het MCL, Leeuwarden. Een perifeer zieken­
huis en onderzoek -wat niet in die kliniek is uitgevoerd- gaan soms moeilijk samen. 
Dank u voor de steun die ik toch altijd heb gevoeld. Beste Loek de Heide, mijn nieu­
we opleider. Door de bezigheden met dit proefschrift heb ik steeds het idee gehad 
dat ik mij niet voor de volle I 00% kon geven voor de opleiding, de kliniek. Gelukkig 
zal dat binnenkort anders zijn. Beste Prof. dr. ROB Gans. lk wil u bedanken dat u mij 
de mogelijkheid heeft geboden om mijn opleidingsplek te bevriezen, zodat ik eerst 
dat wat ik graag wilde, het onderzoek, kon doen. 
De collega's arts-assistenten in het Medisch Centrum Leeuwarden wil ik bedanken 
voor de collegialiteit en de mogelijkheden tot ruilen van diensten en praatjes in ver­
band met muziekoptredens of deadlines. Bedankt ook internisten, intensivisten, long­
artsen, cardiologen, geriaters, medisch microbiologen, chirurgen, verpleegkundigen, 
secretaresses, assistentes en medisch fotografen voor de samenwerking. 
Dear Martina Buhrlen, a friend like you is hard to find. I can't imagine how it would 
have been if you wouldn't have been there, in Agogo. Thank you for sharing your 
house with me every week again, for the laughter and the tears, for the sports and 
the food. 
Dear Katrin Fahndrich, after Martina went, you just let me, my friends and family, into 
your house without any hesitation.You are just the best! 
Dear Virginie Dejoye, thank you for your friendship and for sharing your house and 
food with us during my last visit to Ghana. 
Dear Cristophe Carillon,Alison Ely and Susanne Abels, thank you for your company. 
All of you shared your houses with me for a shorter or longer period of time. I am 
very grateful for that. 
Dear Chris and Elize Schutte, thank you for your friendship and support during our 
gatherings, when I was in Kumasi. 
Dear Marie-Anne Franqueville. I am honored that you allowed me to use some of 
your drawings to illustrate my thesis. Thank you so much! 
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Beste Auke-Willem en Feikje Kampen. Bedankt voor jullie vriendschap en gesprek­
ken. Muziekvriend AW, het afscheidslied zal ik nooit vergeten. Of ik nou in Ghana of 
in Leeuwarden woon, we zien elkaar niet vaak - maar als we elkaar zien is het goed. 
Dat ik nu I Ox bij je ben geweest om de omslag van het boekje aan te laten passen 
heeft daar trouwens verandering in gebracht. Misschien dat ik nu aan het lezen van 
jouw boek toekom! Feikje, bedankt voor het ons altijd maar weer voorzien van een 
van de eerste (?) levensbehoeften. 
Beste paranimf, Sandra. lk weet nog dat je mij in Emmen vroeg of ik het meende, dat 
ik iemand zocht om mee naar Brazilie te gaan. Jammer dat het ons niet gelukt is iets 
in Ghana te plannen, ook al hadden jullie al bijna geboekt. Ook al toon ik soms weinig 
commitment, de vriendschap zal voor mij altijd blijven. 
Beste paranimf, Esther. Bedankt voor je vriendschap hier in Leeuwarden. Het was 
fijn om samen onderwijsdagen voor te bereiden en onszelf te motiveren tot werk, 
wetenschap en meer. Bedankt voor het mij uit bed bellen en voor de gezellige maal­
tijden. 
Beste onderbuuf, Aafke Stapert. Bedankt dat je nooit klaagt, bijvoorbeeld over mijn 
getoeter. Bedankt voor je maaltijden en massages toen het schrijven bijna ten einde 
liep, maar ik ook bijna ten einde liep .. 
Christengemeente Buitenpost, bij jullie voel ik me thuis als ik er weer ben. Bedankt 
voor het meeleven v66r, en tijdens het project. 
Naast de wetenschappelijke en klinische inspanningen heb ik gemerkt dat ik niet 
zonder muziek kan. lk dank alle leden van Muziekvereniging Joost Wiersma, Harmo­
nie'67 en de andere ad hoc muziekvrienden voor jullie aandeel hierin. Muziek is een 
van de mooiste dingen die bestaan. 
Ferdinand van Nispen, als jij niet op mijn weg gekomen was dan was er geen lay-out 
geweest. lk had het niet kunnen doen tussen mijn bedrijven door, en ik weet niet wie 
het anders zo snel nog voor elkaar zou hebben gekregen. Mijn hartelijke dank. 
Lieve Pap en Mam. Bedankt voor de liefde en de steun die ik van jullie heb gekregen. 
Jullie hebben mij uiteindelijk de mogelijkheden gegeven om te doen wat ik wilde 
doen, mijn waardering hiervoor is groat. Het halen en brengen naar Schiphol, het 
pakken, verslepen en wegen van koffers en monsters, het regelen van grate en kleine 
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dingen, niets was teveel. Beste Pap, ik weet nog dat je mij vroeg of ik niet toch maar 
meteen aan de opleiding tot internist zou gaan beginnen toen die mogelijkheid er was. 
lk weet dat pap het beste met mij voor heeft - gelukkig is er niets ernstigs gebeurd 
daar in het zwarte Afrika. lk weet niet precies hoeveel dagen of weken het pap heeft 
gekost om alle oppervlakte sheets in te scannen, maar ik weet wel dat het er vele 
moeten zijn geweest. Gezien ons beider perfectionisme zal de betrouwbaarheid van 
de oppervlakteberekeningen waar we daarna samen weken aan gewerkt hebben, niet 
slecht zijn. Beste Mam, mam weet hoe het is om voor langere tijd in een andere wereld 
te leven en hoe moeilijk het is om weer terug te komen. Mam wist dat dit mijn diepste 
wens was, en heeft mij hier daarom altijd in gesteund, bedankt hiervoor. lk heb het heel 
erg gewaardeerd dat jullie mij kwamen bezoeken, en ik zie ons nog in de bush fufu en 
vis met de handen eten. Pap heeft de vaccinaties overleefd en mam de buikloop. Wat 
was het fijn dat ik weer in Nederland was toen pap ziek werd. lk hou van jullie. 
Beste Thelly, bedankt voor de interesse en de liefde voor de ander die Thelly altijd 
met zich meedraagt. Het meedenken en de steun heb ik erg gewaardeerd. Bedankt 
voor het tijdelijke onderdak toen ik tussen mijn reizen door Nederland was. Het was 
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